

Phase 3 Trial of ¹⁷⁷Lu-Dotatate for Midgut

New England Journal of Medicine

376, 125-135

DOI: [10.1056/nejmoa1607427](https://doi.org/10.1056/nejmoa1607427)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Radionuclide Therapy for Neuroendocrine Tumors. <i>Current Oncology Reports</i> , 2017, 19, 9.	1.8	113
2	Carcinoid syndrome in neuroendocrine tumors: a prognostic effect?. <i>Lancet Oncology</i> , The, 2017, 18, 426-428.	5.1	3
3	Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1401-1407.	2.8	64
4	NTR Is the New SSTR? Perspective for Neurotensin Receptor 1 (NTR)â€Directed Theranostics. <i>Journal of Nuclear Medicine</i> , 2017, 58, 934-935.	2.8	5
5	PET Imaging for Endocrine Malignancies: From Woe to Go. <i>Journal of Nuclear Medicine</i> , 2017, 58, 878-880.	2.8	2
7	Molecular targeted therapies in adrenal, pituitary and parathyroid malignancies. <i>Endocrine-Related Cancer</i> , 2017, 24, R239-R259.	1.6	16
8	Molecular imaging in the investigation of hypoglycaemic syndromes and their management. <i>Endocrine-Related Cancer</i> , 2017, 24, R203-R221.	1.6	36
9	Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. <i>Journal of Cancer Research and Clinical Oncology</i> , 2017, 143, 1209-1224.	1.2	14
10	Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 4617-4624.	3.2	399
11	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues. <i>Neuroendocrinology</i> , 2017, 105, 295-309.	1.2	229
12	The underestimated role of somatostatin analogs in the NETTER-1 trial. <i>Future Oncology</i> , 2017, 13, 1287-1289.	1.1	8
13	Effect of hormone secretory syndromes on neuroendocrine tumor prognosis. <i>Endocrine-Related Cancer</i> , 2017, 24, R261-R274.	1.6	43
14	Multislice PET/CT in Neuroendocrine Tumors. <i>Medical Radiology</i> , 2017, , 675-689.	0.0	0
15	SSTR-Mediated Imaging in Breast Cancer: Is There a Role for Radiolabeled Somatostatin Receptor Antagonists?. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1609-1614.	2.8	21
16	Biodistribution, Pharmacokinetics, and Dosimetry of ¹⁷⁷ Lu-, ⁹⁰ Y-, and ¹¹¹ In-Labeled Somatostatin Receptor Antagonist OPS201 in Comparison to the Agonist ¹⁷⁷ Lu-DOTATATE: The Mass Effect. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1435-1441.	2.8	100
17	Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. <i>American Journal of Roentgenology</i> , 2017, 209, 277-288.	1.0	68
18	Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. <i>JAMA Oncology</i> , 2017, 3, 1335.	3.4	2,289
19	The conflict between treatment optimization and registration of radiopharmaceuticals with fixed activity posology in oncological nuclear medicine therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1783-1786.	3.3	48

#	ARTICLE	IF	CITATIONS
20	Early efficacy of and toxicity from lutetium-177-DOTATATE treatment in patients with progressive metastatic NET. Nuclear Medicine Communications, 2017, 38, 593-600.	0.5	15
21	Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3278-3287.	1.8	125
22	The Surgical Management of Small Bowel Neuroendocrine Tumors. Pancreas, 2017, 46, 715-731.	0.5	262
23	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas, 2017, 46, 707-714.	0.5	241
24	May we challenge the ENETS guidelines in pancreatic neuroendocrine neoplasms? A quiz for French experts. Digestive and Liver Disease, 2017, 49, 809-819.	0.4	0
25	Tratamiento con 177Lu-DOTATATE: pasado, presente y futuro. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2017, 36, 69-71.	0.0	0
26	Pitfalls in the response evaluation after peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate. Endocrine-Related Cancer, 2017, 24, 243-251.	1.6	45
27	Long-term results and tolerability of tandem peptide receptor radionuclide therapy with 90Y/177Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Annals of Nuclear Medicine, 2017, 31, 347-356.	1.2	47
28	¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors. New England Journal of Medicine, 2017, 376, 1390-1392.	13.9	35
29	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. New England Journal of Medicine, 2017, 376, 1389-1390.	13.9	21
30	Precision Medicine in Adrenal Disorders: the Next Generation. Endocrine Practice, 2017, 23, 672-679.	1.1	3
31	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Systemic Therapy - Biotherapy and Novel Targeted Agents. Neuroendocrinology, 2017, 105, 266-280.	1.2	122
32	Thymic Neuroendocrine Neoplasms: Biological Behaviour and Therapy. Neuroendocrinology, 2017, 105, 105-114.	1.2	39
33	Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1095-1096.	3.3	0
34	Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. Current Treatment Options in Oncology, 2017, 18, 14.	1.3	52
35	The role of liquid biopsies to manage and predict PRRT for NETs. Nature Reviews Gastroenterology and Hepatology, 2017, 14, 331-332.	8.2	14
36	Reply to: Predicting the outcome of peptide receptor radionuclide therapy in neuroendocrine tumors: the importance of dual-tracer imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 1777-1778.	3.3	1
37	Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects. Expert Opinion on Pharmacotherapy, 2017, 18, 1679-1689.	0.9	21

#	ARTICLE	IF	CITATIONS
38	Echocardiography in functional midgut neuroendocrine tumors: When and how often. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 411-421.	2.6	6
39	Update on radionuclide therapy in oncology (Review). Oncology Letters, 2017, 14, 7011-7015.	0.8	18
40	Molecular radiotheranostics for neuroendocrine tumours. Clinical Medicine, 2017, 17, 462-468.	0.8	6
42	Clinical benefit of systemic treatment in patients with advanced pancreatic and gastrointestinal neuroendocrine tumours according to ESMO-MCBS and ASCO framework. Annals of Oncology, 2017, 28, 3022-3027.	0.6	15
43	Theranostics of Neuroendocrine Tumors. Visceral Medicine, 2017, 33, 358-366.	0.5	28
44	Safety and Effectiveness of ¹⁷⁷ Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors. Clinical Nuclear Medicine, 2017, 42, 822-828.	0.7	15
46	Medical Therapy of Gastrointestinal Neuroendocrine Tumors. Visceral Medicine, 2017, 33, 352-356.	0.5	14
47	Radionuclides in oncology clinical practice – review of the literature. Dalton Transactions, 2017, 46, 14475-14487.	1.6	4
48	Efficacy of Peptide Receptor Radionuclide Therapy in a United States-Based Cohort of Metastatic Neuroendocrine Tumor Patients. Pancreas, 2017, 46, 1121-1126.	0.5	22
49	More \hat{I}^{\pm} Than \hat{I}^2 for Prostate Cancer?. Journal of Nuclear Medicine, 2017, 58, 1709-1710.	2.8	12
50	Digestive System Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Neuroendocrinology, 2017, 105, 412-425.	1.2	119
51	Clinical History of the Theranostic Radionuclide Approach to Neuroendocrine Tumors and Other Types of Cancer: Historical Review Based on an Interview of Eric P. Krenning by Rachel Levine. Journal of Nuclear Medicine, 2017, 58, 3S-9S.	2.8	66
52	Somatostatin Receptor Antagonists for Imaging and Therapy. Journal of Nuclear Medicine, 2017, 58, 61S-66S.	2.8	188
53	Iodine Symporter Targeting with ¹²⁴ I/ ¹³¹ I Theranostics. Journal of Nuclear Medicine, 2017, 58, 34S-38S.	2.8	39
54	Somatostatin Receptor Targeting Compounds. Journal of Nuclear Medicine, 2017, 58, 54S-60S.	2.8	38
55	Theranostic Concepts: More Than Just a Fashion Trend? Introduction and Overview. Journal of Nuclear Medicine, 2017, 58, 1S-2S.	2.8	36
56	Precision Medicine and PET/Computed Tomography: Emerging Themes for Future Clinical Practice. PET Clinics, 2017, 12, xi-xii.	1.5	6
57	Cyto-histology in NET: what is necessary today and what is the future?. Reviews in Endocrine and Metabolic Disorders, 2017, 18, 381-391.	2.6	18

#	ARTICLE	IF	CITATIONS
58	Concomitant ¹⁷⁷ Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2017, 42, e457-e466.	0.7	56
59	PET-Computed Tomography and Precision Medicine in Pancreatic Adenocarcinoma and Pancreatic Neuroendocrine Tumors. <i>PET Clinics</i> , 2017, 12, 407-421.	1.5	8
61	Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review. <i>Endocrine</i> , 2017, 57, 366-375.	1.1	33
62	The safety of available treatments options for neuroendocrine tumors. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1149-1161.	1.0	29
63	Nuclear Medicine and Molecular Imaging—An Impactful Decade of Contributions to Patient Care and Driving Precision Medicine. <i>American Journal of Roentgenology</i> , 2017, 209, 241-242.	1.0	2
64	Peptide Receptor Radionuclide Therapy-Induced Gitelman-like Syndrome. <i>American Journal of Kidney Diseases</i> , 2017, 70, 725-728.	2.1	1
65	Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors. <i>Seminars in Oncology</i> , 2017, 44, 141-156.	0.8	22
66	Carcinoid syndrome and neuroendocrine tumours. <i>Medicine</i> , 2017, 45, 543-546.	0.2	1
68	New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification. <i>Endocrine Reviews</i> , 2017, 38, 489-515.	8.9	241
69	Randomized Controlled Trials in Neuroendocrine Tumors. <i>Surgical Oncology Clinics of North America</i> , 2017, 26, 751-765.	0.6	2
70	The Role of PET/MR Imaging in Precision Medicine. <i>PET Clinics</i> , 2017, 12, 489-501.	1.5	7
71	Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review. <i>Clinical Therapeutics</i> , 2017, 39, 2146-2157.	1.1	19
72	The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors. <i>Targeted Oncology</i> , 2017, 12, 757-774.	1.7	1
73	Update in the Therapy of Advanced Neuroendocrine Tumors. <i>Current Treatment Options in Oncology</i> , 2017, 18, 72.	1.3	18
74	Gastrointestinal Tract Malignancies: Obstacles and Advancements. <i>Clinical Therapeutics</i> , 2017, 39, 2122-2124.	1.1	2
75	Individualised ¹⁷⁷ Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1480-1489.	3.3	144
76	Recent advances in the imaging of pheochromocytomas and paragangliomas. <i>International Journal of Endocrine Oncology</i> , 2017, 4, 137-144.	0.4	0
77	Carcinoid heart disease: a guide for screening and timing of surgical intervention. <i>Netherlands Heart Journal</i> , 2017, 25, 471-478.	0.3	20

#	ARTICLE	IF	CITATIONS
78	Response assessment with the CXCR4-directed positron emission tomography tracer [68Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities. <i>EJNMMI Research</i> , 2017, 7, 51.	1.1	24
79	Targeted radionuclide therapy in combined-modality regimens. <i>Lancet Oncology</i> , The, 2017, 18, e414-e423.	5.1	115
80	¹⁷⁷ Lu-PSMA Radioligand Therapy for Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1196-1200.	2.8	159
81	The place of liver transplantation in the treatment of hepatic metastases from neuroendocrine tumors: Pros and cons. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2017, 18, 473-483.	2.6	26
83	Is there still a role for the hepatic locoregional treatment of metastatic neuroendocrine tumors in the era of systemic targeted therapies?. <i>World Journal of Gastroenterology</i> , 2017, 23, 2640.	1.4	21
84	Emerging use of everolimus in the treatment of neuroendocrine tumors. <i>Cancer Management and Research</i> , 2017, Volume 9, 215-224.	0.9	14
85	The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. <i>Theranostics</i> , 2017, 7, 1159-1163.	4.6	49
86	Theranostics in nuclear medicine practice. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 4821-4828.	1.0	161
87	Clinical and Preclinical Advances in Gastroenteropancreatic Neuroendocrine Tumor Therapy. <i>Frontiers in Endocrinology</i> , 2017, 8, 341.	1.5	12
88	Low Grade Neuroendocrine Tumors of the Lung. <i>Frontiers in Oncology</i> , 2017, 7, 119.	1.3	12
89	Determination of Mammalian Target of Rapamycin Hyperactivation as Prognostic Factor in Well-Differentiated Neuroendocrine Tumors. <i>Gastroenterology Research and Practice</i> , 2017, 2017, 1-9.	0.7	7
90	Management Options for Advanced Low or Intermediate Grade Gastroenteropancreatic Neuroendocrine Tumors: Review of Recent Literature. <i>International Journal of Surgical Oncology</i> , 2017, 2017, 1-14.	0.3	8
91	Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. <i>BioMed Research International</i> , 2017, 2017, 1-12.	0.9	25
92	Absorbed dose estimates from a single measurement one to three days after the administration of ¹⁷⁷ Lu-DOTATATE/-TOC. <i>Nuklearmedizin - NuclearMedicine</i> , 2017, 56, 219-224.	0.3	11
93	Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 1265-1269.	1.8	4
94	Hedgehog inhibitor sonidegib potentiates ¹⁷⁷ Lu-octreotate therapy of GOT1 human small intestine neuroendocrine tumors in nude mice. <i>BMC Cancer</i> , 2017, 17, 528.	1.1	24
95	Gastroenteropancreatic neuroendocrine tumors and the NETTER-1 trial. <i>International Journal of Endocrine Oncology</i> , 2017, 4, 155-157.	0.4	0
96	Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 5013-5030.	1.0	8

#	ARTICLE	IF	CITATIONS
97	Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach. <i>Theranostics</i> , 2017, 7, 1489-1498.	4.6	82
98	Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives. <i>Biologics: Targets and Therapy</i> , 2017, Volume 11, 115-122.	3.0	12
99	Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 495-503.	0.7	9
100	Guidelines for the management of neuroendocrine tumours by the Brazilian gastrointestinal tumour group. <i>Ecancelmedicalscience</i> , 2017, 11, 716.	0.6	16
101	Recent advances in the biology and therapy of medullary thyroid carcinoma. <i>F1000Research</i> , 2017, 6, 2184.	0.8	18
102	The role of peptide receptor radionuclide therapy in advanced/metastatic thoracic neuroendocrine tumors. <i>Journal of Thoracic Disease</i> , 2017, 9, S1511-S1523.	0.6	21
103	Phase 1b study of pasireotide, everolimus, and selective internal radioembolization therapy for unresectable neuroendocrine tumors with hepatic metastases. <i>Cancer</i> , 2018, 124, 1992-2000.	2.0	17
104	Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 123, 7-20.	2.0	89
105	Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2018, 19, 145-158.	2.6	23
106	Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 471-480.	1.6	1
107	Genetic heterogeneity of primary lesion and metastasis in small intestine neuroendocrine tumors. <i>Scientific Reports</i> , 2018, 8, 3811.	1.6	42
108	Theranostic radiopharmaceuticals: established agents in current use. <i>British Journal of Radiology</i> , 2018, 91, 20170969.	1.0	81
109	Targeted alpha and beta radiotherapy: An overview of radiopharmaceutical and clinical aspects. <i>Medicine Nucleaire</i> , 2018, 42, 32-44.	0.2	20
110	Gastroenteropancreatic neuroendocrine neoplasms: genes, therapies and models. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	39
111	PRRT genomic signature in blood for prediction of ¹⁷⁷ Lu-octreotate efficacy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1155-1169.	3.3	101
112	Prospective observational study of ¹⁷⁷ Lu-DOTA-octreotate therapy in 200 patients with advanced metastasized neuroendocrine tumours (NETs): feasibility and impact of a dosimetry-guided study protocol on outcome and toxicity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 970-988.	3.3	179
113	Peptide receptor radionuclide therapy for neuroendocrine tumours. <i>Clinical and Translational Imaging</i> , 2018, 6, 101-111.	1.1	3
114	Neuroendocrine neoplasms of rectum: A management update. <i>Cancer Treatment Reviews</i> , 2018, 66, 45-55.	3.4	52

#	ARTICLE	IF	CITATIONS
116	Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors. <i>Pharmacoeconomics</i> , 2018, 36, 1005-1013.	1.7	11
117	Radio-pharmaceuticals for cancer treatment: are they ready for prime time yet?. <i>Annals of Oncology</i> , 2018, 29, 1594-1597.	0.6	6
118	External Beam Radiotherapy in the Treatment of Gastroenteropancreatic Neuroendocrine Tumours: A Systematic Review. <i>Clinical Oncology</i> , 2018, 30, 400-408.	0.6	25
119	Recent Topics Around Multiple Endocrine Neoplasia Type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 1296-1301.	1.8	28
120	Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 471-478.	1.4	5
121	Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog ¹⁷⁷ Lu-DOTA-EB-TATE in Patients with Advanced Metastatic Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1699-1705.	2.8	66
122	Molecular imaging and theranostic approaches in pheochromocytoma and paraganglioma. <i>Cell and Tissue Research</i> , 2018, 372, 393-401.	1.5	37
124	Investigation of receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE in patients with GEP-NEN and a high Ki-67 proliferation index. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 923-930.	3.3	56
125	Trends in oncologic hybrid imaging. <i>European Journal of Hybrid Imaging</i> , 2018, 2, 1.	0.6	25
126	Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases. <i>Clinical Cancer Research</i> , 2018, 24, 2182-2193.	3.2	68
127	Peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTA-octreotate. <i>Nuclear Medicine Communications</i> , 2018, 39, 236-246.	0.5	20
128	2016 New Horizons Lecture: Beyond Imaging – Radiology of Tomorrow. <i>Radiology</i> , 2018, 286, 764-775.	3.6	33
129	Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis. <i>Cell and Tissue Research</i> , 2018, 372, 379-392.	1.5	16
130	Time-dependent transcriptional response of GOT1 human small intestine neuroendocrine tumor after ¹⁷⁷ Lu[Lu]-octreotate therapy. <i>Nuclear Medicine and Biology</i> , 2018, 60, 11-18.	0.3	7
132	Telotristat ethyl: a novel agent for the therapy of carcinoid syndrome diarrhea. <i>Future Oncology</i> , 2018, 14, 1155-1164.	1.1	8
133	Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2018, 43, 186-187.	0.7	1
134	Radiotheranostics in Cancer Diagnosis and Management. <i>Radiology</i> , 2018, 286, 388-400.	3.6	91
135	PET/MRI for Clinical Pediatric Oncologic Imaging. , 2018, , 401-432.		1

#	ARTICLE	IF	CITATIONS
136	PET/MRI in Neuroendocrine Tumours. , 2018, , 291-304.		1
137	Prostate-specific membrane antigen theranostics. <i>Current Opinion in Urology</i> , 2018, 28, 197-204.	0.9	39
138	Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. <i>Surgery</i> , 2018, 163, 761-767.	1.0	65
139	Reply: Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists. <i>Journal of Nuclear Medicine</i> , 2018, 59, 547-548.	2.8	6
140	Functional Renal Imaging with 2-Deoxy-2- ¹⁸ F-Fluorosorbitol PET in Rat Models of Renal Disorders. <i>Journal of Nuclear Medicine</i> , 2018, 59, 828-832.	2.8	26
141	Morphological and Functional Imaging for Detecting and Assessing the Resectability of Neuroendocrine Liver Metastases. <i>Neuroendocrinology</i> , 2018, 106, 74-88.	1.2	44
142	Anesthetic Management of Patients With Carcinoid Syndrome and Carcinoid Heart Disease: The Mount Sinai Algorithm. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2018, 32, 1023-1031.	0.6	21
143	The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines. <i>Neuroendocrinology</i> , 2018, 106, 357-365.	1.2	57
144	Lu-177-Based Peptide Receptor Radionuclide Therapy for Advanced Neuroendocrine Tumors. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 208-215.	0.6	25
145	A Lymph Node Ratio-Based Staging Model Is Superior to the Current Staging System for Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 187-195.	1.8	18
146	Advanced neuroendocrine tumours of the small intestine and pancreas: clinical developments, controversies, and future strategies. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 404-415.	5.5	56
147	Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 190-199.	0.6	42
148	Current Consensus on I-131 MIBG Therapy. <i>Nuclear Medicine and Molecular Imaging</i> , 2018, 52, 254-265.	0.6	57
149	Síndrome de Cushing ectípico: descripci3n de 9 casos. <i>Endocrinologia, Diabetes Y Nutrici3n</i> , 2018, 65, 255-264.	0.1	13
150	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	0.6	54
151	Alphatherapy, the new impetus to targeted radionuclide therapy?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1362-1363.	3.3	1
152	Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial. <i>World Journal of Surgery</i> , 2018, 42, 506-513.	0.8	23
153	Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. <i>British Journal of Radiology</i> , 2018, 91, 20180041.	1.0	50

#	ARTICLE	IF	CITATIONS
154	Outcomes of Cytoreductive Surgery for Metastatic Low-Grade Neuroendocrine Tumors in the Setting of Extrahepatic Metastases. <i>Annals of Surgical Oncology</i> , 2018, 25, 1768-1774.	0.7	22
155	Drug Delivery in Cancer Therapy, Quo Vadis?. <i>Molecular Pharmaceutics</i> , 2018, 15, 3603-3616.	2.3	85
156	IFN- γ in advanced well-differentiated neuroendocrine tumors: the neglected drug?. <i>Future Oncology</i> , 2018, 14, 897-899.	1.1	1
157	Neuroradiological and Neuropathological Changes After ^{177}Lu -Octreotate Peptide Receptor Radionuclide Therapy of Refractory Esthesioneuroblastoma. <i>Operative Neurosurgery</i> , 2018, 15, 100-109.	0.4	16
158	Nuclear Imaging Enters a New Era: Combining Diagnosis and Therapy, Nuclear Medicine Has the Potential to Advance Cancer Treatment and Care. <i>IEEE Pulse</i> , 2018, 9, 4-8.	0.1	0
159	Recent advances in theranostics and challenges for the future. <i>British Journal of Radiology</i> , 2018, 91, 20170893.	1.0	60
160	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	1.6	18
161	SSTR-RADS Version 1.0 as a Reporting System for SSTR PET Imaging and Selection of Potential PRRT Candidates: A Proposed Standardization Framework. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1085-1091.	2.8	58
162	Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. <i>Cancer Treatment Reviews</i> , 2018, 66, 1-6.	3.4	26
163	Receptor Occupancy Imaging Studies in Oncology Drug Development. <i>AAPS Journal</i> , 2018, 20, 43.	2.2	12
164	From Initial Description by Wermer to Presentâ€”Day MEN1: What have We Learned?. <i>World Journal of Surgery</i> , 2018, 42, 1031-1035.	0.8	9
165	Primary Ovarian Carcinoid: Extensive Clinical Experience With an Underrecognized Uncommon Entity. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 466-471.	1.2	11
166	Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. <i>Neuroendocrinology</i> , 2018, 106, 211-220.	1.2	35
167	Dose Mapping After Endoradiotherapy with ^{177}Lu -DOTATATE/DOTATOC by a Single Measurement After 4 Days. <i>Journal of Nuclear Medicine</i> , 2018, 59, 75-81.	2.8	125
168	Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours. , 2018, 181, 49-75.		9
169	Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival. <i>JAMA Oncology</i> , 2018, 4, 183.	3.4	76
170	Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 402-411.	3.3	13
171	PET and SPECT imaging of melanoma: the state of the art. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 132-150.	3.3	29

#	ARTICLE	IF	CITATIONS
172	The utility of ⁶⁸ Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. <i>Future Oncology</i> , 2018, 14, 111-122.	1.1	61
173	Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2018, 59, 66-74.	2.8	228
174	Advantages and Limits of Targeted Radionuclide Therapy with Somatostatin Antagonists. <i>Journal of Nuclear Medicine</i> , 2018, 59, 546-547.	2.8	3
175	Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2018, 106, 318-323.	1.2	7
176	Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 262-277.	3.3	97
177	A New Type of Prostate Cancer Imaging: Will ⁶⁴ CuCl ₂ PET/CT Flourish or Vanish?. <i>Journal of Nuclear Medicine</i> , 2018, 59, 442-443.	2.8	5
178	Molecular alterations of neuroendocrine tumours of the lung. <i>Histopathology</i> , 2018, 72, 142-152.	1.6	37
179	Multidisciplinary management of refractory insulinomas. <i>Clinical Endocrinology</i> , 2018, 88, 615-624.	1.2	32
180	Carcinoid-syndrome: recent advances, current status and controversies. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2018, 25, 22-35.	1.2	83
181	Preoperative ⁶⁸ Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions. <i>World Journal of Surgery</i> , 2018, 42, 498-505.	0.8	26
182	Prognostic and predictive role of the PI3K-AKT-mTOR pathway in neuroendocrine neoplasms. <i>Clinical and Translational Oncology</i> , 2018, 20, 561-569.	1.2	10
183	Role of Functional Imaging in the Diagnosis of Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018, , 109-121.	0.0	0
184	Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2018, 59, 452-458.	2.8	88
185	Small Bowel Neuroendocrine Tumors: Big Advances in the Land of Small Tumors. <i>Journal of Oncology Practice</i> , 2018, 14, 485-486.	2.5	0
186	Well differentiated neuroendocrine tumors, a single center experience. <i>Journal of Oncological Science</i> , 2018, 4, 119-124.	0.1	0
187	Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 292-299.	1.8	9
188	Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors. <i>Journal of Oncology Practice</i> , 2018, 14, 487-489.	2.5	0
189	Management of Small Bowel Neuroendocrine Tumors. <i>Journal of Oncology Practice</i> , 2018, 14, 471-482.	2.5	58

#	ARTICLE	IF	CITATIONS
190	Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With ¹⁷⁷ Lu-Dotatate in the Phase III NETTER-1 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2578-2584.	0.8	276
191	New options for neuroendocrine thymic tumors medical treatment. <i>Mediastinum</i> , 2018, 2, 30-30.	0.6	1
192	Practical management of toxicities associated with targeted therapies for advanced gastroenteropancreatic neuroendocrine tumors. <i>Annals of Gastroenterology</i> , 2018, 31, 140-150.	0.4	5
193	Radioactive drugs emerge from the shadows to storm the market. <i>Nature Biotechnology</i> , 2018, 36, 1125-1127.	9.4	27
194	Gastrointestinal Neuroendocrine Tumor Syndromes (GI NETS). , 2018, , 597-616.		0
195	⁶⁸ Ga PET Imaging in Patients With Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2018, 43, 802-810.	0.7	50
196	Management of functional neuroendocrine tumors of the pancreas. <i>Gland Surgery</i> , 2018, 7, 20-27.	0.5	56
197	Liver transplantation for unresectable pancreatic neuroendocrine tumors with liver metastases in an era of transplant oncology. <i>Gland Surgery</i> , 2018, 7, 42-46.	0.5	27
198	¹⁷⁷ Lu-DOTATATE Therapy in Radioiodine-refractory Differentiated Thyroid Cancer. <i>Clinical Nuclear Medicine</i> , 2018, 43, e346-e351.	0.7	20
199	ACR's ACNM Practice Parameter for the Performance of Fluorine-18 Fluciclovine-PET/CT for Recurrent Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2018, 43, 909-917.	0.7	47
200	International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature. <i>Pharmacological Reviews</i> , 2018, 70, 763-835.	7.1	163
201	ASO Author Reflections: Cyto reduction for Extrahepatic Metastatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2018, 25, 866-867.	0.7	0
202	Implementation of patient dosimetry in the clinical practice after targeted radiotherapy using [¹⁷⁷ Lu-DOTA0, Tyr3]-octreotate. <i>EJNMMI Research</i> , 2018, 8, 103.	1.1	31
203	Feasibility of simplifying renal dosimetry in ¹⁷⁷ Lu peptide receptor radionuclide therapy. <i>EJNMMI Physics</i> , 2018, 5, 12.	1.3	60
204	Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT). <i>EJNMMI Physics</i> , 2018, 5, 10.	1.3	9
205	Predictive power of the post-treatment scans after the initial or first two courses of [¹⁷⁷ Lu]-DOTA-TATE. <i>EJNMMI Physics</i> , 2018, 5, 36.	1.3	11
206	Molecular Imaging in Oncology Using Positron Emission Tomography. <i>Deutsches A&#x0308;rztblatt International</i> , 2018, 115, 175-181.	0.6	27
208	¹⁸ F-florbetaben whole-body PET/MRI for evaluation of systemic amyloid deposition. <i>EJNMMI Research</i> , 2018, 8, 66.	1.1	27

#	ARTICLE	IF	CITATIONS
209	Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA0,Tyr3]-Octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach. EJNMMI Research, 2018, 8, 76.	1.1	19
210	Pancreatic Islet Cell Tumors. , 2018, , 626-634.		0
211	Pregnancy and Delivery After PRRT Without Sequelae. Clinical Nuclear Medicine, 2018, 43, 842-845.	0.7	2
212	Gastrointestinal Hormones in Cancer. , 2018, , 579-586.		0
213	ACR Practice Parameter for the Performance of Gallium-68 DOTATATE PET/CT for Neuroendocrine Tumors. Clinical Nuclear Medicine, 2018, 43, 899-908.	0.7	29
214	A systematic review and meta-analysis of gastrointestinal events associated with nonoperative therapies for neuroendocrine tumors. OncoTargets and Therapy, 2018, Volume 11, 7655-7668.	1.0	2
215	Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors. Seminars in Oncology, 2018, 45, 236-248.	0.8	54
216	Management of Advanced Small Bowel Cancer. Current Treatment Options in Oncology, 2018, 19, 69.	1.3	25
218	The theranostic promise for Neuroendocrine Tumors in the late 2010s - Where do we stand, where do we go?. Theranostics, 2018, 8, 6088-6100.	4.6	59
219	Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy. Current Opinion in Supportive and Palliative Care, 2018, 12, 359-365.	0.5	11
220	My burning issues in neuroendocrine tumours (NET). Memo - Magazine of European Medical Oncology, 2018, 11, 313-316.	0.3	0
221	¹⁷⁷ Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours. Nuclear Medicine Communications, 2018, 39, 789-796.	0.5	53
222	Targeted radiotherapy of pigmented melanoma with ¹³¹ I-IPN. Journal of Experimental and Clinical Cancer Research, 2018, 37, 306.	3.5	12
223	Management of Typical and Atypical Pulmonary Carcinoids Based on Different Established Guidelines. Cancers, 2018, 10, 510.	1.7	53
224	The eye of the beholder: orbital metastases from midgut neuroendocrine tumors, a two institution experience. Cancer Imaging, 2018, 18, 47.	1.2	24
225	Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours. World Journal of Gastroenterology, 2018, 24, 2152-2162.	1.4	20
226	Gastroenteropancreatic Neuroendocrine Tumors. Ca-A Cancer Journal for Clinicians, 2018, 68, 471-487.	157.7	378
227	Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours. Cancer Treatment Reviews, 2018, 70, 209-222.	3.4	12

#	ARTICLE	IF	CITATIONS
228	Targeted Alpha Therapy, an Emerging Class of Cancer Agents. <i>JAMA Oncology</i> , 2018, 4, 1765.	3.4	143
229	Neuroendocrine tumors with hepatic metastases: A review of evolving treatment options. <i>Liver Research</i> , 2018, 2, 92-99.	0.5	6
230	The Evolving Role of Nuclear Medicine and Molecular Imaging: Theranostics and Personalized Therapeutic Applications. <i>Molecular Imaging and Radionuclide Therapy</i> , 2018, 27, 1-2.	0.3	6
231	Efficacy Evaluation of Combination Treatment Using Gemcitabine and Radioimmunotherapy with 90Y-Labeled Fully Human Anti-CD147 Monoclonal Antibody O59-053 in a BxPC-3 Xenograft Mouse Model of Refractory Pancreatic Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2979.	1.8	18
232	Systemic Therapy for the Management of Neuroendocrine Tumor Liver Metastases. , 2018, , 267-277.		0
233	Peptide receptor radionuclide therapy as a new tool in treatment-refractory sarcoidosis - initial experience in two patients. <i>Theranostics</i> , 2018, 8, 644-649.	4.6	11
234	Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy. <i>Radiation Research</i> , 2018, 190, 236.	0.7	18
235	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. <i>Neuroendocrinology</i> , 2018, 107, 375-386.	1.2	78
236	Report of metastatic ileal neuroendocrine tumor to the submandibular gland. <i>International Journal of Surgery Case Reports</i> , 2018, 53, 1-4.	0.2	1
238	Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT. <i>EJNMMI Physics</i> , 2018, 5, 25.	1.3	45
239	Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver. <i>Seminars in Oncology</i> , 2018, 45, 232-235.	0.8	22
240	Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors. <i>F1000Research</i> , 2018, 7, 1148.	0.8	28
241	Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors. <i>Clinical Journal of Oncology Nursing</i> , 2018, 22, 565-568.	0.3	3
242	Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy. <i>Pancreas</i> , 2018, 47, e55-e56.	0.5	6
243	Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine neoplasms. <i>Oncotarget</i> , 2018, 9, 16932-16950.	0.8	109
244	Small Bowel and Colorectal Carcinoids. <i>Clinics in Colon and Rectal Surgery</i> , 2018, 31, 301-308.	0.5	16
245	An introduction to the clinical practice of theranostics in oncology. <i>British Journal of Radiology</i> , 2018, 91, 20180440.	1.0	47
246	Liver Resection for Neuroendocrine Metastases and the Obligation to Individualize Care. <i>Annals of Surgical Oncology</i> , 2018, 25, 3787-3789.	0.7	1

#	ARTICLE	IF	CITATIONS
247	Dosimetry methods and clinical applications in peptide receptor radionuclide therapy for neuroendocrine tumours: a literature review. <i>EJNMMI Research</i> , 2018, 8, 89.	1.1	53
248	A method for tumor dosimetry based on hybrid planar ^{67}Ga -SPECT/CT images and semiautomatic segmentation. <i>Medical Physics</i> , 2018, 45, 5004-5018.	1.6	16
249	Management of Liver Neuroendocrine Tumors in 2018. <i>JAMA Oncology</i> , 2018, 4, 1605.	3.4	13
250	Somatostatin receptor 2A protein expression characterizes anaplastic oligodendrogliomas with favorable outcome. <i>Acta Neuropathologica Communications</i> , 2018, 6, 89.	2.4	12
251	Role of biomarker tests for diagnosis of neuroendocrine tumours. <i>Nature Reviews Endocrinology</i> , 2018, 14, 656-669.	4.3	84
252	Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. <i>British Journal of Radiology</i> , 2018, 91, 20180308.	1.0	50
253	Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 909-928.	0.9	53
254	Radiation exposure after ^{177}Lu -DOTATATE and ^{177}Lu -PSMA-617 therapy. <i>Annals of Nuclear Medicine</i> , 2018, 32, 499-502.	1.2	10
255	Correlation of dose with toxicity and tumour response to ^{90}Y - and ^{177}Lu -PRRT provides the basis for optimization through individualized treatment planning. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2426-2441.	3.3	94
256	Neuroendocrine carcinoma arising in a tailgut cyst. <i>International Journal of Surgery Case Reports</i> , 2018, 49, 91-95.	0.2	13
257	PET Radiopharmaceuticals: What's New, What's Reimbursed, and What's Next?. <i>Journal of Nuclear Medicine Technology</i> , 2018, 46, 12-16.	0.4	15
258	Neuroendocrine Tumor Therapy: ^{177}Lu -DOTATATE. <i>American Journal of Roentgenology</i> , 2018, 211, 278-285.	1.0	76
259	Imaging Prostate Cancer With Prostate-Specific Membrane Antigen PET/CT and PET/MRI: Current and Future Applications. <i>American Journal of Roentgenology</i> , 2018, 211, 286-294.	1.0	25
260	The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 4672-4679.	3.2	51
261	The Current State of Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1706-1707.	2.8	3
262	Novel Structural Modification Based on Evans Blue Dye to Improve Pharmacokinetics of a Somatostatin-Receptor-Based Theranostic Agent. <i>Bioconjugate Chemistry</i> , 2018, 29, 2448-2454.	1.8	20
263	Response to Single Low-dose ^{177}Lu -DOTA-EB-TATE Treatment in Patients with Advanced Neuroendocrine Neoplasm: A Prospective Pilot Study. <i>Theranostics</i> , 2018, 8, 3308-3316.	4.6	28
264	Gallium-68: methodology and novel radiotracers for positron emission tomography (2012-2017). <i>Pharmaceutical Patent Analyst</i> , 2018, 7, 193-227.	0.4	12

#	ARTICLE	IF	CITATIONS
265	[¹⁷⁷ Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer. <i>Lancet Oncology</i> , The, 2018, 19, e372.	5.1	3
266	[¹⁷⁷ Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer – Author's reply. <i>Lancet Oncology</i> , The, 2018, 19, e373.	5.1	10
267	PRRT with Radiolabeled Peptides: Indications, Procedures, and Results. , 2018, , 289-295.		0
268	Dosimetry in PRRT. , 2018, , 297-313.		2
269	Guidelines on Radioisotope Treatment of Neuroendocrine Tumors. , 2018, , 315-320.		0
270	Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors. <i>Medical Oncology</i> , 2018, 35, 123.	1.2	10
271	Developments in the treatment of carcinoid syndrome – impact of telotristat. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 323-329.	0.9	6
272	Section Editor's Notebook: ⁶⁸Ga- and ¹⁷⁷Lu-DOTATATE Theragnosticsâ€™Personalized Care and Improving Patient Outcomes. <i>American Journal of Roentgenology</i> , 2018, 211, 244-245.	1.0	3
273	Guidance on ¹⁷⁷Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division. <i>Journal of Nuclear Medicine Technology</i> , 2018, 46, 237-244.	0.4	19
274	PET/MRI for Gastrointestinal Imaging. <i>Gastroenterology Clinics of North America</i> , 2018, 47, 691-714.	1.0	5
275	Advanced Typical and Atypical Carcinoid Tumours of the Lung: Management Recommendations. <i>Current Oncology</i> , 2018, 25, 86-93.	0.9	38
276	Somatostatin receptor type 2 as a radiotheranostic PET reporter gene for oncologic interventions. <i>Theranostics</i> , 2018, 8, 3380-3391.	4.6	11
277	The human somatostatin receptor type 2 as an imaging and suicide reporter gene for pluripotent stem cell-derived therapy of myocardial infarction. <i>Theranostics</i> , 2018, 8, 2799-2813.	4.6	12
278	â€™Albumin Hitchhikingâ€™with an Evans Blue Analog for Cancer Theranostics. <i>Theranostics</i> , 2018, 8, 812-814.	4.6	20
279	Octreotide Does Not Inhibit Proliferation in Five Neuroendocrine Tumor Cell Lines. <i>Frontiers in Endocrinology</i> , 2018, 9, 146.	1.5	26
280	Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer. <i>Diagnostics</i> , 2018, 8, 16.	1.3	90
281	Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 837-860.	1.1	63
282	Current treatment strategies for patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs). <i>Clinical Diabetes and Endocrinology</i> , 2018, 4, 16.	1.3	51

#	ARTICLE	IF	CITATIONS
283	The recent European approval of lutetium (¹⁷⁷ Lu) oxodotreotide increases treatment options for gastroenteropancreatic neuroendocrine tumors. <i>International Journal of Endocrine Oncology</i> , 2018, 5, IJE09.	0.4	8
284	When and How to Use Somatostatin Analogues. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 549-555.	1.2	10
285	New Treatments for the Carcinoid Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 557-576.	1.2	8
286	Recurrent loss of heterozygosity correlates with clinical outcome in pancreatic neuroendocrine cancer. <i>Npj Genomic Medicine</i> , 2018, 3, 18.	1.7	37
287	External radiation exposure, excretion, and effective half-life in ¹⁷⁷ Lu-PSMA-targeted therapies. <i>EJNMMI Research</i> , 2018, 8, 32.	1.1	51
289	[¹⁷⁷ Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 825-833.	5.1	823
290	Duodenal neuroendocrine neoplasms: a still poorly recognized clinical entity. <i>Scandinavian Journal of Gastroenterology</i> , 2018, 53, 835-842.	0.6	29
291	Changes in biodistribution on ⁶⁸ Ga-DOTA-Octreotate PET/CT after long acting somatostatin analogue therapy in neuroendocrine tumour patients may result in pseudoprogression. <i>Cancer Imaging</i> , 2018, 18, 3.	1.2	45
292	Fast GPU-based Monte Carlo code for SPECT/CT reconstructions generates improved ¹⁷⁷ Lu images. <i>EJNMMI Physics</i> , 2018, 5, 1.	1.3	41
293	Impressive Response to Tandem Treatment With [⁹⁰ Y]DOTATOC and [¹⁷⁷ Lu]DOTATOC in Grade 3 Pancreatic Neuroendocrine Carcinoma. <i>Clinical Nuclear Medicine</i> , 2018, 43, 506-508.	0.7	3
294	The Ectopic Adrenocorticotrophic Hormone Syndrome. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 409-425.	1.2	56
295	Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics. <i>Theranostics</i> , 2018, 8, 369-383.	4.6	68
296	Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. <i>British Journal of Radiology</i> , 2018, 91, 20180108.	1.0	27
297	Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. <i>Frontiers in Endocrinology</i> , 2018, 9, 515.	1.5	82
298	Subcellular Targeting of Theranostic Radionuclides. <i>Frontiers in Pharmacology</i> , 2018, 9, 996.	1.6	67
299	Economic analysis of inadequate symptom control in carcinoid syndrome in the United States. <i>Future Oncology</i> , 2018, 14, 2361-2370.	1.1	7
300	Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications. <i>Annals of Nuclear Medicine</i> , 2018, 32, 512-522.	1.2	37
301	Nuclear medicine in the era of personalised medicine. <i>Internal Medicine Journal</i> , 2018, 48, 497-499.	0.5	2

#	ARTICLE	IF	CITATIONS
302	Peptide Receptor Radiotherapy Comes of Age. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 615-625.	1.2	7
303	Current Chemotherapy Use in Neuroendocrine Tumors. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 603-614.	1.2	12
304	Gastrinomas. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 577-601.	1.2	58
305	The NETest. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 485-504.	1.2	91
306	The Genesis of the Neuroendocrine Tumors Concept. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 711-731.	1.2	17
307	The clinical applications of The Cancer Genome Atlas project for bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2018, 18, 973-980.	1.1	12
308	Lung and Thymic Carcinoids. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018, 47, 699-709.	1.2	7
309	SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival. <i>Endocrine</i> , 2018, 62, 639-647.	1.1	9
310	Molecular imaging and molecular diagnostics: two sides of the same coin?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1645-1648.	3.3	6
311	NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 693-702.	2.3	289
313	Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE in Carcinoid Heart Disease: A Contraindication or a Promising Treatment Approach Bettering Chances for Corrective Surgery?. <i>Journal of Nuclear Medicine Technology</i> , 2018, 46, 292-294.	0.4	5
314	Ectopic Cushing syndrome: Report of 9 cases. <i>Endocrinology & Diabetes & Nutrition (English Ed)</i> , 2018, 65, 255-264.	0.1	0
315	Peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTA-TATE as a promising treatment of malignant insulinoma: a series of case reports and literature review. <i>Journal of Endocrinological Investigation</i> , 2019, 42, 249-260.	1.8	26
316	⁶⁸ Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. <i>Journal of Nuclear Medicine</i> , 2019, 60, 386-392.	2.8	468
317	Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 148-163.	2.3	60
318	Advancing Targeted Radionuclide Therapy Through the National Cancer Institute's Small Business Innovation Research Pathway. <i>Journal of Nuclear Medicine</i> , 2019, 60, 41-49.	2.8	10
319	Twelve-Year Follow-up After Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 524-529.	2.8	28
320	Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients. <i>Journal of Nuclear Medicine</i> , 2019, 60, 377-385.	2.8	81

#	ARTICLE	IF	CITATIONS
321	Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy. <i>Molecular Imaging and Biology</i> , 2019, 21, 582-590.	1.3	62
322	Evaluation of the Interaction of Amino Acid Infusion on ¹⁷⁷ Lu-Dotatate Pharmacokinetics in Patients with Gastroenteropancreatic Neuroendocrine Tumors. <i>Clinical Pharmacokinetics</i> , 2019, 58, 213-222.	1.6	7
323	Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival With or Without Liver Treatment. <i>Annals of Surgery</i> , 2019, 270, 1131-1137.	2.1	57
324	Somatostatin analogs in association with peptide receptor radionucleotide therapy in advanced well-differentiated NETs. <i>Future Oncology</i> , 2019, 15, 3015-3024.	1.1	3
325	Management of Well-Differentiated High-Grade (G3) Neuroendocrine Tumors. <i>Current Treatment Options in Oncology</i> , 2019, 20, 74.	1.3	17
326	Induction and rejoining of DNA double-strand breaks in the lymphocytes of prostate cancer patients after radium-223 treatment as assessed by the ¹²⁵ I-H2AX foci assay. <i>Nuklearmedizin - NuclearMedicine</i> , 2019, 58, 387-394.	0.3	2
327	Neuroendocrine Tumors in Pediatrics. <i>Global Pediatric Health</i> , 2019, 6, 2333794X1986271.	0.3	12
328	FDG PET imaging in large vessel vasculitis: Stuck at the first hurdle?. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1357-1360.	0.9	0
329	Hepatic micrometastases outside macrometastases are present in all patients with ileal neuroendocrine primary tumour at the time of liver resection. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1003-1007.	0.6	8
330	Salvage PRRT with ¹⁷⁷ Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival. <i>BMC Cancer</i> , 2019, 19, 788.	1.1	64
331	Personalized kidney dosimetry in ¹⁷⁷ Lu-octreotate treatment of neuroendocrine tumours: a comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations. <i>Physics in Medicine and Biology</i> , 2019, 64, 175004.	1.6	8
332	Intra-Arterial Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor Liver Metastases. <i>Digestive Disease Interventions</i> , 2019, 03, 081-090.	0.3	9
333	Palliative Radiation Therapy for Bone Metastases in Neuroendocrine Neoplasms. <i>Advances in Radiation Oncology</i> , 2019, 4, 513-519.	0.6	12
334	Systemic treatment for lung carcinoids: from bench to bedside. <i>Clinical and Translational Medicine</i> , 2019, 8, 22.	1.7	15
335	EANM procedure guidelines for radionuclide therapy with ¹⁷⁷ Lu-labelled PSMA-ligands (¹⁷⁷ Lu-PSMA-RLT). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2536-2544.	3.3	265
336	Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a ¹⁷⁷ Lu-DOTATATE patient study. <i>Physics in Medicine and Biology</i> , 2019, 64, 175006.	1.6	26
337	The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1065-1069.	5.1	54
338	From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 422-437.	2.5	30

#	ARTICLE	IF	CITATIONS
339	Carcinoid Syndrome: Updates and Review of Current Therapy. <i>Current Treatment Options in Oncology</i> , 2019, 20, 70.	1.3	16
340	Chelators and metal complex stability for radiopharmaceutical applications. <i>Radiochimica Acta</i> , 2019, 107, 1087-1120.	0.5	35
341	Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy. <i>Scientific Reports</i> , 2019, 9, 10634.	1.6	53
342	Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers—Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT. <i>Journal of Clinical Medicine</i> , 2019, 8, 1060.	1.0	20
343	Quality of life in patients with midgut NET following peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2252-2259.	3.3	20
344	Targeted Radionuclide Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma: From Low-Specific-Activity to High-Specific-Activity Iodine-131 Metaiodobenzylguanidine. <i>Cancers</i> , 2019, 11, 1018.	1.7	54
345	Prognostic value of somatostatin receptor expressing tumor volume calculated from ⁶⁸ Ga-DOTATATE PET/CT in patients with well-differentiated neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2244-2251.	3.3	43
346	The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. <i>Current Treatment Options in Oncology</i> , 2019, 20, 72.	1.3	7
347	Lutathera®: The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy. <i>Pharmaceuticals</i> , 2019, 12, 114.	1.7	218
348	Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3049.	1.8	110
349	Long-Term Effect of ¹⁷⁷ Lu-Dotatate on Severe and Refractory Hypoglycemia Associated with Malignant Insulinoma. <i>AACE Clinical Case Reports</i> , 2019, 5, e330-e333.	0.4	6
350	NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2019, 60, 937-943.	2.8	95
351	PET/CT for Evaluation of Ovarian Cancer. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 484-492.	2.5	35
352	Molecular radionuclide imaging of pancreatic neoplasms. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 559-570.	3.7	15
353	Novel Target Selection for Nuclear Medicine Studies. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 357-368.	2.5	12
354	¹⁷⁷ Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1023-1031.	1.4	60
355	Peptide receptor radionuclide therapy plus somatostatin analogues for a neuroendocrine tumour combined and maintenance treatment. <i>Clinical and Translational Imaging</i> , 2019, 7, 373-376.	1.1	5
356	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. <i>Pancreatology</i> , 2019, 19, 1067-1073.	0.5	15

#	ARTICLE	IF	CITATIONS
357	Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4949.	1.8	15
358	<p>Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 7537-7556.	0.9	3
359	Merkel Cell Carcinoma – Current Controversies and Future Directions. <i>Clinical Oncology</i> , 2019, 31, 789-796.	0.6	15
360	Current Management of Pheochromocytoma/Paraganglioma: A Guide for the Practicing Clinician in the Era of Precision Medicine. <i>Cancers</i> , 2019, 11, 1505.	1.7	120
361	Management of Gastrointestinal Neuroendocrine Tumors. <i>Clinical Medicine Insights: Endocrinology and Diabetes</i> , 2019, 12, 117955141988405.	1.0	42
362	Letter to the Editor: “The Inflammation-Based Index Can Predict Response and Improve Patient Selection in NETs Treated With PRRT: A Pilot Study” <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 5104-5105.	1.8	1
363	Non-Pharmacological Therapeutic Options for Liver Metastases in Advanced Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2019, 8, 1907.	1.0	20
364	Gemcitabine potentiates the anti-tumour effect of radiation on medullary thyroid cancer. <i>PLoS ONE</i> , 2019, 14, e0225260.	1.1	7
366	Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. <i>Endocrine Reviews</i> , 2019, 40, 1573-1604.	8.9	196
367	Eastern Canadian Gastrointestinal Cancer Consensus Conference 2018. <i>Current Oncology</i> , 2019, 26, 665-681.	0.9	2
369	“Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis” <i>Clinical Endocrinology</i> , 2019, 91, 718-727.	1.2	71
370	Clinical trials in molecular radiotherapy – Tribulations and Triumphs Report of the NCRI CTRad meeting held at the Lift Islington, 8 June 2018. <i>British Journal of Radiology</i> , 2019, 92, 20190117.	1.0	1
371	What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?. <i>Korean Journal of Radiology</i> , 2019, 20, 5.	1.5	79
372	Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1926-1936.	1.9	37
373	Radiation precautions for inpatient and outpatient ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours. <i>EJNMMI Physics</i> , 2019, 6, 7.	1.3	33
374	Production and characterization of no-carrier-added ¹⁶¹ Tb as an alternative to the clinically-applied ¹⁷⁷ Lu for radionuclide therapy. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 12.	1.8	56
376	Transcriptional effects of ¹⁷⁷ Lu-octreotate therapy using a priming treatment schedule on GOT1 tumor in nude mice. <i>EJNMMI Research</i> , 2019, 9, 28.	1.1	3
377	Treatment strategies for neuroendocrine liver metastases: an update. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 327-335.	0.5	4

#	ARTICLE	IF	CITATIONS
378	Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist ¹⁷⁷ Lu-Satoreotide Tetraxetan. <i>Clinical Cancer Research</i> , 2019, 25, 6939-6947.	3.2	69
379	The Future of Nuclear Medicine as an Independent Specialty. <i>Journal of Nuclear Medicine</i> , 2019, 60, 3S-12S.	2.8	47
380	Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2019, 60, 13S-19S.	2.8	172
381	Nuclear Medicine and Wall Street: An Evolving Relationship. <i>Journal of Nuclear Medicine</i> , 2019, 60, 20S-24S.	2.8	29
382	Exploring Tumor Heterogeneity Using PET Imaging: The Big Picture. <i>Cancers</i> , 2019, 11, 1282.	1.7	43
383	Molecular imaging of bacterial infections: Overcoming the barriers to clinical translation. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	99
384	Peptide Receptor Radiotherapy: Current Approaches and Future Directions. <i>Current Treatment Options in Oncology</i> , 2019, 20, 77.	1.3	40
385	Molecular Imaging and Therapy for Neuroendocrine Tumors. <i>Current Treatment Options in Oncology</i> , 2019, 20, 78.	1.3	46
386	The in vivo fate of ²²⁵ Ac daughter nuclides using polymersomes as a model carrier. <i>Scientific Reports</i> , 2019, 9, 11671.	1.6	52
387	Insights into the biology and treatment strategies of pancreatic neuroendocrine tumors. <i>Annals of Pancreatic Cancer</i> , 2019, 2, 12-12.	1.2	14
388	Therapy of Patients with Neuroendocrine Neoplasia—Evidence-Based Approaches and New Horizons. <i>Journal of Clinical Medicine</i> , 2019, 8, 1474.	1.0	8
389	Integrating Early Rapid Post-peptide Receptor Radionuclide Therapy Quality Assurance Scan into the Outpatient Setting. <i>Journal of Nuclear Medicine & Radiation Therapy</i> , 2019, 10, .	0.2	4
390	⁶⁸ Ga-DOTATATE PET/CT parameters predict response to peptide receptor radionuclide therapy in neuroendocrine tumours. <i>Radiotherapy and Oncology</i> , 2019, 141, 108-115.	0.3	62
392	ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals. <i>Annals of the ICRP</i> , 2019, 48, 5-95.	3.0	45
394	Management of Small Bowel Neuroendocrine Tumors. <i>Cancers</i> , 2019, 11, 1395.	1.7	25
395	PET/MRI for neuroendocrine tumors: a match made in heaven or just another hype?. <i>Clinical and Translational Imaging</i> , 2019, 7, 405-413.	1.1	15
396	Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7014-7023.	3.2	47
397	Nuclear Theranostics in Asia: In vivo Companion Diagnostics. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 1-6.	0.6	4

#	ARTICLE	IF	CITATIONS
398	A Care Process Model to Deliver ¹⁷⁷ Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 663.	1.3	4
399	Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. <i>Seminars in Nuclear Medicine</i> , 2019, 49, 237-243.	2.5	64
400	Perspectives for Concepts of Individualized Radionuclide Therapy, Molecular Radiotherapy, and Theranostic Approaches. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 167-171.	0.6	9
401	Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 569-576.	0.9	20
402	Evaluation and Management of Neuroendocrine Tumors of the Pancreas. <i>Surgical Clinics of North America</i> , 2019, 99, 793-814.	0.5	69
403	Inversion 16 (inv(16)) acute myeloid leukemia (AML) following treatment with radiation, capecitabine, and temozolomide in a patient with metastatic neuroendocrine tumor (NET). <i>Leukemia and Lymphoma</i> , 2019, 60, 2793-2797.	0.6	3
404	Treatment Options for Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2019, 11, 828.	1.7	55
405	Novel Molecular Probes. , 2019, , 315-346.		0
406	Interaction between somatostatin analogues and targeted therapies in neuroendocrine tumor cells. <i>PLoS ONE</i> , 2019, 14, e0218953.	1.1	10
407	Implementing f-Block Metal Ions in Medicine: Tuning the Size Selectivity of Expanded Macrocycles. <i>Inorganic Chemistry</i> , 2019, 58, 10483-10500.	1.9	55
408	Current status of SSR-directed imaging and therapy in meningioma. <i>Clinical and Translational Imaging</i> , 2019, 7, 171-180.	1.1	5
410	The association of intra-therapeutic heterogeneity of somatostatin receptor expression with morphological treatment response in patients undergoing PRRT with [¹⁷⁷ Lu]-DOTATATE. <i>PLoS ONE</i> , 2019, 14, e0216781.	1.1	14
411	Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. , 2019, , 43-64.		0
412	Clinical characteristics, treatment outcomes and potential novel therapeutic options for patients with neuroendocrine carcinoma of the prostate. <i>Oncotarget</i> , 2019, 10, 17-29.	0.8	21
413	Treatments for patients with advanced neuroendocrine tumors: a network meta-analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985367.	1.4	7
414	Nuclear Medicine Theranostics: Between Atoms and Patients. , 2019, , 1-9.		3
415	The next era of renal radionuclide imaging: novel PET radiotracers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1773-1786.	3.3	32
416	Will ¹⁷⁷ Lu-DOTATATE Treatment Become More Effective in Salvage Meningioma Patients, When Boosting Somatostatin Receptor Saturation? A Promising Case on Intra-arterial Administration. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1649-1652.	0.9	17

#	ARTICLE	IF	CITATIONS
417	Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1902-1910.	3.3	37
418	<i>Nuclear Medicine Therapy</i> , 2019, , .		5
419	Call to arms: need for radiobiology in molecular radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1588-1590.	3.3	23
420	Surgery for Gastroenteropancreatic Neuroendocrine Tumor Liver Metastases. <i>Digestive Disease Interventions</i> , 2019, 03, 030-037.	0.3	0
421	Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety. <i>Molecules</i> , 2019, 24, 1855.	1.7	68
422	Peptide receptor radionuclide therapy after NETTER-1 clinical trial: what should not be left behind. <i>Clinical and Translational Imaging</i> , 2019, 7, 155-157.	1.1	2
423	Therapy With ¹⁷⁷ Lu-DOTATATE: Clinical Implementation and Impact on Care of Patients With Neuroendocrine Tumors. <i>American Journal of Roentgenology</i> , 2019, 213, 309-317.	1.0	31
425	Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy. <i>Annales D'Endocrinologie</i> , 2019, 80, 166-171.	0.6	5
426	<i>Molecular Imaging Companion Diagnostics</i> , 2019, , 201-228.		2
427	Radiopharmaceuticals targeting PSMA for imaging and/or therapy. <i>Medecine Nucleaire</i> , 2019, 43, 284-286.	0.2	0
428	Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy. <i>Clinical Cancer Research</i> , 2019, 25, 4775-4790.	3.2	26
429	Safety and outcomes of ¹⁷⁷ Lu-DOTATATE for neuroendocrine tumours: experience in New South Wales, Australia. <i>Internal Medicine Journal</i> , 2019, 49, 1268-1277.	0.5	14
430	Gastrointestinal Neuroendocrine Tumors: Clinical and Pathological Correlates. <i>Digestive Disease Interventions</i> , 2019, 03, 003-013.	0.3	0
432	Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review. <i>Cureus</i> , 2019, 11, e3986.	0.2	19
433	Molecular imaging and therapy of somatostatin receptor positive tumors. <i>Clinical Imaging</i> , 2019, 56, 146-154.	0.8	28
434	Concomitant ¹⁷⁷ Lu-DOTATATE and capecitabine therapy in malignant paragangliomas. <i>EJNMMI Research</i> , 2019, 9, 13.	1.1	36
435	Expanding the Indication for Novel Theranostic ¹⁷⁷ Lu-Dotatate Peptide Receptor Radionuclide Therapy: Proof-of-Concept of PRRT in Merkel Cell Cancer. <i>Case Reports in Oncology</i> , 2019, 12, 98-103.	0.3	11
436	Systemic Treatment Options for Carcinoid Syndrome: A Systematic Review. <i>Oncology</i> , 2019, 96, 273-289.	0.9	13

#	ARTICLE	IF	CITATIONS
437	Encoded Library Technologies as Integrated Lead Finding Platforms for Drug Discovery. <i>Molecules</i> , 2019, 24, 1629.	1.7	71
438	Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2019, 73, 124.	0.2	2
439	How rapid advances in imaging are defining the future of precision radiation oncology. <i>British Journal of Cancer</i> , 2019, 120, 779-790.	2.9	69
440	¹¹¹ In-Pentetreotide Scintigraphy Versus ⁶⁸ Ga-DOTATATE PET: Impact on Krenning Scores and Effect of Tumor Burden. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1266-1269.	2.8	66
441	Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids. <i>Clinical Lung Cancer</i> , 2019, 20, e376-e392.	1.1	35
442	Symptomatic and Radiological Response to ¹⁷⁷ Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1336-1344.	1.8	95
443	Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response. <i>Cancers</i> , 2019, 11, 268.	1.7	34
444	Side Effects of CXC-Chemokine Receptor 4-directed Endoradiotherapy with Pentixather Before Hematopoietic Stem Cell Transplantation. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1399-1405.	2.8	37
445	Neuroendocrine Tumours. , 2019, , 1229-1257.		0
446	Clinical management of difficult to treat macroprolactinomas. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 179-192.	1.2	6
447	First experience of durable cytoreduction in chronic lymphoid leukemia with ¹⁷⁷ Lu-DOTATATE. <i>Medical Oncology</i> , 2019, 36, 41.	1.2	1
448	Bone Marrow Absorbed Doses and Correlations with Hematologic Response During ¹⁷⁷ Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1406-1413.	2.8	41
449	Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2019, 8, 403.	1.0	23
450	Parameters to Predict Progression-Free and Overall Survival After Peptide Receptor Radionuclide Therapy: A Multivariate Analysis in 782 Patients. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1259-1265.	2.8	27
451	Radiopharmaceuticals for Relapsed or Refractory Leukemias. <i>Frontiers in Oncology</i> , 2019, 9, 97.	1.3	3
452	Peptide Receptor Radionuclide Therapy as a Novel Treatment for Metastatic and Invasive Pheochromocytoma and Paraganglioma. <i>Neuroendocrinology</i> , 2019, 109, 287-298.	1.2	48
453	Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms. <i>Journal of Nuclear Medicine</i> , 2019, 60, 882-891.	2.8	19
454	Oncogene Panel Sequencing Analysis Identifies Candidate Actionable Genes in Advanced Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. <i>Endocrine Practice</i> , 2019, 25, 580-588.	1.1	9

#	ARTICLE	IF	CITATIONS
455	Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. <i>Endocrine</i> , 2019, 66, 417-424.	1.1	25
456	Novel PET tracers: added value for endocrine disorders. <i>Endocrine</i> , 2019, 64, 14-30.	1.1	23
457	Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls. <i>BMC Cancer</i> , 2019, 19, 325.	1.1	38
458	Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2019, 37, 834-849.	0.8	66
459	Theranostic Outcomes in Clinical Practice of Oncology: What, So What, Now What? What's More. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 135-140.	0.7	14
460	Radionuclide therapy targeting PSMA for the treatment of metastatic prostate cancer: Current point of view and ways of improvement. <i>Medecine Nucleaire</i> , 2019, 43, 275-279.	0.2	2
461	Multimodality Imaging of Ileal Neuroendocrine (Carcinoid) Tumor. <i>American Journal of Roentgenology</i> , 2019, 213, 45-53.	1.0	5
462	An Overview of Targeted Radiotherapy. , 2019, , 85-100.		5
463	Eruption of Metastatic Paraganglioma After Successful Therapy with 177Lu/90Y-DOTATOC and 177Lu-DOTATATE. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 223-230.	0.6	9
464	Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 1012-1021.	1.9	46
465	Pheochromocytomas and Paragangliomas: From Genetic Diversity to Targeted Therapies. <i>Cancers</i> , 2019, 11, 436.	1.7	33
466	Current management of neuroblastoma and future direction. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 138, 38-43.	2.0	60
467	Long-term control with chemoradiation of initially metastatic mixed adenoneuroendocrine carcinoma of the rectum: a case report. <i>Journal of Medical Case Reports</i> , 2019, 13, 82.	0.4	8
468	Novel Structured Reporting Systems for Theranostic Radiotracers. <i>Journal of Nuclear Medicine</i> , 2019, 60, 577-584.	2.8	24
469	Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1240-1246.	2.8	35
470	Current Status and Growth of Nuclear Theranostics in Singapore. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 96-101.	0.6	1
471	Caring for Patients Receiving 177Lu-DOTATATE, Lutathera®: A Treatment of Hope for Patients With Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Radiology Nursing</i> , 2019, 38, 28-32.	0.2	6
472	Systemic treatment of pancreatic neuroendocrine tumors. <i>Surgical Practice</i> , 2019, 23, 48-58.	0.1	0

#	ARTICLE	IF	CITATIONS
473	Nuclear Medicine Theranostics: Perspective from Pakistan. Nuclear Medicine and Molecular Imaging, 2019, 53, 38-41.	0.6	1
474	Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances. Journal of Nuclear Medicine, 2019, 60, 721-727.	2.8	15
475	Perspectives in Radiomics for Personalized Medicine and Theranostics. Nuclear Medicine and Molecular Imaging, 2019, 53, 164-166.	0.6	11
476	Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. Hpb, 2019, 21, 773-783.	0.1	31
477	Abdominal Manifestations of Neuroendocrine Tumors. Digestive Disease Interventions, 2019, 03, 014-029.	0.3	1
478	Systemic Therapy for Neuroendocrine Neoplasms. Digestive Disease Interventions, 2019, 03, 063-070.	0.3	0
479	Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors. Digestive Disease Interventions, 2019, 03, 071-080.	0.3	0
480	Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors. JAMA Oncology, 2019, 5, 489.	3.4	2
481	Therapeutic Options for Neuroendocrine Tumors. JAMA Oncology, 2019, 5, 480.	3.4	67
483	Assessment of NETest Clinical Utility in a U.S. Registry-Based Study. Oncologist, 2019, 24, 783-790.	1.9	57
484	Meta-Analysis of Randomized Clinical Trials Comparing Active Treatment with Placebo in Metastatic Neuroendocrine Tumors. Oncologist, 2019, 24, e1315-e1320.	1.9	8
485	Treatment of Gastroenteropancreatic Neuroendocrine Tumors. Surgical Pathology Clinics, 2019, 12, 1045-1053.	0.7	11
486	7. Maligne Erkrankungen Des Gastrointestinaltrakts. , 2019, , 145-192.		0
488	Excellent Response to 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in a Patient With Progressive Metastatic Castration-Resistant Prostate Cancer With Neuroendocrine Differentiation After 177Lu-PSMA Therapy. Clinical Nuclear Medicine, 2019, 44, 876-878.	0.7	11
489	Role of Serial 68Ga DOTANOC PET-CT Scans in Follow-up of Metastatic Bronchial Carcinoid. Clinical Nuclear Medicine, 2019, 44, 602-603.	0.7	1
490	Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors. Current Treatment Options in Oncology, 2019, 20, 87.	1.3	2
491	<p>A Patient-Reported Outcomes Analysis Of Lanreotide In The Treatment Of NETs Patients With Carcinoid Syndrome: Evidence From The ELECT Trial</p>. Patient Related Outcome Measures, 2019, Volume 10, 335-343.	0.7	3
492	Clinical Outcome Assessments Toolbox for Radiopharmaceuticals. Frontiers in Oncology, 2019, 9, 1028.	1.3	1

#	ARTICLE	IF	CITATIONS
493	177Lu-DOTATATE peptide receptor radionuclide therapy versus Everolimus in advanced pancreatic neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2019, 40, 1195-1203.	0.5	28
494	Eighty per cent more patients in 10 years of UK molecular radiotherapy. <i>Nuclear Medicine Communications</i> , 2019, 40, 657-661.	0.5	10
495	Metastatic or locally advanced mediastinal neuroendocrine tumours. <i>Nuclear Medicine Communications</i> , 2019, 40, 947-957.	0.5	8
496	Efficacy of 177Lu Peptide Receptor Radionuclide Therapy for the Treatment of Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2019, 44, 719-727.	0.7	23
497	Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms. <i>Annals of Surgery</i> , 2021, 274, e45-e53.	2.1	22
499	Early Prediction of Treatment Response of Neuroendocrine Hepatic Metastases after Peptide Receptor Radionuclide Therapy with ⁹⁰ Y-DOTATOC Using Diffusion Weighted and Dynamic Contrast-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-12.	0.4	15
500	Radiopharmaceutical Therapy. <i>Health Physics</i> , 2019, 116, 175-178.	0.3	19
501	Safety and Efficacy of Combined Peptide Receptor Radionuclide Therapy and Liver Selective Internal Radiation Therapy in a Patient With Metastatic Neuroendocrine Tumor. <i>Clinical Nuclear Medicine</i> , 2019, 44, e286-e288.	0.7	6
502	Metastatic Insulinoma Controlled by Targeted Radionuclide Therapy With 177Lu-DOTATATE in a Patient With Solitary Kidney and MEN-1 Syndrome. <i>Clinical Nuclear Medicine</i> , 2019, 44, e415-e417.	0.7	6
503	Perspective of neo-adjuvant/conversion and adjuvant therapy for pancreatic neuroendocrine tumors. <i>Journal of Pancreatology</i> , 2019, 2, 91-99.	0.3	4
504	Management of Diarrhea in Patients With Carcinoid Syndrome. <i>Pancreas</i> , 2019, 48, 961-972.	0.5	31
505	Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2019, 44, e329-e335.	0.7	47
506	Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors. <i>Pancreas</i> , 2019, 48, 948-952.	0.5	14
507	Management of Aggressive Pituitary Tumors – A 2019 Update. <i>Hormone and Metabolic Research</i> , 2019, 51, 755-764.	0.7	16
508	Role of Adjuvant Chemotherapy in Pulmonary Carcinoids: An NCDB Analysis. <i>Anticancer Research</i> , 2019, 39, 6835-6842.	0.5	16
509	Delayed Response (Partial Remission) 3 Years After Peptide Receptor Radionuclide Therapy in a Patient Participating in the NETTER-1 Trial. <i>Clinical Nuclear Medicine</i> , 2019, 44, 223-226.	0.7	8
510	Current Treatment Options in Gastroenteropancreatic Neuroendocrine Carcinoma. <i>Oncologist</i> , 2019, 24, 1076-1088.	1.9	18
512	Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2019, 108, 18-25.	1.2	9

#	ARTICLE	IF	CITATIONS
513	The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types. <i>Oncologist</i> , 2019, 24, 54-61.	1.9	6
514	Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. <i>Drugs</i> , 2019, 79, 21-42.	4.9	54
515	Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus. <i>Journal of Nuclear Medicine</i> , 2019, 60, 7-8.	2.8	10
516	New Developments in Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 167-171.	2.8	41
517	Current best practice in the management of neuroendocrine tumors. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , 2019, 10, 204201881880469.	1.4	38
518	Integrating molecular nuclear imaging in clinical research to improve anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 241-255.	12.5	56
519	Impact of Tumor Burden on Quantitative [⁶⁸ Ga] DOTATOC Biodistribution. <i>Molecular Imaging and Biology</i> , 2019, 21, 790-798.	1.3	10
520	The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms. <i>Annals of Nuclear Medicine</i> , 2019, 33, 147-152.	1.2	6
521	Management of NETs in the Precision Medicine Era. , 2019, , 575-589.		0
522	⁶⁴ Cu-SARTATE PET Imaging of Patients with Neuroendocrine Tumors Demonstrates High Tumor Uptake and Retention, Potentially Allowing Prospective Dosimetry for Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2019, 60, 777-785.	2.8	98
523	Characterization of somatostatin receptors (SSTRs) expression and antiproliferative effect of somatostatin analogues in aggressive thyroid cancers. <i>Surgery</i> , 2019, 165, 64-68.	1.0	15
524	Tumor Lysis Syndrome: A Rare but Serious Complication of Radioligand Therapies. <i>Journal of Nuclear Medicine</i> , 2019, 60, 752-755.	2.8	17
525	Radiotheranostics with radiolanthanides: Design, development strategies, and medical applications. <i>Coordination Chemistry Reviews</i> , 2019, 383, 104-131.	9.5	35
526	The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 101-108.	1.3	12
527	Radioembolization with ⁹⁰ Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 413-425.	0.9	70
528	Metformin Reduces Renal Uptake of Radiotracers and Protects Kidneys from Radiation-Induced Damage. <i>Molecular Pharmaceutics</i> , 2019, 16, 808-815.	2.3	12
529	Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies. <i>Bioconjugate Chemistry</i> , 2019, 30, 487-502.	1.8	73
530	Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives. <i>Annals of Nuclear Medicine</i> , 2019, 33, 244-251.	1.2	6

#	ARTICLE	IF	CITATIONS
532	Effective cytoreduction can be achieved in patients with numerous neuroendocrine tumor liver metastases (NETLMs). <i>Surgery</i> , 2019, 165, 166-175.	1.0	68
533	Targeted Alpha Particle Therapy for Neuroendocrine Tumours: The Next Generation of Peptide Receptor Radionuclide Therapy. <i>Neuroendocrinology</i> , 2019, 108, 256-264.	1.2	73
534	Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 718-727.	3.3	17
535	Neurotheranostics as personalized medicines. <i>Advanced Drug Delivery Reviews</i> , 2019, 148, 252-289.	6.6	63
536	Surgery Provides Long-Term Survival in Patients with Metastatic Neuroendocrine Tumors Undergoing Resection for Non-Hormonal Symptoms. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 122-134.	0.9	22
537	Radioactive Main Group and Rare Earth Metals for Imaging and Therapy. <i>Chemical Reviews</i> , 2019, 119, 902-956.	23.0	293
538	Liver Cancers. , 2019, , .		2
539	SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic and bronchial neuroendocrine neoplasms (NENs) (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 55-63.	1.2	17
540	A Patient With an Elevated α -Fetoprotein Level and Liver Masses. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 97.	3.8	2
541	Treatment of aggressive recurrent meningiomas: spinning towards peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 537-538.	3.3	8
542	Noninvasive Monitoring of Suicide Gene Therapy by Using Multimodal Molecular Imaging. <i>Methods in Molecular Biology</i> , 2019, 1895, 123-134.	0.4	2
543	Current Status of Theranostics in Jordan. <i>Nuclear Medicine and Molecular Imaging</i> , 2019, 53, 7-10.	0.6	8
544	Transition metal compounds as cancer radiosensitizers. <i>Chemical Society Reviews</i> , 2019, 48, 540-557.	18.7	89
545	Personalized ^{177}Lu -octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 728-742.	3.3	109
546	Recent advances in the diagnosis and management of pancreatic neuroendocrine tumours. <i>Frontline Gastroenterology</i> , 2019, 10, 269-274.	0.9	8
547	Metastatic Pheochromocytoma: Spinning Towards More Promising Treatment Options. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2019, 127, 117-128.	0.6	40
548	Liver Resection for Neuroendocrine Tumor Liver Metastases Within Milan Criteria for Liver Transplantation. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 93-100.	0.9	20
549	Salvage peptide receptor radionuclide therapy with [^{177}Lu -DOTA,Tyr 3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 704-717.	3.3	90

#	ARTICLE	IF	CITATIONS
550	Radiation protection in therapy with radiopharmaceuticals. <i>International Journal of Radiation Biology</i> , 2019, 95, 1427-1430.	1.0	4
551	Treatment challenges in and outside a network setting: Gastrointestinal neuroendocrine tumours. <i>European Journal of Surgical Oncology</i> , 2019, 45, 52-59.	0.5	18
552	Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. <i>Tumori</i> , 2019, 105, 113-120.	0.6	9
553	Very high specific activity erbium 169Er production for potential receptor-targeted radiotherapy. <i>Nuclear Instruments & Methods in Physics Research B</i> , 2020, 463, 468-471.	0.6	17
554	Ca ²⁺ Channel Toolkit in Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2020, 110, 147-154.	1.2	2
555	Non-Invasive Imaging Methodologies for Assessment of Radiation Damage to Bone Marrow and Kidneys from Peptide Receptor Radionuclide Therapy. <i>Neuroendocrinology</i> , 2020, 110, 130-138.	1.2	4
556	Advances in the Diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. <i>Endocrine Reviews</i> , 2020, 41, 371-403.	8.9	116
557	Neuroendocrine Neoplasms of the Small Bowel and Pancreas. <i>Neuroendocrinology</i> , 2020, 110, 444-476.	1.2	70
558	Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 194-200.	1.8	32
559	Radioembolization with 90Y Resin Microspheres of Neuroendocrine Liver Metastases After Initial Peptide Receptor Radionuclide Therapy. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 246-253.	0.9	37
560	Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 38-52.	2.0	50
561	Elderly Patients with Metastatic Neuroendocrine Tumors Are Undertreated and Have Shorter Survival: The LyREMeNET Study. <i>Neuroendocrinology</i> , 2020, 110, 653-661.	1.2	6
562	ALPPS in neuroendocrine liver metastases not amenable for conventional resection – lessons learned from an interim analysis of the International ALPPS Registry. <i>Hpb</i> , 2020, 22, 537-544.	0.1	43
563	Liver Transplantation and Hepatobiliary Surgery. <i>Updates in Surgery Series</i> , 2020, , .	0.0	0
564	The functioning side of the pancreas: a review on insulinomas. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 139-148.	1.8	32
565	Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 881-894.	3.3	47
566	Early Outcomes of Surgery for Carcinoid Heart Disease. <i>Heart Lung and Circulation</i> , 2020, 29, 742-747.	0.2	12
567	Management of Ileal Neuroendocrine Tumors with Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1530-1539.	0.9	11

#	ARTICLE	IF	CITATIONS
568	Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 907-921.	3.3	21
569	Prognostic and predictive value of nuclear imaging in endocrine oncology. <i>Endocrine</i> , 2020, 67, 9-19.	1.1	9
570	Comment on the Paper by Lemelin et al. Entitled "Elderly Patients with Metastatic Neuroendocrine Tumors Are Undertreated and Have Shorter Survival: The LyREMeNET Study". <i>Neuroendocrinology</i> , 2020, 110, 721-722.	1.2	0
571	Broadening horizons with ²²⁵ Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to ¹⁷⁷ Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 934-946.	3.3	115
572	Head-to-Head Comparison of ⁶⁸ Ga-DOTA-JR11 and ⁶⁸ Ga-DOTATATE PET/CT in Patients with Metastatic, Well-Differentiated Neuroendocrine Tumors: A Prospective Study. <i>Journal of Nuclear Medicine</i> , 2020, 61, 897-903.	2.8	46
573	Prolonged response to ¹⁷⁷ Lu-DOTATATE therapy of a bone marrow infiltration in a refractory thymic neuro endocrine tumor. <i>Investigational New Drugs</i> , 2020, 38, 1196-1199.	1.2	0
574	Development or maintenance? Dual-oriented human resource system, employee achievement motivation, and work well-being. <i>Human Resource Management</i> , 2020, 59, 311-325.	3.5	21
575	¹⁷⁷ Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2020, 110, 662-670.	1.2	34
576	Advances in the Diagnosis and Management of Nonfunctional Pancreatic Neuroendocrine Tumors. , 2020, , 221-232.		0
577	Theranostics: Leveraging Molecular Imaging and Therapy to Impact Patient Management and Secure the Future of Nuclear Medicine. <i>Journal of Nuclear Medicine</i> , 2020, 61, 311-318.	2.8	40
578	Particle filter de-noising of voxel-specific time-activity-curves in personalized ¹⁷⁷ Lu therapy. <i>Zeitschrift Fur Medizinische Physik</i> , 2020, 30, 116-134.	0.6	2
579	Indium-111 labelling of liposomal HEGF for radionuclide delivery via ultrasound-induced cavitation. <i>Journal of Controlled Release</i> , 2020, 319, 222-233.	4.8	9
580	The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 1-33.	0.5	226
581	A growth model of neuroendocrine tumor surrogates and the efficacy of a novel somatostatin-receptor-guided antibody-drug conjugate: Perspectives on clinical response?. <i>Surgery</i> , 2020, 167, 197-203.	1.0	4
582	Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: A step-by-step approach. <i>European Journal of Radiology</i> , 2020, 122, 108743.	1.2	8
583	Twelve-Year Survival of a Patient With Lymph Node, Pulmonary, Bone, Cardiac and Intraspinal Metastases of a Rectal Neuroendocrine Neoplasm Treated With Peptide Receptor Radionuclide Therapy "The Value of Salvage Peptide Receptor Radionuclide Therapy. <i>Clinical Nuclear Medicine</i> , 2020, 45, e198-e200.	0.7	1
585	Comparison of ⁶⁸ Ga-Dotatate PET/CT and ¹⁸ F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient. <i>Annales D'Endocrinologie</i> , 2020, 81, 39-43.	0.6	1
586	Inflammation-Based Index and ⁶⁸ Ga-DOTATOC PET "Derived Uptake and Volumetric Parameters Predict Outcome in Neuroendocrine Tumor Patients Treated with ⁹⁰ Y-DOTATOC. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1014-1020.	2.8	28

#	ARTICLE	IF	CITATIONS
587	Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 145, 102835.	2.0	35
588	New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 183-191.	0.9	9
589	The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. <i>Advances in Medical Sciences</i> , 2020, 65, 18-29.	0.9	38
590	Renal Neuroendocrine Neoplasms: A Single-center Experience. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e343-e349.	0.9	14
591	Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?. <i>Human Pathology</i> , 2020, 96, 8-33.	1.1	114
592	¹⁸ F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging. <i>Theranostics</i> , 2020, 10, 1-16.	4.6	117
593	Endocrinological Toxicity Secondary to Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Trends in Endocrinology and Metabolism</i> , 2020, 31, 239-255.	3.1	8
594	ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors. <i>Theranostics</i> , 2020, 10, 151-165.	4.6	23
595	PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 895-906.	3.3	73
596	NEN: Advancement in Diagnosis and Minimally Invasive Therapy. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2020, 192, 422-430.	0.7	5
597	Preliminary Studies of ¹⁷⁷ Lu-Diethylenetriamine Penta-Acetic Acid-Deoxyglucose in Hepatic Tumor-Bearing Mice. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 33-40.	0.7	3
598	Imaging DNA Damage Repair In Vivo After ¹⁷⁷ Lu-DOTATATE Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 743-750.	2.8	33
599	Evaluation of [⁶⁸ Ga]Ga-DATA-TOC for imaging of neuroendocrine tumours: comparison with [⁶⁸ Ga]Ga-DOTA-NOC PET/CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 860-869.	3.3	14
600	Molecular imaging and radionuclide therapy of neuroendocrine tumors. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 16-21.	1.2	7
601	¹⁷⁷ Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1187-1194.	2.8	20
602	Invited Commentary: Nuclear Theranostics—The Path Forward. <i>Radiographics</i> , 2020, 40, 1741-1742.	1.4	1
603	Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant ¹⁸ F-FDG Uptake. <i>Neuroendocrinology</i> , 2021, 111, 998-1004.	1.2	19
604	Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report. <i>BMC Gastroenterology</i> , 2020, 20, 324.	0.8	0

#	ARTICLE	IF	CITATIONS
605	PRRT: identikit of the perfect patient. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 563-579.	2.6	14
606	Neuroendocrine tumours: what gastroenterologists need to know. <i>Frontline Gastroenterology</i> , 2022, 13, 50-56.	0.9	8
607	Personalisation of Molecular Radiotherapy through Optimisation of Theragnostics. <i>Journal of Personalized Medicine</i> , 2020, 10, 174.	1.1	6
608	New frontiers in imaging including radiomics updates for pancreatic neuroendocrine neoplasms. <i>Abdominal Radiology</i> , 2022, 47, 3078-3100.	1.0	18
609	Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 495-510.	2.6	36
610	Timing of peptide receptor radiotargeted therapy in relation to cardiac valve surgery for carcinoid heart disease in patients with neuroendocrine metastases and cardiac syndrome. A single-centre study from a centre of excellence. <i>Nuclear Medicine Communications</i> , 2020, 41, 575-581.	0.5	3
611	Ga-68 DOTATATE PET/CT and F-18 FDG PET/CT in the evaluation of low and intermediate versus high-grade neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2020, 41, 1060-1065.	0.5	6
612	Recent developments and ongoing trials in transplant oncology. <i>Liver International</i> , 2020, 40, 2326-2344.	1.9	6
613	Neuroendocrine Tumors. <i>Radiologic Clinics of North America</i> , 2020, 58, 1161-1171.	0.9	3
614	Combination Strategies to Improve Targeted Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1544-1552.	2.8	42
615	Incidental primary breast cancer detected on surveillance 68Ga-DOTATATE PET/CT in a patient with metastatic neuroendocrine carcinoma. <i>Radiology Case Reports</i> , 2020, 15, 1344-1347.	0.2	6
616	Recent advances in clinical trial design considerations in Theragnostics. <i>Contemporary Clinical Trials</i> , 2020, 96, 106100.	0.8	4
617	Neutron-activated theranostic radionuclides for nuclear medicine. <i>Nuclear Medicine and Biology</i> , 2020, 90-91, 55-68.	0.3	21
618	Cost-effectiveness of Lutetium [177Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France. <i>Journal of Medical Economics</i> , 2020, 23, 1534-1541.	1.0	4
619	Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2317-2324.	0.9	0
620	Oncology-Inspired Treatment Options for COVID-19. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1720-1723.	2.8	15
621	Genetic and epigenetic alterations in pancreatic neuroendocrine tumors. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 567-577.	0.6	14
622	²³² Th-Spallation-Produced ²²⁵ Ac with Reduced ²²⁷ Ac Content. <i>Inorganic Chemistry</i> , 2020, 59, 12156-12165.	1.9	44

#	ARTICLE	IF	CITATIONS
623	Modern therapeutic approaches for the treatment of malignant liver tumours. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 755-772.	8.2	120
624	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 863-881.	0.5	88
625	A Ki-67 Index to Predict Treatment Response to the Capecitabine Temozolomide (CAPTEM) Regimen in Neuroendocrine Neoplasms: A Retrospective Multicenter Study. <i>Neuroendocrinology</i> , 2020, 111, 752-763.	1.2	16
626	Peptide-Drug Conjugates and Their Targets in Advanced Cancer Therapies. <i>Frontiers in Chemistry</i> , 2020, 8, 571.	1.8	143
627	Sequence of Therapy and Survival in Patients with Advanced Pancreatic Neuroendocrine Tumours. <i>Current Oncology</i> , 2020, 27, 215-219.	0.9	0
628	Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3655.	1.0	23
629	Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3679.	1.0	13
630	Liver Transplantation for Neuroendocrine Metastases. <i>Current Transplantation Reports</i> , 2020, 7, 317-323.	0.9	0
631	Light-Emitting Probes for Labeling Peptides. <i>Cell Reports Physical Science</i> , 2020, 1, 100257.	2.8	7
632	Carcinoid Heart Disease: How to Diagnose and Treat in 2020?. <i>Clinical Medicine Insights: Cardiology</i> , 2020, 14, 117954682096810.	0.6	9
633	New Bifunctional Chelator $3p\text{-C}_{10}$ -NEPA for Potential Applications in Lu(III) and Y(III) Radionuclide Therapy and Imaging. <i>ACS Omega</i> , 2020, 5, 28615-28620.	1.6	2
634	Management of refractory hypoglycaemia in a metastatic neuroendocrine tumour co-secreting serotonin and insulin. <i>BMJ Case Reports</i> , 2020, 13, e236659.	0.2	0
635	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). <i>Cancers</i> , 2020, 12, 1988.	1.7	12
636	Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival. <i>Journal of Clinical Medicine</i> , 2020, 9, 2502.	1.0	8
637	Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms. <i>Surgical Pathology Clinics</i> , 2020, 13, 377-397.	0.7	30
638	Somatostatin Receptor-Targeted Radioligand Therapy in Head and Neck Paraganglioma. <i>World Neurosurgery</i> , 2020, 143, e391-e399.	0.7	13
639	Successful and Safe Treatment With ^{177}Lu -DOTATATE (Lutathera) of Progressive Metastatic Pancreatic Neuroendocrine Tumor Under Hemodialysis. <i>Clinical Nuclear Medicine</i> , 2020, 45, e400-e402.	0.7	4
640	Neuroendocrine liver metastases: a contemporary review of treatment strategies. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 440-451.	0.7	37

#	ARTICLE	IF	CITATIONS
641	Radiopharmaceutical therapy in cancer: clinical advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 589-608.	21.5	370
642	Cardiac Metastases in Patients with Neuroendocrine Tumours: Clinical Features, Therapy Outcomes, and Prognostic Implications. <i>Neuroendocrinology</i> , 2021, 111, 907-924.	1.2	9
643	Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions. <i>Digestive Disease Interventions</i> , 2020, 04, 134-147.	0.3	3
644	DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage. <i>Cancers</i> , 2020, 12, 2098.	1.7	57
645	Image-Guided Interventions in Oncology. , 2020, , .		1
646	Surgery and Perioperative Management in Small Intestinal Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 2319.	1.0	15
647	Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1577-1598.	0.5	58
648	Neuroendocrine breast carcinoma: a rare but challenging entity. <i>Medical Oncology</i> , 2020, 37, 70.	1.2	27
649	Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain. <i>Journal of Clinical Medicine</i> , 2020, 9, 2622.	1.0	22
650	Tumour Biology Characterisation by Imaging in Clinic. <i>Medical Radiology</i> , 2020, , 325-360.	0.0	0
651	Clinicopathological Features of Gastroesophageal Neuroendocrine Neoplasms. <i>Current Gastroenterology Reports</i> , 2020, 22, 50.	1.1	1
652	Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy. <i>Cancer Imaging</i> , 2020, 20, 57.	1.2	31
654	First clinical study of a pegylated diabody ¹²⁴ I-labeled PEG-AVP0458 in patients with tumor-associated glycoprotein 72 positive cancers. <i>Theranostics</i> , 2020, 10, 11404-11415.	4.6	13
655	Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs). <i>Lung Cancer</i> , 2020, 150, 70-75.	0.9	26
656	HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target. <i>Surgical Oncology</i> , 2020, 35, 460-465.	0.8	1
657	Impact of dead time on quantitative ¹⁷⁷ Lu-SPECT (QSPECT) and kidney dosimetry during PRRT. <i>EJNMMI Physics</i> , 2020, 7, 32.	1.3	11
659	Advancements in Assay Technologies and Strategies to Enable Drug Discovery. <i>ACS Chemical Biology</i> , 2020, 15, 2636-2648.	1.6	16
660	Understanding the treatment algorithm of patients with metastatic pancreatic neuroendocrine neoplasms: A single-institution retrospective analysis comparing outcomes of chemotherapy, molecular targeted therapy and peptide receptor radionuclide therapy in 255 patients. <i>Neuroendocrinology</i> , 2020, 111, 863-875.	1.2	3

#	ARTICLE	IF	CITATIONS
661	Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 1489-1499.	5.1	94
662	Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2020, 21, 1500-1512.	5.1	106
663	Europium-Diethylenetriaminepentaacetic Acid Loaded Radioluminescence Liposome Nanoplatform for Effective Radioisotope-Mediated Photodynamic Therapy. <i>ACS Nano</i> , 2020, 14, 13004-13015.	7.3	41
664	Somatostatinoma and Neurofibromatosis Type 1-A Case Report and Review of the Literature. <i>Diagnostics</i> , 2020, 10, 620.	1.3	9
665	Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments. <i>Current Treatment Options in Oncology</i> , 2020, 21, 86.	1.3	6
666	Effect of Octreotide Long-Acting Release on Tregs and MDSC Cells in Neuroendocrine Tumour Patients: A Pivotal Prospective Study. <i>Cancers</i> , 2020, 12, 2422.	1.7	5
667	Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. <i>Lancet Oncology</i> , The, 2020, 21, e431-e443.	5.1	51
668	The future of radiotherapy is molecular. <i>Physical and Engineering Sciences in Medicine</i> , 2020, 43, 755-759.	1.3	3
669	Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 884.	1.1	32
670	Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 3807-3820.	1.8	16
671	¹⁷⁷ Lutetium SPECT/CT: Evaluation of collimator, photopeak and scatter correction. <i>Journal of Applied Clinical Medical Physics</i> , 2020, 21, 272-277.	0.8	13
672	Comparison of different calculation techniques for absorbed dose assessment in patient specific peptide receptor radionuclide therapy. <i>PLoS ONE</i> , 2020, 15, e0236466.	1.1	9
674	Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. <i>The Cochrane Library</i> , 0, , .	1.5	1
675	Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. <i>Molecules</i> , 2020, 25, 4012.	1.7	69
676	Phase 0 Radiopharmaceuticalâ€“Agent Clinical Development. <i>Frontiers in Oncology</i> , 2020, 10, 1310.	1.3	8
678	Phase I Study of P-cadherinâ€“targeted Radioimmunotherapy with 90Y-FF-21101 Monoclonal Antibody in Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5830-5842.	3.2	17
679	How I treat neuroendocrine tumours. <i>ESMO Open</i> , 2020, 5, e000811.	2.0	14
680	The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future. <i>Diagnostics</i> , 2020, 10, 1083.	1.3	23

#	ARTICLE	IF	CITATIONS
681	Evaluating cost-effectiveness in the management of neuroendocrine neoplasms. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 647-663.	2.6	3
682	Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors. <i>Diagnostics</i> , 2020, 10, 1059.	1.3	21
683	Laparoscopic Liver Transplantation. <i>Annals of Surgery</i> , 2020, 272, 894-896.	2.1	0
684	Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 3507.	1.0	17
685	Role of Diet in the Management of Carcinoid Syndrome: Clinical Recommendations for Nutrition in Patients with Neuroendocrine Tumors. <i>Nutrition and Cancer</i> , 2020, , 1-10.	0.9	4
686	Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. <i>Journal of Critical Care</i> , 2020, 60, 319-322.	1.0	3
687	Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT). <i>Endocrine Pathology</i> , 2020, 31, 119-131.	5.2	13
688	Targeted systemic and peptide radio-ligand therapy for aggressive pituitary tumors and carcinomas. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 277-286.	2.6	8
689	Small Bowel Neuroendocrine Tumors. <i>Current Problems in Surgery</i> , 2020, 57, 100823.	0.6	12
690	<p>Peptide Receptor Radionuclide Therapy for the Treatment of Pancreatic Neuroendocrine Tumors: Recent Insights</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 3545-3555.	1.0	27
691	Combining radiolabelled therapies for neuroendocrine neoplasms. <i>Nature Reviews Endocrinology</i> , 2020, 16, 347-348.	4.3	4
692	Midgut Neuroendocrine Tumors with Liver-only Metastases: Benefit of Primary Tumor Resection. <i>Annals of Surgical Oncology</i> , 2020, 27, 4525-4532.	0.7	13
693	A Neuroendocrine Tumor Specialty Center in New Orleansâ€™ (NOLANETS) Response to Patient Care During the COVID â€”19 Pandemic. <i>Oncologist</i> , 2020, 25, 548-551.	1.9	4
694	Peptide receptor radionuclide therapy as a two-step strategy for initially unresectable liver disease from neuroendocrine tumors: a single-center experience. <i>Endocrine</i> , 2020, 70, 187-193.	1.1	8
695	Targeting of peptideâ€”binding receptors on cancer cells with peptideâ€”drug conjugates. <i>Peptide Science</i> , 2020, 112, e24171.	1.0	38
696	Nuclear medicine and molecular imaging advances in the 21st century. <i>British Journal of Radiology</i> , 2020, 93, 20200095.	1.0	42
697	Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice. <i>Neuroendocrinology</i> , 2021, 111, 207-216.	1.2	13
698	Achieving objective response in treatment of non-resectable neuroendocrine tumors does not predict longer time to progression compared to achieving stable disease. <i>BMC Cancer</i> , 2020, 20, 466.	1.1	2

#	ARTICLE	IF	CITATIONS
699	Safety, tolerability and clinical implementation of ⁶⁸ Ga-ready-to-use™ 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). <i>ESMO Open</i> , 2020, 5, e000650.	2.0	12
700	Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors. <i>PLoS ONE</i> , 2020, 15, e0233720.	1.1	2
701	Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers. <i>Clinical Cancer Research</i> , 2020, 26, 4454-4459.	3.2	110
702	A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2223-2226.	3.3	2
703	Optimal strategy of systemic treatment for unresectable pancreatic neuroendocrine tumors based upon opinion of Japanese experts. <i>Pancreatology</i> , 2020, 20, 944-950.	0.5	14
704	Enhancing the anti-tumour activity of 177Lu-DOTA-octreotate radionuclide therapy in somatostatin receptor-2 expressing tumour models by targeting PARP. <i>Scientific Reports</i> , 2020, 10, 10196.	1.6	54
705	Pathogenesis and Clinical Management of Mesenteric Fibrosis in Small Intestinal Neuroendocrine Neoplasms: A Systematic Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1777.	1.0	14
706	Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 581-594.	2.6	29
707	Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1677.	1.0	23
708	Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 188.	1.0	7
709	Improved radiosynthesis of 123I-MAPi, an auger theranostic agent. <i>International Journal of Radiation Biology</i> , 2020, , 1-7.	1.0	13
710	Prostate-specific membrane antigen theranostics in advanced prostate cancer: an evolving option. <i>BJU International</i> , 2020, 126, 525-535.	1.3	14
711	Molecular Imaging and Therapy of Liver Tumors. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 419-433.	2.5	4
712	Imaging for Response Assessment in Cancer Clinical Trials. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 488-504.	2.5	22
713	Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities. <i>Current Treatment Options in Oncology</i> , 2020, 21, 25.	1.3	10
714	Targeted β -Emitter Therapy of Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 171-176.	2.5	30
715	Textural analysis of hybrid DOTATOC-PET/MRI and its association with histological grading in patients with liver metastases from neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2020, 41, 363-369.	0.5	16
716	Prognostic Value of ¹⁸ F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1560-1569.	2.8	48

#	ARTICLE	IF	CITATIONS
717	Realising the potential of radioligand therapy: policy solutions for the barriers to implementation across Europe. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1335-1339.	3.3	7
718	Long-term results of multimodal peptide receptor radionuclide therapy and fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. <i>Clinical and Translational Radiation Oncology</i> , 2020, 22, 29-32.	0.9	20
719	Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort. <i>Oncologist</i> , 2020, 25, 572-578.	1.9	6
721	(Radio)Theranostic Patient Management in Oncology Exemplified by Neuroendocrine Neoplasms, Prostate Cancer, and Breast Cancer. <i>Pharmaceuticals</i> , 2020, 13, 39.	1.7	10
722	The therapeutic efficacy of ¹⁷⁷ Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors. <i>Medicine (United States)</i> , 2020, 99, e19304.	0.4	26
723	Manifestations of Glucagonoma Syndrome. <i>AACE Clinical Case Reports</i> , 2020, 6, e46-e49.	0.4	2
724	A phase IIa trial of molecular radiotherapy with ¹⁷⁷ lutetium DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2348-2357.	3.3	23
726	Theranostic approaches in nuclear medicine: current status and future prospects. <i>Expert Review of Medical Devices</i> , 2020, 17, 331-343.	1.4	63
727	Loss of copy of MIR1-2 increases CDK4 expression in ileal neuroendocrine tumors. <i>Oncogenesis</i> , 2020, 9, 37.	2.1	3
728	Radiopharmaceuticals for Breast Cancer and Neuroendocrine Tumors: Two Examples of How Tissue Characterization May Influence the Choice of Therapy. <i>Cancers</i> , 2020, 12, 781.	1.7	8
729	Dose escalation of an Evans blue- ⁶⁴ Cu-DOTA-EB-TATE in the treatment of metastatic neuroendocrine tumors. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 947-957.	3.3	18
730	Advances in the Diagnosis and Management of Gastrinoma. , 2020, , 207-219.		0
731	Treatment Patterns and Health Resource Use Among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Treated at a Tertiary Referral Center. <i>Oncologist</i> , 2020, 25, e644-e650.	1.9	9
732	Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1326-1330.	2.8	22
733	⁶⁴ Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1491-1497.	2.8	27
734	Evolution of Neuroendocrine Tumor Therapy. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 145-163.	0.6	9
735	Management of Small Bowel Neuroendocrine Tumors. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 223-241.	0.6	17
736	Management of Other Gastric and Duodenal Neuroendocrine Tumors. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 253-266.	0.6	5

#	ARTICLE	IF	CITATIONS
737	Surgical management of pancreatic neuroendocrine liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 590-600.	0.6	19
738	Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 447-464.	2.5	30
739	Nephrotoxicity/renal failure after therapy with ⁹⁰ Yttrium- and ¹⁷⁷ Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review. <i>Nuclear Medicine Communications</i> , 2020, 41, 601-617.	0.5	14
740	Nuclear Imaging of Neuroendocrine Tumors. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 209-221.	0.6	10
741	Synthesis and Evaluation of a Macrocyclic Actinium-225 Chelator, Quality Control and In Vivo Evaluation of ²²⁵ Ac-MSH Peptide. <i>Chemistry - A European Journal</i> , 2020, 26, 11435-11440.	1.7	41
742	The Landmark Series: Neuroendocrine Tumor Liver Metastases. <i>Annals of Surgical Oncology</i> , 2020, 27, 3270-3280.	0.7	23
743	Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1094-1095.	2.8	6
744	Advances in Molecular Classification and Therapeutic Opportunities in Meningiomas. <i>Current Oncology Reports</i> , 2020, 22, 84.	1.8	17
745	North American Neuroendocrine Tumor Society Guide for Neuroendocrine Tumor Patient Health Care Providers During COVID-19. <i>Pancreas</i> , 2020, 49, 723-728.	0.5	6
746	Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA). <i>Tj ETQq1 1 0.7843 147gBT /Overlock 10</i>		
747	The INTERNET STUDY: A phase II study of everolimus in patients with fluorodeoxyglucose (¹⁸ F) positron emission tomography positive intermediate grade pancreatic neuroendocrine tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 150-157.	0.7	2
748	Update on Pathophysiology, Treatment, and Complications of Carcinoid Syndrome. <i>Journal of Oncology</i> , 2020, 2020, 1-11.	0.6	40
749	Influence of pretreatment with everolimus or sunitinib on the subacute hematotoxicity of ¹⁷⁷ Lu-DOTATATE PRRT. <i>Acta Oncologica</i> , 2020, 59, 644-651.	0.8	7
750	Systemic Therapy of Neuroendocrine Neoplasia: Single Center Experience from a Cohort of 110 Consecutive Cases. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-9.	0.6	2
751	Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. <i>Lancet Oncology</i> , The, 2020, 21, 561-570.	5.1	48
752	Holmium-166 radioembolisation after peptide receptor radionuclide therapy: much needed data to help inform future research. <i>Lancet Oncology</i> , The, 2020, 21, 478-479.	5.1	0
753	¹⁷⁷ Lu-DOTATATE Therapy of Advanced Pancreatic Neuroendocrine Tumors Heavily Pretreated with Chemotherapy: Analysis of Outcome, Safety, and Their Determinants. <i>Neuroendocrinology</i> , 2021, 111, 330-343.	1.2	31
756	Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2358-2371.	3.3	9

#	ARTICLE	IF	CITATIONS
757	Radioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2106-2112.	3.3	37
758	Intratumoral Fibrosis and Tumor Growth Pattern as Prognostic Factors in Optimally Resected Pancreatic Neuroendocrine Neoplasms. <i>Pancreas</i> , 2020, 49, 255-260.	0.5	11
759	Medical Treatment of Gastrointestinal Neuroendocrine Neoplasms. <i>Hormone and Metabolic Research</i> , 2020, 52, 614-620.	0.7	7
760	Successful Intra-arterial Peptide Receptor Radionuclide Therapy of DOTATOC-Negative High-Grade Liver Metastases of a Pancreatic Neuroendocrine Neoplasm Using 177Lu-DOTA-LM3. <i>Clinical Nuclear Medicine</i> , 2020, 45, e165-e168.	0.7	5
761	Peptide Receptor Radionuclide Therapy Using 225Ac-DOTATOC Achieves Partial Remission in a Patient With Progressive Neuroendocrine Liver Metastases After Repeated 125I-Emitter Peptide Receptor Radionuclide Therapy. <i>Clinical Nuclear Medicine</i> , 2020, 45, 241-243.	0.7	24
762	Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2372-2382.	3.3	79
763	Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent 177Lu-DOTATOC therapy. <i>Annals of Nuclear Medicine</i> , 2020, 34, 244-253.	1.2	11
764	Radiotheranostics: a roadmap for future development. <i>Lancet Oncology</i> , The, 2020, 21, e146-e156.	5.1	151
766	<i>Nuclear Medicine Imaging</i> , 2020, , 685-694.		0
767	The underreporting of phase III chemo-therapeutic clinical trial data of older patients with cancer: A systematic review. <i>Journal of Geriatric Oncology</i> , 2020, 11, 369-379.	0.5	20
768	Influence of Gender on Therapy and Outcome of Neuroendocrine Tumors of Gastroenteropancreatic Origin: A Single-Center Analysis. <i>Visceral Medicine</i> , 2020, 36, 20-27.	0.5	5
769	Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 922-933.	3.3	31
771	Current and potential applications of positron emission tomography for multiple myeloma and plasma cell disorders. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101148.	0.7	9
772	Gene Expression Signatures Identify Novel Therapeutics for Metastatic Pancreatic Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2011-2021.	3.2	40
773	Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges. <i>Bioconjugate Chemistry</i> , 2020, 31, 483-491.	1.8	32
774	A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2290-2296.	3.2	215
775	FAP: The Next Billion Dollar Nuclear Theranostics Target?. <i>Journal of Nuclear Medicine</i> , 2020, 61, 163-165.	2.8	64
776	The radiosensitizer Onalespib increases complete remission in 177Lu-DOTATATE-treated mice bearing neuroendocrine tumor xenografts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 980-990.	3.3	18

#	ARTICLE	IF	CITATIONS
777	In Vivo Instability of ¹⁷⁷ Lu-DOTATATE During Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1337-1340.	2.8	17
778	NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of ¹⁷⁷ Lu-DOTATATE Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2020, 61, 222-227.	2.8	77
779	Standardized image quality for ⁶⁸ Ga-DOTA-TATE PET/CT. <i>EJNMMI Research</i> , 2020, 10, 27.	1.1	11
780	Pituitary Function after High-Dose ¹⁷⁷ Lu-DOTATATE Therapy and Long-Term Follow-Up. <i>Neuroendocrinology</i> , 2021, 111, 344-353.	1.2	12
781	From Theranostics to Immunotheranostics: the Concept. <i>Nuclear Medicine and Molecular Imaging</i> , 2020, 54, 81-85.	0.6	3
782	Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 844-860.	0.6	571
784	Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD,) <i>TJ ETQ</i> 0.0 0 rgBT/O	0.4	0
785	Complete remission of inoperable hepatic and bone metastases due to neuroendocrine pancreatic tumour 3 years after peptide receptor radionuclide therapy. <i>BMJ Case Reports</i> , 2020, 13, e233263.	0.2	2
786	La dosimétrie est-elle vraiment utile pour la radiothérapie interne vectorisée? <i>Medecine Nucleaire</i> , 2020, 44, 140-143.	0.2	0
788	Rapid Thermodynamically Stable Complex Formation of [^{nat} /111 ^{In}] ³⁺ , [^{nat} /90 ^Y] ³⁺ , and [^{nat} /177 ^{Lu}] ³⁺ with H ₆ dppa. <i>Inorganic Chemistry</i> , 2020, 59, 7238-7251.	1.9	5
789	Oncology in 2050 – A Retrospective?. <i>Oncologist</i> , 2020, 25, e1127-e1130.	1.9	1
790	Recent advances of PET imaging in clinical radiation oncology. <i>Radiation Oncology</i> , 2020, 15, 88.	1.2	75
791	The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2020, 27, 1788-1792.	0.7	15
792	Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy. <i>JAMA Oncology</i> , 2020, 6, 1086.	3.4	30
793	Estimation of ⁴⁷ Sc and ¹⁷⁷ Lu production rates from their natural targets in Kyoto University Research Reactor. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2020, 324, 1099-1107.	0.7	5
794	LGR5 marks targetable tumor-initiating cells in mouse liver cancer. <i>Nature Communications</i> , 2020, 11, 1961.	5.8	49
795	Treatment-related changes in neuroendocrine tumors as assessed by textural features derived from ⁶⁸ Ga-DOTATOC PET/MRI with simultaneous acquisition of apparent diffusion coefficient. <i>BMC Cancer</i> , 2020, 20, 326.	1.1	38
796	Effect of metastatic site on survival in patients with neuroendocrine neoplasms (NENs). An analysis of SEER data from 2010 to 2014. <i>BMC Endocrine Disorders</i> , 2020, 20, 44.	0.9	14

#	ARTICLE	IF	CITATIONS
797	Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward. <i>Current Topics in Medicinal Chemistry</i> , 2020, 20, 2959-2969.	1.0	27
798	Primary Neuroendocrine Neoplasms of the Breast: Case Series and Literature Review. <i>Cancers</i> , 2020, 12, 733.	1.7	17
799	Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine. <i>Cancers</i> , 2020, 12, 821.	1.7	10
800	Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia. <i>Cancers</i> , 2020, 12, 832.	1.7	27
801	[¹⁸ F]FET- ¹²⁵ I-TOCA: The Design, Evaluation and Clinical Translation of a Fluorinated Octreotide. <i>Cancers</i> , 2020, 12, 865.	1.7	13
802	The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors. <i>Cancer</i> , 2020, 126, 2561-2565.	2.0	2
803	The efficacy of ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 1533-1543.	1.2	29
804	High somatostatin receptor expression and efficacy of somatostatin analogues in patients with metastatic Merkel cell carcinoma*. <i>British Journal of Dermatology</i> , 2021, 184, 319-327.	1.4	28
805	¹⁷⁷ Lu-PRRT in advanced gastrointestinal neuroendocrine tumors: 10-year follow-up of the IRST phase II prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 152-160.	3.3	20
806	Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. <i>Surgery</i> , 2021, 169, 162-167.	1.0	4
807	Antiproliferative Effect of Above-Label Doses of Somatostatin Analogs for the Management of Gastroenteropancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2021, 111, 650-659.	1.2	14
808	Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 69-72.	2.8	30
809	Intraarterial Peptide Receptor Radionuclide Therapy Using ⁹⁰ Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2021, 62, 221-227.	2.8	9
810	Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 237-251.	0.7	7
811	Molecular targeting therapies for neuroblastoma: Progress and challenges. <i>Medicinal Research Reviews</i> , 2021, 41, 961-1021.	5.0	150
812	Dissimilar DNA Damage to Blood Lymphocytes After ¹⁷⁷ Lu-Labeled DOTATOC or Prostate-Specific Membrane Antigen Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 379-385.	2.8	5
813	Preclinical Characterization of the Radioimmunoconjugate ¹¹¹ In or ⁹⁰ Y-FF-21101 Against a P-Cadherin ⁺ Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate. <i>Journal of Nuclear Medicine</i> , 2021, 62, 232-239.	2.8	3
814	The Evolving Management of Peritoneal Surface Malignancies. <i>Current Problems in Surgery</i> , 2021, 58, 100860.	0.6	2

#	ARTICLE	IF	CITATIONS
815	Update on gastroenteropancreatic neuroendocrine tumors. <i>Digestive and Liver Disease</i> , 2021, 53, 171-182.	0.4	45
816	Peptide Receptor Radionuclide Therapy â€œ Prospects for Personalised Treatment. <i>Clinical Oncology</i> , 2021, 33, 92-97.	0.6	8
817	Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. <i>Oncologist</i> , 2021, 26, 115-119.	1.9	15
818	Development and validation of the HPLC method for quality control of radiolabelled DOTA-TATE and DOTA-TOC preparations. <i>Nuclear Medicine and Biology</i> , 2021, 93, 63-73.	0.3	4
819	How We Do It: A Multidisciplinary Approach to ¹⁷⁷ Lu DOTATATE Peptide Receptor Radionuclide Therapy. <i>Radiology</i> , 2021, 298, 261-274.	3.6	21
820	Paediatric Molecular Radiotherapy: Challenges and Opportunities. <i>Clinical Oncology</i> , 2021, 33, 80-91.	0.6	6
821	The Rapid Evolution of Theranostics in Radiation Oncology. <i>Seminars in Radiation Oncology</i> , 2021, 31, 1-2.	1.0	5
822	Theranostics: The Role of Quantitative Nuclear Medicine Imaging. <i>Seminars in Radiation Oncology</i> , 2021, 31, 28-36.	1.0	10
823	Radiopharmaceuticals for Neuroendocrine Tumors. <i>Seminars in Radiation Oncology</i> , 2021, 31, 60-70.	1.0	10
824	Radiopharmaceutical Chemistry and Drug Developmentâ€™What's Changed?. <i>Seminars in Radiation Oncology</i> , 2021, 31, 3-11.	1.0	11
825	Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is â‰¥10%?. <i>Oncologist</i> , 2021, 26, 294-301.	1.9	17
827	Managing carcinoid heart disease in patients with neuroendocrine tumors. <i>Annales D'Endocrinologie</i> , 2021, 82, 187-192.	0.6	4
828	Overcoming Barriers to Radiopharmaceutical Therapy (RPT): An Overview From the NRG-NCI Working Group on Dosimetry of Radiopharmaceutical Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 905-912.	0.4	13
829	PET detectives: Molecular imaging for pheochromocytomas and paragangliomas in the genomics era. <i>Clinical Endocrinology</i> , 2021, 95, 13-28.	1.2	9
830	Challenges and opportunities in the delivery of cancer therapeutics: update on recent progress. <i>Therapeutic Delivery</i> , 2021, 12, 55-76.	1.2	42
831	Does the proteasome inhibitor bortezomib sensitize to DNA-damaging therapy in gastroenteropancreatic neuroendocrine neoplasms? â€œ A preclinical assessment in vitro and in vivo. <i>Neoplasia</i> , 2021, 23, 80-98.	2.3	8
832	Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 93, 102141.	3.4	43
833	Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response. <i>Theranostics</i> , 2021, 11, 491-505.	4.6	23

#	ARTICLE	IF	CITATIONS
834	At the Bedside: Profiling and treating patients with CXCR4-expressing cancers. <i>Journal of Leukocyte Biology</i> , 2021, 109, 953-967.	1.5	15
835	Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugatesâ€”new perspectives for folate receptorâ€”targeted radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 972-983.	3.3	10
836	Long-term outcome of indigenous ¹⁷⁷ Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting. <i>British Journal of Radiology</i> , 2021, 94, 20201041.	1.0	19
837	Role of Primary Tumor Resection for Metastatic Small Bowel Neuroendocrine Tumors. <i>World Journal of Surgery</i> , 2021, 45, 213-218.	0.8	14
838	Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of ¹⁷⁷ Lu-DOTA-EB-TATE. <i>Journal of Nuclear Medicine</i> , 2021, 62, 386-392.	2.8	15
839	Deep-Learning Generation of Synthetic Intermediate Projections Improves ¹⁷⁷ Lu SPECT Images Reconstructed with Sparsely Acquired Projections. <i>Journal of Nuclear Medicine</i> , 2021, 62, 528-535.	2.8	25
840	High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT. <i>Journal of Nuclear Medicine</i> , 2021, 62, 514-520.	2.8	11
841	Prostate-specific Membrane Antigen Imaging and Theranostics Impact Patient Outcomes. <i>European Urology Focus</i> , 2021, 7, 229-230.	1.6	1
842	¹³¹ I-Tocotrienolâ€”Loaded Liposomes for Radioprotection from Hematopoietic Side Effects Caused by Radiotherapeutic Drugs. <i>Journal of Nuclear Medicine</i> , 2021, 62, 584-590.	2.8	6
843	Multimodal Imaging of 2-Cycle PRRT with ¹⁷⁷ Lu-DOTA-JR11 and ¹⁷⁷ Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. <i>Journal of Nuclear Medicine</i> , 2021, 62, 393-398.	2.8	14
844	Efficacy of Lutetium-Peptide Receptor Radionuclide Therapy in Inducing Prolonged Tumour Regression in Small-Bowel Neuroendocrine Tumours: A Case of Favourable Response to Retreatment after Initial Objective Response. <i>Oncology Research and Treatment</i> , 2021, 44, 276-280.	0.8	2
845	Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review. <i>World Journal of Nuclear Medicine</i> , 2021, 20, 329-335.	0.3	9
846	Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma. <i>Theranostics</i> , 2021, 11, 9022-9037.	4.6	13
847	Pancreatic Neuroendocrine Tumors. , 2021, , 938-948.e4.		0
848	Molecular Signatures and Their Clinical Utility in Pancreatic Neuroendocrine Tumors. <i>Frontiers in Endocrinology</i> , 2020, 11, 575620.	1.5	8
849	Evolution of the Mesenteric Mass in Small Intestinal Neuroendocrine Tumours. <i>Cancers</i> , 2021, 13, 443.	1.7	12
850	Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma. <i>Frontiers in Endocrinology</i> , 2020, 11, 587065.	1.5	4
851	Initial clinical evaluation of indigenous ^{90Y} -DOTATATE in sequential duo-PRRT approach (¹⁷⁷ Lu-DOTATATE and ^{90Y} -DOTATATE) in neuroendocrine tumors with large bulky disease: Observation on tolerability, ^{90Y} -DOTATATE post- PRRT imaging characteristics (bremsstrahlung and PETCT) and early adverse effects. <i>World Journal of Nuclear Medicine</i> . 2021. 20. 73-81.	0.3	5

#	ARTICLE	IF	CITATIONS
852	Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 289-297.	0.6	11
853	Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110180.	1.4	21
854	Chemoembolization Versus Radioembolization for Neuroendocrine Liver Metastases: A Meta-analysis Comparing Clinical Outcomes. <i>Annals of Surgical Oncology</i> , 2021, 28, 1950-1958.	0.7	10
855	Current practices in oncology drug delivery. , 2021, , 17-26.		1
856	Internal Radiotherapy Using Radionuclides. , 2021, , 139-151.		0
857	Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110426.	1.4	16
858	Therapy in Poorly Differentiated Neuroendocrine Neoplasms (NEN G3). , 2021, , 309-323.		0
859	NETs of the Lung. , 2021, , 163-178.		1
860	Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery. <i>New Journal of Chemistry</i> , 2021, 45, 5291-5321.	1.4	39
861	Nanotheranostics and biocompatibility. , 2021, , 51-60.		0
862	Neuroendocrine Neoplasms: Identification of Novel Metabolic Circuits of Potential Diagnostic Utility. <i>Cancers</i> , 2021, 13, 374.	1.7	3
863	Succinate dehydrogenase-deficient gastrointestinal stromal tumor: from diagnostic dilemma to novel personalised therapy in 2 case reports. <i>Translational Cancer Research</i> , 2021, 10, 0-0.	0.4	6
864	Desmoplastic mesenteric lesions do not respond radiographically to peptide receptor radionuclide therapy. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12936.	1.2	3
865	Temporal analysis of type 1 interferon activation in tumor cells following external beam radiotherapy or targeted radionuclide therapy. <i>Theranostics</i> , 2021, 11, 6120-6137.	4.6	34
866	Radiopharmaceuticals in Clinical Diagnosis and Therapy. , 2021, , 103-118.		1
867	Radioactive Metals in Imaging and Therapy. , 2021, , 706-740.		6
868	⁶⁸ Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients. <i>Frontiers in Medicine</i> , 2020, 7, 601853.	1.2	11
869	Jejunoileal Neuroendocrine Tumors. , 2021, , 157-177.		0

#	ARTICLE	IF	CITATIONS
870	Neoadjuvant and Adjuvant Treatment Strategies for Well-Differentiated Neuroendocrine Tumors. , 2021, , 75-86.		0
871	Carcinoid Heart Disease. , 2021, , 139-151.		0
872	Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2566-2572.	3.3	8
873	Ectopic ACTH syndrome caused by thymic neuroendocrine tumor: a case report and literature review. Annals of Palliative Medicine, 2021, .	0.5	0
874	The Safety and Efficacy of the Repeated PRRT with [90Y]Y/[177Lu]Lu-DOTATATE in Patients with NET. International Journal of Endocrinology, 2021, 2021, 1-10.	0.6	12
875	Treatment of Intestinal NETs (Including Appendix). , 2021, , 201-210.		0
876	Treatment of Pancreatic Neuroendocrine Tumors. , 2021, , 191-199.		0
878	Addition of ¹³¹ I-MIBG to PRRT (⁹⁰ Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2021, 62, 1274-1277.	2.8	11
879	Lutetium oxodotreotide (177Lu-Dotatate) for the treatment of unresectable or metastatic progressive gastroenteropancreatic neuroendocrine tumors: a cost-effectiveness analysis for Scotland. BMC Cancer, 2021, 21, 10.	1.1	6
880	The role of [68Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRα gastrointestinal stromal tumours (GIST). EJNMMI Research, 2021, 11, 5.	1.1	4
881	From Diagnosis to Therapy – PET Imaging for Pheochromocytomas and Paragangliomas. Current Urology Reports, 2021, 22, 2.	1.0	4
882	Lutetium Lu-177 Dotatate Flare Reaction. Advances in Radiation Oncology, 2021, 6, 100623.	0.6	2
884	Radioreceptor Therapy. , 2021, , 149-159.		0
885	Compound Screening. , 2021, , .		0
886	Yttrium-90 SIRT in NET. , 2021, , 231-239.		0
887	Treatment of NET-Related Symptoms. , 2021, , 101-111.		0
888	PET Imaging in Neuro-Endocrine Neoplasms (NEN). , 2021, , .		0
889	Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors. Endocrine Pathology, 2021, 32, 169-191.	5.2	26

#	ARTICLE	IF	CITATIONS
890	Dosimetry and Dose Calculation: Its Necessity in Radiopeptide Therapy. , 2021, , 141-162.		0
891	Distal Pancreatectomy, Pancreatoduodenectomy and Total Pancreatectomy for Pancreatic Neuroendocrine Tumors “ Same Organ, Different Outcomes. , 2021, 05, .		0
892	A combination of surgery, theranostics, and liquid biopsy - a personalised oncologic approach to treatment of patients with advanced metastatic neuroendocrine neoplasms. International Journal of Medical Sciences, 2021, 18, 2166-2175.	1.1	7
893	Neuroendocrine Peritoneal Metastases. , 2021, , 283-291.		0
894	The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [177Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis. Cancers, 2021, 13, 635.	1.7	10
895	Theranostic SPECT reconstruction for improved resolution: application to radionuclide therapy dosimetry. EJNMMI Physics, 2021, 8, 16.	1.3	10
896	Predictive factors of tumor sink effect: Insights from 177Lu-Prostate-specific membrane antigen therapy. Annals of Nuclear Medicine, 2021, 35, 529-539.	1.2	8
897	Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma. Scientific Reports, 2021, 11, 3731.	1.6	7
898	Combined use of 177Lu-DOTATATE and metronomic capecitabine (Lu-X) in FDG-positive gastro-entero-pancreatic neuroendocrine tumors. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3260-3267.	3.3	29
899	Chemical Promiscuity of Non-Macrocyclic Multidentate Chelating Ligands for Radiometal Ions: $H_{4\text{neunpa-NH}_2}$ vs $H_{4\text{noneunpa}}$. Inorganic Chemistry, 2021, 60, 4076-4092.	1.9	12
900	ASO Author Reflections: Indolent Growth and Small Bowel Neuroendocrine Tumor Management. Annals of Surgical Oncology, 2021, 28, 2752-2753.	0.7	0
901	Clinical Features, Management, and Molecular Characteristics of Familial Small Bowel Neuroendocrine Tumors. Frontiers in Endocrinology, 2021, 12, 622693.	1.5	9
902	Immunotherapeutics at the spearhead: current status in targeting neuroendocrine neoplasms. Endocrine, 2021, 73, 232-239.	1.1	4
903	Quantitative ^{68}Ga -DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with ^{177}Lu -DOTATATE. Journal of Nuclear Medicine, 2021, 62, 1406-1414.	2.8	40
904	Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker. Journal of Nuclear Medicine, 2021, 62, 1278-1284.	2.8	25
905	Treatment Outcomes of Well-Differentiated High-Grade Neuroendocrine Tumors. Oncologist, 2021, 26, 383-388.	1.9	21
906	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. European Journal of Cancer, 2021, 144, 200-214.	1.3	12
907	Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms. Cancers, 2021, 13, 962.	1.7	25

#	ARTICLE	IF	CITATIONS
909	Trends in peptide drug discovery. <i>Nature Reviews Drug Discovery</i> , 2021, 20, 309-325.	21.5	792
910	Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography. <i>Diabetes</i> , 2021, 70, 842-853.	0.3	10
911	mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms. <i>Frontiers in Oncology</i> , 2020, 10, 578380.	1.3	3
912	Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT. <i>Scientific Reports</i> , 2021, 11, 3622.	1.6	34
913	Cost-Effectiveness Analysis of 68Ga DOTA-TATE PET/CT, 111In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors. <i>Diagnostics</i> , 2021, 11, 334.	1.3	14
914	Efficacy of 177Lu-Dotatate Therapy in the Treatment of Recurrent Meningioma. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2021, 5, 236-240.	1.2	5
915	Detection and therapy of neuroblastoma minimal residual disease using [64/67Cu]Cu-SARTATE in a preclinical model of hepatic metastases. <i>EJNMMI Research</i> , 2021, 11, 20.	1.1	14
916	Treatment personalization in gastrointestinal neuroendocrine tumors. <i>Current Treatment Options in Oncology</i> , 2021, 22, 29.	1.3	10
917	PSMA-targeted radiopharmaceutical therapy in patients with metastatic castration-resistant prostate cancer. <i>Lancet, The</i> , 2021, 397, 768-769.	6.3	5
919	A clinical score for neuroendocrine tumor patients under consideration for Lu-177-DOTATATE therapy. <i>Endocrine-Related Cancer</i> , 2021, 28, 203-212.	1.6	4
920	Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma. <i>Clinical Nuclear Medicine</i> , 2021, 46, 540-548.	0.7	10
921	⁶⁴ Cu/ ¹⁷⁷ Lu-DOTA-diZD, a Small-Molecule-Based Theranostic Pair for Triple-Negative Breast Cancer. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 2705-2713.	2.9	5
922	Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3408-3421.	3.3	24
923	Carcinoid Heart Disease: a Review. <i>Current Oncology Reports</i> , 2021, 23, 48.	1.8	7
924	Long-Term Survival and Value of 18F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with 177Lu-DOTATATE. <i>Life</i> , 2021, 11, 198.	1.1	4
925	Drug Development in Neuroendocrine Tumors: What Is on the Horizon?. <i>Current Treatment Options in Oncology</i> , 2021, 22, 43.	1.3	8
926	Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy. <i>Diagnostics</i> , 2021, 11, 504.	1.3	12
927	Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy. <i>Current Oncology Reports</i> , 2021, 23, 46.	1.8	8

#	ARTICLE	IF	CITATIONS
928	The Chinese guidelines for the diagnosis and treatment of pancreatic neuroendocrine neoplasms (2020). <i>Journal of Pancreatology</i> , 2021, 4, 1-17.	0.3	4
929	Evaluation of Ac-Lys0(IRDye800CW)Tyr3-octreotate as a novel tracer for SSTR2-targeted molecular fluorescence guided surgery in meningioma. <i>Journal of Neuro-Oncology</i> , 2021, 153, 211-222.	1.4	7
930	Characterisation of 99mTc EDDA/HYNIC-TOC (Tektrotyd) physiological and neuroendocrine tumour uptake using SPECT/CT standardised uptake values: initial experience. <i>Nuclear Medicine Communications</i> , 2021, 42, 935-939.	0.5	5
931	Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3 rd -line treatment. <i>World Journal of Gastroenterology</i> , 2021, 27, 976-989.	1.4	3
932	Liver-Directed Therapies for Neuroendocrine Neoplasms. <i>Current Oncology Reports</i> , 2021, 23, 44.	1.8	8
933	Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use. <i>PLoS ONE</i> , 2021, 16, e0248133.	1.1	7
934	Current Management of Appendiceal Neoplasms. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 118-132.	1.8	18
935	We Can Make a Difference: Investigator-driven Prostate-specific Membrane Antigen Radiotheranostics for Prostate Cancer. <i>European Urology Focus</i> , 2021, 7, 227-228.	1.6	0
936	Origin of the Isomer Stability of Polymethylated DOTA Chelates Complexed with Ln 3+ Ions. <i>European Journal of Inorganic Chemistry</i> , 2021, 2021, 1428-1440.	1.0	5
937	Small bowel radiology. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 267-274.	1.0	7
938	CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. <i>Diagnostics</i> , 2021, 11, 605.	1.3	18
939	Gastroenteropancreatic neuroendocrine neoplasms: A clinical snapshot. <i>World Journal of Gastrointestinal Surgery</i> , 2021, 13, 231-255.	0.8	19
940	Eficacia de lutecio-177 DOTATATE/TOC en pacientes con tumores neuroendocrinos bien diferenciados en estado avanzado. Ensayo clínico fase II. <i>Revista Colombiana De Cancerología</i> , 2021, 25, .	0.0	2
941	Treatment of advanced gastroenteropancreatic neuroendocrine neoplasia, are we on the way to personalised medicine?. <i>Gut</i> , 2021, 70, 1768-1781.	6.1	28
942	High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. <i>Clinical Cancer Research</i> , 2021, 27, 2989-2995.	3.2	42
943	Assessment of $\hat{1}^3$ -H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2021, 13, 1516.	1.7	5
944	Microfluidics-Coupled Radioluminescence Microscopy for <i>In Vitro</i> Radiotracer Kinetic Studies. <i>Analytical Chemistry</i> , 2021, 93, 4425-4433.	3.2	3
945	Misleading ⁶⁸ GALLIUM- ϵ dotatate PET scan in a patient with a history of a pheochromocytoma: Unsuspected uptake in papillary thyroid carcinoma metastases. <i>Journal of Neuroendocrinology</i> , 2021, 33, e12964.	1.2	1

#	ARTICLE	IF	CITATIONS
946	Somatostatin receptor radionuclide therapy in neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2021, 28, R81-R93.	1.6	9
947	Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors: A Comprehensive Literature Review. <i>Cureus</i> , 2021, 13, e14006.	0.2	4
948	First-in-Humans Study of the SSTR Antagonist ¹⁷⁷ Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1571-1581.	2.8	44
949	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021, 146, 56-73.	1.3	120
950	Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. <i>JAMA Network Open</i> , 2021, 4, e212274.	2.8	13
951	Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1712-1718.	2.8	12
952	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 94, 102168.	3.4	6
953	Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review. <i>Journal of Clinical Medicine</i> , 2021, 10, 1267.	1.0	27
954	Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. <i>Frontiers in Endocrinology</i> , 2021, 12, 625312.	1.5	25
955	In Vivo Biodistribution and Efficacy Evaluation of NeoB, a Radiotracer Targeted to GRPR, in Mice Bearing Gastrointestinal Stromal Tumor. <i>Cancers</i> , 2021, 13, 1051.	1.7	11
956	Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1320-1320.	2.8	3
957	Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors. <i>Frontiers in Endocrinology</i> , 2021, 12, 676973.	1.5	1
958	An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	56
959	Nanomaterial Complexes Enriched With Natural Compounds Used in Cancer Therapies: A Perspective for Clinical Application. <i>Frontiers in Oncology</i> , 2021, 11, 664380.	1.3	8
960	Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3041-3042.	3.3	1
961	Peptide Receptor Radionuclide Therapy in Patients With Neurofibromatosis Type 2. <i>Clinical Nuclear Medicine</i> , 2021, 46, e312-e316.	0.7	6
962	Neuroendocrine liver metastases: The role of liver transplantation. <i>Transplantation Reviews</i> , 2021, 35, 100595.	1.2	4
964	Radiological and Clinical Efficacy of Intra-Arterial ⁹⁰ Y-DOTATATE in Patients with Unresectable, Progressive, Liver Dominant Neuroendocrine Neoplasms. <i>Journal of Clinical Medicine</i> , 2021, 10, 1794.	1.0	4

#	ARTICLE	IF	CITATIONS
965	Real-world management and patient perspectives on QOL with neuroendocrine tumors: An ANZ perspective. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 3-10.	0.7	1
966	Evaluation of SSTR2 Expression in SI-NETs and Relation to Overall Survival after PRRT. <i>Cancers</i> , 2021, 13, 2035.	1.7	7
967	Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). <i>Seminars in Cancer Biology</i> , 2022, 79, 141-162.	4.3	18
968	Dosimetric Evaluation of the Effect of Receptor Heterogeneity on the Therapeutic Efficacy of Peptide Receptor Radionuclide Therapy: Correlation with DNA Damage Induction and In Vivo Survival. <i>Journal of Nuclear Medicine</i> , 2022, 63, 100-107.	2.8	8
969	Targeted Cancer Therapy: What's New in the Field of Neuroendocrine Neoplasms?. <i>Cancers</i> , 2021, 13, 1701.	1.7	19
970	Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion. <i>Cancer Research and Treatment</i> , 2021, 53, 291-300.	1.3	8
971	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. <i>Pancreas</i> , 2021, 50, 469-493.	0.5	55
972	Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4016-4027.	3.3	14
973	An Overview on Molecular Characterization of Thymic Tumors: Old and New Targets for Clinical Advances. <i>Pharmaceuticals</i> , 2021, 14, 316.	1.7	13
974	A Case of Metastatic VIPoma With Complete Response to Peptide Radionuclide Receptor Therapy. <i>Pancreas</i> , 2021, 50, e45-e46.	0.5	0
975	Treating neuroendocrine neoplasms in the setting of HIV infection. <i>Translational Science of Rare Diseases</i> , 2021, 5, 143-159.	1.6	1
976	High-specific-activity ¹³¹ Iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma. <i>Future Oncology</i> , 2021, 17, 1131-1141.	1.1	2
977	Use of PET Imaging in Neuro-Oncological Surgery. <i>Cancers</i> , 2021, 13, 2093.	1.7	23
978	Targeting signal pathways triggered by cyclic peptides in cancer: Current trends and future challenges. <i>Archives of Biochemistry and Biophysics</i> , 2021, 701, 108776.	1.4	4
979	Nuclear Medicine beyond VISION. <i>Journal of Nuclear Medicine</i> , 2021, 62, jnumed.121.262441.	2.8	5
980	Nephrotoxicity and hematotoxicity one year after four cycles of peptide receptor radionuclide therapy (PRRT) and its impact on future treatment planning – A retrospective analysis. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2022, 41, 138-145.	0.1	5
981	Current Status and Trends in Peptide Receptor Radionuclide Therapy in the Past 20 Years (2000–2019): A Bibliometric Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 624534.	1.6	24
982	Economic evaluation of orphan drug Lutetium-Octreotate vs. Octreotide long-acting release for patients with an advanced midgut neuroendocrine tumour in the Netherlands. <i>European Journal of Health Economics</i> , 2021, 22, 991-999.	1.4	0

#	ARTICLE	IF	CITATIONS
983	Chemotherapy in NEN: still has a role?. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 595-614.	2.6	13
984	EANM position paper on the role of radiobiology in nuclear medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3365-3377.	3.3	23
985	"Present and future of immunotherapy in Neuroendocrine Tumors". <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 615-636.	2.6	21
986	¹⁷⁷ Lu-DOTATATE in older patients with metastatic neuroendocrine tumours: safety, efficacy and health-related quality of life. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3582-3594.	3.3	7
987	Liver metastases. <i>Nature Reviews Disease Primers</i> , 2021, 7, 27.	18.1	190
988	Incidence and risk factors for sustained hepatic function toxicity 6 months after radioembolization: analysis of the radiation-emitting sir-spheres in non-resectable liver tumor (RESIN) registry. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 639-657.	0.6	6
989	Better Management for Neuroendocrine Neoplasms: A Complex Task Ahead. <i>Journal of Clinical Medicine</i> , 2021, 10, 1859.	1.0	0
990	PET Molecular Imaging: A Holistic Review of Current Practice and Emerging Perspectives for Diagnosis, Therapeutic Evaluation and Prognosis in Clinical Oncology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4159.	1.8	41
991	Peptide receptor radionuclide therapy for treatment of metastatic neuroendocrine tumors in children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29056.	0.8	7
992	Efficacy of FOLFOX Chemotherapy in Metastatic Enteropancreatic Neuroendocrine Tumors. <i>Anticancer Research</i> , 2021, 41, 2071-2078.	0.5	6
993	Theranostics in Oncology – Thriving, Now More than Ever. <i>Diagnostics</i> , 2021, 11, 805.	1.3	3
994	Rare case of pancreatic neuroendocrine tumour presenting as paraneoplastic hypercalcaemia. <i>BMJ Case Reports</i> , 2021, 14, e240786.	0.2	0
995	Octreotide long-acting release (LAR) in combination with other therapies for treatment of neuroendocrine neoplasia: a systematic review. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 845-855.	0.6	4
996	Multiple endocrine neoplasia type 2: A review. <i>Seminars in Cancer Biology</i> , 2022, 79, 163-179.	4.3	32
997	Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy. <i>Pancreas</i> , 2021, 50, 513-515.	0.5	5
998	Clinical Perspectives of Theranostics. <i>Molecules</i> , 2021, 26, 2232.	1.7	16
999	Medical imaging and nuclear medicine: a Lancet Oncology Commission. <i>Lancet Oncology</i> , The, 2021, 22, e136-e172.	5.1	129
1000	Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2021, 32, 439-451.	0.6	101

#	ARTICLE	IF	CITATIONS
1001	Bismuth-213 for Targeted Radionuclide Therapy: From Atom to Bedside. <i>Pharmaceutics</i> , 2021, 13, 599.	2.0	45
1002	Improvements Of ¹¹¹ In Spect Images Reconstructed with Sparsely Acquired Projections by Deep Learning Generated Synthetic Projections. <i>Radiation Protection Dosimetry</i> , 2021, 195, 152-157.	0.4	3
1003	Clinical Utility of ¹⁸ F-FDG PET in Neuroendocrine Tumors Prior to Peptide Receptor Radionuclide Therapy: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1813.	1.7	34
1004	Nuclear medicine and molecular imaging in clinical practice: yesterday, today and tomorrow. <i>Terapevticheskii Arkhiv</i> , 2021, 93, 357-362.	0.2	1
1005	Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With?. <i>Current Oncology Reports</i> , 2021, 23, 80.	1.8	1
1006	Acquired hepatocerebral degeneration in a metastatic neuroendocrine tumor long-term survivor – an update on neuroendocrine neoplasms treatment: A case report. <i>World Journal of Hepatology</i> , 2021, 13, 611-619.	0.8	0
1007	Prognostic Implications of the Immune Tumor Microenvironment in Patients With Pancreatic and Gastrointestinal Neuroendocrine Tumors. <i>Pancreas</i> , 2021, 50, 719-726.	0.5	5
1008	Penetrating the Blood-Brain Barrier with New Peptide-Porphyrin Conjugates Having anti-HIV Activity. <i>Bioconjugate Chemistry</i> , 2021, 32, 1067-1077.	1.8	21
1009	Résultats et perspectives des traitements par Lutathera des tumeurs neuroendocrines à l'hôpital de Beaujon, centre RENATEN. <i>Medecine Nucleaire</i> , 2021, 45, 119-126.	0.2	0
1010	Descripción de la metodología para la cuantificación dosimétrica en tratamientos con ¹⁷⁷ Lu-DOTATATE. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 167-178.	0.0	0
1011	Combination Therapy, a Promising Approach to Enhance the Efficacy of Radionuclide and Targeted Radionuclide Therapy of Prostate and Breast Cancer. <i>Pharmaceutics</i> , 2021, 13, 674.	2.0	7
1012	Computed tomography (CT)-defined sarcopenia and myosteatosis are prevalent in patients with neuroendocrine neoplasms (NENs) treated with peptide receptor radionuclide therapy (PRRT). <i>European Journal of Clinical Nutrition</i> , 2022, 76, 143-149.	1.3	8
1013	Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. <i>Frontiers in Endocrinology</i> , 2021, 12, 679000.	1.5	29
1014	Description of the methodology for dosimetric quantification in treatments with ¹⁷⁷ Lu-DOTATATE. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2021, 40, 167-178.	0.1	0
1015	Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 1185-1196.	0.6	8
1016	Radioembolization for Metastatic Neuroendocrine Tumors. <i>Digestive Disease Interventions</i> , 0, 05, .	0.3	0
1017	Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [¹⁷⁷ Lu]Lu-DOTATATE in a panel of cancer cell lines. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, 68-79.	0.3	7
1018	Methods for preparation and administration of lutetium-177 oxodotreotide 3.7 GBq: proceedings from an Italian advisory board. <i>Clinical and Translational Imaging</i> , 2021, 9, 277-280.	1.1	0

#	ARTICLE	IF	CITATIONS
1019	Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors: Current Management and Future Directions. <i>Cancers</i> , 2021, 13, 2448.	1.7	13
1020	State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. <i>Current Opinion in Oncology</i> , 2021, 33, 378-385.	1.1	3
1021	The development and validation of a high performance liquid chromatography method to determine the radiochemical purity of [¹⁷⁷ Lu]Lu-HA-DOTA-TATE in pharmaceutical preparations. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2021, 1171, 122605.	1.2	6
1022	Value of a patient-reported-outcome measure of carcinoid syndrome symptoms. <i>European Journal of Endocrinology</i> , 2021, 184, 711-722.	1.9	3
1023	Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. <i>BMC Cancer</i> , 2021, 21, 597.	1.1	6
1024	Efficacy and Safety of ¹⁷⁷ Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study. <i>Journal of Nuclear Medicine</i> , 2022, 63, 218-225.	2.8	22
1025	Kinetic isotope effects and synthetic strategies for deuterated carbon-11 and fluorine-18 labelled PET radiopharmaceuticals. <i>Nuclear Medicine and Biology</i> , 2021, 96-97, 112-147.	0.3	6
1026	Activity and Safety of Immune Checkpoint Inhibitors in Neuroendocrine Neoplasms: A Systematic Review and Meta-Analysis. <i>Pharmaceuticals</i> , 2021, 14, 476.	1.7	16
1027	Challenges and future options for the production of lutetium-177. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2329-2335.	3.3	20
1028	Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>Acta Oncologica</i> , 2021, 60, 931-941.	0.8	32
1029	Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. <i>ChemMedChem</i> , 2021, 16, 2909-2941.	1.6	44
1030	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. <i>Clinical Lung Cancer</i> , 2021, 22, 161-169.	1.1	17
1031	Peptide Receptor Radionuclide Therapy With ¹⁷⁷ Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e3665-e3672.	1.8	23
1032	Radiation-Induced Immunity and Toxicities: The Versatility of the cGAS-STING Pathway. <i>Frontiers in Immunology</i> , 2021, 12, 680503.	2.2	31
1033	Why bother with alpha particles?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 7-17.	3.3	20
1034	Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6413.	1.8	12
1035	Functioning and nonfunctioning pNENs. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 284-290.	0.6	3
1036	State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4396-4414.	3.3	85

#	ARTICLE	IF	CITATIONS
1037	Personalized Management of Pheochromocytoma and Paraganglioma. <i>Endocrine Reviews</i> , 2022, 43, 199-239.	8.9	127
1038	Survival predictors of ¹⁷⁷ Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 225-236.	1.2	14
1039	The Impact of ⁶⁸ Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. <i>Frontiers in Endocrinology</i> , 2021, 12, 654975.	1.5	16
1040	Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. <i>PLoS ONE</i> , 2021, 16, e0252574.	1.1	5
1041	Marked improvement in hyperammonaemic encephalopathy from multimodal treatment of metastatic neuroendocrine tumour. <i>BMJ Case Reports</i> , 2021, 14, e241191.	0.2	2
1042	Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. <i>Annals of Surgery</i> , 2021, 274, 481-490.	2.1	22
1043	Metastatic well-differentiated pancreatic neuroendocrine tumors to the liver: a narrative review of systemic and surgical management. <i>Journal of Pancreatology</i> , 2021, 4, 82-89.	0.3	2
1044	Precision medicine and theranostics using radiopharmaceuticals in oncology. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 359-361.	1.1	6
1045	Hematological Markers as Predictors of Treatment Outcomes with Lutetium ¹⁷⁷ (¹⁷⁷ Lu)-DOTATATE in Patients with Advanced Neuroendocrine Tumors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2022, 37, 23-29.	0.7	6
1046	USE OF ¹⁷⁷ Lu-PSMA FOR RADIONUCLIDE THERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER. <i>Siberian Journal of Oncology</i> , 2021, 20, 115-123.	0.1	3
1047	Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷ Lu-FAP-2286: First-in-Humans Results. <i>Journal of Nuclear Medicine</i> , 2022, 63, 415-423.	2.8	136
1048	Severe metabolic acidosis and hyperkalemia after peptide receptor radionuclide therapy. A case report, review of the literature and proposed treatment algorithm. <i>Journal of Onco-Nephrology</i> , 2021, 5, 122-128.	0.3	0
1049	Targeted radionuclide therapy: an emerging field in solid tumours. <i>Current Opinion in Oncology</i> , 2021, 33, 493-499.	1.1	14
1050	Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours. <i>Current Treatment Options in Oncology</i> , 2021, 22, 73.	1.3	6
1051	Medical treatment of neuroendocrine neoplasms. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 139-144.	0.6	0
1052	Kidney Doses in ¹⁷⁷ Lu-Based Radioligand Therapy in Prostate Cancer: Is Dose Estimation Based on Reduced Dosimetry Measurements Feasible?. <i>Journal of Nuclear Medicine</i> , 2022, 63, 253-258.	2.8	8
1053	Peptide receptor radionuclide therapy for GEP-NET: consolidated knowledge and innovative applications. <i>Clinical and Translational Imaging</i> , 2021, 9, 423-438.	1.1	3
1054	Circulating biomarkers of gastroenteropancreatic and lung neuroendocrine neoplasms: The times they are a changinâ€¢ <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 18, 243-253.	0.6	4

#	ARTICLE	IF	CITATIONS
1056	Targeted Radionuclide Therapy Using Auger Electron Emitters: The Quest for the Right Vector and the Right Radionuclide. <i>Pharmaceutics</i> , 2021, 13, 980.	2.0	14
1057	Finding the Appropriate Therapeutic Strategy in Patients with Neuroendocrine Tumors of the Pancreas: Guideline Recommendations Meet the Clinical Reality. <i>Journal of Clinical Medicine</i> , 2021, 10, 3023.	1.0	9
1058	Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes. <i>Frontiers in Oncology</i> , 2021, 11, 710900.	1.3	4
1059	Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Na ⁺ ve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The ^{GETNE}-1408 Trial. <i>Oncologist</i> , 2021, 26, 941-949.	1.9	12
1060	Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer. <i>Cancers</i> , 2021, 13, 3607.	1.7	9
1061	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). <i>Journal of Clinical Oncology</i> , 2021, 39, 2304-2312.	0.8	49
1062	Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT. <i>Current Oncology</i> , 2021, 28, 2823-2829.	0.9	5
1063	Rapid Progression After ¹⁷⁷ Lu-DOTATATE in Patients With Neuroendocrine Tumors. <i>Pancreas</i> , 2021, 50, 890-894.	0.5	4
1064	Intraarterial Administration Boosts ¹⁷⁷ Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 406-409.	2.8	13
1065	Potential for Increasing Uptake of Radiolabeled ⁶⁸ Ga-DOTATOC and ¹²³ I-MIBG in Patients with Midgut Neuroendocrine Tumors Using a Histone Deacetylase Inhibitor Vorinostat. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 632-641.	0.7	9
1066	Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 727-739.	1.4	5
1067	Highly Symptomatic Progressing Cardiac Paraganglioma With Intracardiac Extension Treated With ¹⁷⁷ Lu-DOTATATE: A Case Report. <i>Frontiers in Endocrinology</i> , 2021, 12, 705271.	1.5	2
1068	Radiation therapy-associated toxicity: Etiology, management, and prevention. <i>Ca-A Cancer Journal for Clinicians</i> , 2021, 71, 437-454.	157.7	129
1069	Gastroenteropancreatic grade 3 neuroendocrine tumors: a single entity or a heterogeneous group? A retrospective analysis. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 317-325.	1.8	7
1070	An Impressive Approach in Nuclear Medicine. <i>PET Clinics</i> , 2021, 16, 327-340.	1.5	16
1071	Neuroendocrine Tumors. <i>PET Clinics</i> , 2021, 16, 353-364.	1.5	3
1072	Estimation of Health-Related Utilities for ¹⁷⁷ Lu-DOTATATE in GEP-NET Patients Using Utilities Mapped from EORTC QLQ-C30 to EQ-5D-3L and QLU-C10D Utilities. <i>PharmacoEconomics - Open</i> , 2021, 5, 715-725.	0.9	1
1073	Pancytopenia in a Patient With Metastatic Well-Differentiated Neuroendocrine Tumor After Peptide Receptor Radionuclide Therapy. <i>JAMA Oncology</i> , 2021, 7, 1060.	3.4	1

#	ARTICLE	IF	CITATIONS
1074	Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases. <i>BJS Open</i> , 2021, 5, .	0.7	6
1075	Alpha Before Beta. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, .	0.7	4
1076	Overcoming nephrotoxicity in peptide receptor radionuclide therapy using [¹⁷⁷ Lu]Lu-DOTA-TATE for the treatment of neuroendocrine tumours. <i>Nuclear Medicine and Biology</i> , 2021, 102-103, 1-11.	0.3	31
1077	Theranostics in Neuroendocrine Tumors. <i>PET Clinics</i> , 2021, 16, 365-373.	1.5	6
1078	General Concepts in Theranostics. <i>PET Clinics</i> , 2021, 16, 313-326.	1.5	10
1079	Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with ¹⁷⁷ Lu-DOTATATE. <i>Journal of Nuclear Medicine</i> , 2022, 63, 399-405.	2.8	30
1080	Merkel Cell Carcinoma of the Head and Neck: Epidemiology, Pathogenesis, Current State of Treatment and Future Directions. <i>Cancers</i> , 2021, 13, 3506.	1.7	8
1081	From the Magic Bullet to Theranostics: Certitudes and Hypotheses, Trying to Optimize the Somatostatin Model. <i>Cancers</i> , 2021, 13, 3474.	1.7	3
1082	Innovations in Neuro-Oncology. <i>World Neurosurgery</i> , 2021, 151, 386-391.	0.7	5
1083	¹⁷⁷ Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience. <i>JCO Global Oncology</i> , 2021, 7, 1167-1175.	0.8	10
1084	Safety of PSMA-Targeted Molecular Radioligand Therapy with ¹⁷⁷ Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). <i>Journal of Nuclear Medicine</i> , 2021, 62, 1447-1456.	2.8	14
1085	Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice. <i>American Journal of Roentgenology</i> , 2021, 217, 495-506.	1.0	6
1086	Peptide radio receptor therapy: The huff and puff strategy of neuroendocrine disease management. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 19, 52-60.	0.6	0
1087	Toxicity and Tolerability of ¹⁷⁷ Lu-DOTA-TATE PRRT with a Modified Administered Activity Protocol in NETs of Variable Origin – A Phase 2 Registry Study. <i>Current Radiopharmaceuticals</i> , 2021, 14, .	0.3	1
1088	Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias. <i>Cancers</i> , 2021, 13, 4181.	1.7	0
1089	Health-related quality of life and treatment effects in patients with well-differentiated gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. <i>European Journal of Cancer Care</i> , 2021, 30, e13504.	0.7	6
1090	In Vivo Cell Tracking Using PET: Opportunities and Challenges for Clinical Translation in Oncology. <i>Cancers</i> , 2021, 13, 4042.	1.7	11
1091	Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study. <i>EJNMMI Physics</i> , 2021, 8, 63.	1.3	8

#	ARTICLE	IF	CITATIONS
1092	Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, e4903-e4916.	1.8	15
1093	The quality of clinical trials in neuroendocrine tumours; have we learnt from our mistakes? An evaluation of phase II and phase III clinical trials. <i>Journal of Neuroendocrinology</i> , 2021, 33, e13015.	1.2	0
1094	Presentation and survival of gastro-entero-pancreatic neuroendocrine tumors in young adults versus older patients. <i>American Journal of Surgery</i> , 2022, 223, 939-944.	0.9	3
1095	Symptomatic spinal metastases from neuroendocrine neoplasms: surgical outcomes and prognostic analysis. <i>Clinical Neurology and Neurosurgery</i> , 2021, 207, 106710.	0.6	0
1096	Neuroendocrine Neoplasm of the Breast Presenting as a Liver Metastasis: A Rare Diagnostic Challenge. <i>Cureus</i> , 2021, 13, e16860.	0.2	1
1097	Radiolabeling of Human Serum Albumin With Terbium-161 Using Mild Conditions and Evaluation of in vivo Stability. <i>Frontiers in Medicine</i> , 2021, 8, 675122.	1.2	8
1098	PSMA Theranostics: A "Must Have" in Every Prostate Cancer Center. Illustration of Two Clinical Cases and Review of the Literature. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e235-e247.	0.9	2
1099	68Ga-DOTATATE PET-CT as a tool for radiation planning and evaluating treatment responses in the clinical management of meningiomas. <i>Radiation Oncology</i> , 2021, 16, 151.	1.2	20
1100	Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 54-63.	3.3	35
1101	Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. <i>Oncologist</i> , 2021, 26, 950-955.	1.9	19
1102	Kidney Protection with the Radical Scavenger Î±1-Microglobulin (A1M) during Peptide Receptor Radionuclide and Radioligand Therapy. <i>Antioxidants</i> , 2021, 10, 1271.	2.2	5
1103	Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate. <i>BMC Cancer</i> , 2021, 21, 950.	1.1	4
1104	Renal and Red Marrow Dosimetry in Peptide Receptor Radionuclide Therapy: 20 Years of History and Ahead. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8326.	1.8	7
1105	The aluminium-[18F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2021, 6, 30.	1.8	32
1106	Neuroendocrine neoplasms: Evolving and future treatments. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2021, 19, 15-21.	0.6	4
1107	Serotonergic brain dysfunction in neuroendocrine tumor patients: A scoping review. <i>Comprehensive Psychiatry</i> , 2021, 109, 152244.	1.5	5
1108	Pyridine-containing octadentate ligand NE3TA-PY for formation of neutral complex with 177Lu(III) and 90Y(III) for radiopharmaceutical applications: Synthesis, DFT calculation, radiolabeling, and in vitro complex stability. <i>Journal of Inorganic Biochemistry</i> , 2021, 221, 111436.	1.5	1
1109	A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors. <i>EJNMMI Research</i> , 2021, 11, 73.	1.1	7

#	ARTICLE	IF	CITATIONS
1110	Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials. ESMO Open, 2021, 6, 100171.	2.0	30
1111	Nefrotoxicidad y hematotoxicidad un \pm o despu�s de cuatro ciclos de terapia con p�ptidos marcados con radion�clidos (PRRT) y su impacto en la planificaci�n del tratamiento futuro. Un an�lisis retrospectivo. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 138-145.	0.0	2
1112	Initial clinical experience with ⁹⁰ Y-FAPI-46 radioligand therapy for advanced stage solid tumors: a case series of nine patients. Journal of Nuclear Medicine, 2021, , jnumed.121.262468.	2.8	64
1113	A Facile Procedure for One-Pot Stable Conjugation of Two Proglucagon Cysteine-Containing Peptide Analogs. Frontiers in Endocrinology, 2021, 12, 693958.	1.5	1
1114	Response to Combined Peptide Receptor Radionuclide Therapy and Checkpoint Immunotherapy with Ipilimumab Plus Nivolumab in Metastatic Merkel Cell Carcinoma. Journal of Nuclear Medicine, 2022, 63, 396-398.	2.8	18
1115	Carcinoid syndrome and neuroendocrine tumours. Medicine, 2021, 49, 544-547.	0.2	1
1116	⁹⁰ Y/ ¹⁷⁷ Lu-DOTATOC: From Preclinical Studies to Application in Humans. Pharmaceutics, 2021, 13, 1463.	2.0	19
1117	Metastatic disease to the liver: Locoregional therapy strategies and outcomes. World Journal of Clinical Oncology, 2021, 12, 725-745.	0.9	9
1118	Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTA0-Tyr3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors. Annals of Nuclear Medicine, 2021, 35, 1332-1341.	1.2	8
1119	Application of FLIC model to predict adverse events onset in neuroendocrine tumors treated with PRRT. Scientific Reports, 2021, 11, 19490.	1.6	2
1120	Gastric neuroendocrine neoplasms: A review. World Journal of Clinical Cases, 2021, 9, 7973-7985.	0.3	17
1121	Gastrinoma and Zollinger Ellison syndrome: A roadmap for the management between new and old therapies. World Journal of Gastroenterology, 2021, 27, 5890-5907.	1.4	26
1122	Comparing the Effect of Multiple Histone Deacetylase Inhibitors on SSTR2 Expression and [¹¹¹ In]In-DOTATATE Uptake in NET Cells. Cancers, 2021, 13, 4905.	1.7	11
1123	Modeling early radiation DNA damage occurring during [¹⁷⁷ Lu]Lu-DOTA-[Tyr ³]octreotate radionuclide therapy. Journal of Nuclear Medicine, 2021, , jnumed.121.262610.	2.8	2
1124	How I Treat Neuroendocrine Tumors. Indian Journal of Medical and Paediatric Oncology, 0, , .	0.1	1
1125	Metastatic urinary bladder paraganglioma on Ga-68 DOTATATE PET/CT. Radiology Case Reports, 2021, 16, 2763-2767.	0.2	2
1126	Bombesin Receptor Family Activation and CNS/Neural Tumors: Review of Evidence Supporting Possible Role for Novel Targeted Therapy. Frontiers in Endocrinology, 2021, 12, 728088.	1.5	17
1127	JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis. Journal of Gastroenterology, 2021, 56, 1033-1044.	2.3	58

#	ARTICLE	IF	CITATIONS
1128	Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1192-1199.	2.8	14
1129	Specifically Targeted Transport of Plasma Membrane Transporters: From Potential Mechanisms for Regulating Cell Health or Disease to Applications. <i>Membranes</i> , 2021, 11, 736.	1.4	6
1130	Chemotherapy in Neuroendocrine Tumors. <i>Cancers</i> , 2021, 13, 4872.	1.7	13
1131	Theranostics in oncology: What radiologists want to know. <i>European Journal of Radiology</i> , 2021, 142, 109875.	1.2	2
1132	Combining External Beam Radiation and Radionuclide Therapies: Rationale, Radiobiology, Results and Roadblocks. <i>Clinical Oncology</i> , 2021, 33, 735-743.	0.6	8
1133	The internal dosimetry user group position statement on molecular radiotherapy. <i>British Journal of Radiology</i> , 2021, 94, 20210547.	1.0	6
1134	Peptide-drug conjugate-based novel molecular drug delivery system in cancer. <i>Trends in Pharmacological Sciences</i> , 2021, 42, 857-869.	4.0	64
1135	Role of Artificial Intelligence in Theranostics. <i>PET Clinics</i> , 2021, 16, 627-641.	1.5	12
1136	Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. <i>European Journal of Cancer</i> , 2021, 157, 403-414.	1.3	33
1137	Carcinoid Syndrome Caused by a Small Intestinal Neuroendocrine Tumor. , 2021, , 435-445.		0
1138	Tumor Heterogeneity in Gastro-Entero-Pancreatic Neuroendocrine Neoplasia. <i>Endocrines</i> , 2021, 2, 28-36.	0.4	2
1139	Systemic Therapy Improvements Will Render Locoregional Treatments Obsolete for Patients with Cancer with Liver Metastases. <i>Surgical Oncology Clinics of North America</i> , 2021, 30, 189-204.	0.6	0
1140	The Use of Peptide Receptor Radionuclide Therapy in Patients With Neuroendocrine Tumor Cardiac Metastases. <i>Clinical Nuclear Medicine</i> , 2021, 46, e23-e26.	0.7	2
1141	Causes of Death After Neuroendocrine Tumors Diagnosis. <i>Pancreas</i> , 2021, 50, 47-53.	0.5	5
1142	Update in carcinoid heart disease - the heart of the matter. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 553-561.	2.6	12
1143	Current and future perspectives on functional molecular imaging in nephro-urology: theranostics on the horizon. <i>Theranostics</i> , 2021, 11, 6105-6119.	4.6	13
1144	Treatment of NETs from Rare Origin. , 2021, , 211-229.		0
1145	Treatment of Advanced Gastro-Entero-Pancreatic Neuro-Endocrine Tumors: A Systematic Review and Network Meta-Analysis of Phase III Randomized Controlled Trials. <i>Cancers</i> , 2021, 13, 358.	1.7	11

#	ARTICLE	IF	CITATIONS
1146	Currently available treatment options for neuroendocrine liver metastases. <i>Annals of Gastroenterology</i> , 2021, 34, 130-141.	0.4	8
1147	Clinical-Pathological Conference Series from the Medical University of Graz. <i>Wiener Klinische Wochenschrift</i> , 2021, 133, 515-522.	1.0	0
1148	The Landmark Series: Management of Small Bowel Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2021, 28, 2741-2751.	0.7	16
1150	Gallium-68: Radiolabeling of Radiopharmaceuticals for PET Imaging - A Lot to Consider. , 0, , .		6
1151	A Peptide Meets a Radionuclide to Combat a Rare Tumor. <i>Ochsner Journal</i> , 2021, 21, 306-311.	0.5	0
1152	Chemotherapy-Induced Upregulation of Somatostatin Receptor-2 Increases the Uptake and Efficacy of ¹⁷⁷ Lu-DOTA-Octreotate in Neuroendocrine Tumor Cells. <i>Cancers</i> , 2021, 13, 232.	1.7	15
1153	Receptors for Targeting Gastrointestinal Tract Cancer. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2019, , 141-170.	0.2	1
1154	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	1.0	16
1156	Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments. <i>Seminars in Radiation Oncology</i> , 2020, 30, 181-186.	1.0	21
1157	Overview and Current Status of Peptide Receptor Radionuclide Therapy. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 317-326.	0.6	15
1158	Evidence Base for the Use of PRRT. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 399-404.	2.5	9
1160	Response assessment of somatostatin receptor targeted radioligand therapies for progressive intracranial meningioma. <i>Nuklearmedizin - NuclearMedicine</i> , 2020, 59, 348-355.	0.3	8
1161	High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2020, 27, 162-169.	1.2	14
1162	⁶⁸ Ga-DOTATATE and ¹²³ I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy. <i>Nuclear Medicine Communications</i> , 2020, 41, 1169-1177.	0.5	21
1163	Salvage peptide receptor radionuclide therapy in patients with progressive neuroendocrine tumors: a systematic review and meta-analysis. <i>Nuclear Medicine Communications</i> , 2021, 42, 451-458.	0.5	13
1164	Peptide Receptor Radionuclide Therapy as First-Line Systemic Treatment in Advanced Inoperable/Metastatic Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2020, 45, e393-e399.	0.7	17
1165	Comparison of Contrast-Enhanced CT + CT Enterography and ⁶⁸ Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2020, 45, 848-853.	0.7	8
1166	Liver Transplantation for Colorectal and Neuroendocrine Liver Metastases and Hepatoblastoma. Working Group Report From the ILTS Transplant Oncology Consensus Conference. <i>Transplantation</i> , 2020, 104, 1131-1135.	0.5	30

#	ARTICLE	IF	CITATIONS
1167	Establishment and characterization of a novel neuroendocrine carcinoma cell line derived from a human ascending colon tumor. <i>Cancer Science</i> , 2019, 110, 3708-3717.	1.7	6
1168	Targeted therapy for upper gastrointestinal tract cancer: current and future prospects. <i>Histopathology</i> , 2021, 78, 148-161.	1.6	17
1169	Leptomeningeal metastases of a well-differentiated neuroendocrine tumour: a rare entity. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2018-226557.	0.2	4
1170	Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. <i>Radiographics</i> , 2020, 40, 1715-1740.	1.4	65
1171	Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. <i>Clinical Cancer Research</i> , 2020, 26, 2124-2130.	3.2	132
1172	Current best practice in the management of neuroendocrine tumors. , 0, .		1
1173	PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme?. <i>EJNMMI Research</i> , 2020, 10, 35.	1.1	16
1174	Toxicity of a combined therapy using the mTOR-inhibitor everolimus and PRRT with [¹⁷⁷ Lu]Lu-DOTA-TATE in Lewis rats. <i>EJNMMI Research</i> , 2020, 10, 41.	1.1	6
1175	A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy. <i>EJNMMI Research</i> , 2020, 10, 42.	1.1	11
1176	Tumour-to-liver ratio determined by [⁶⁸ Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours. <i>EJNMMI Research</i> , 2020, 10, 63.	1.1	22
1177	Extravasation of [¹⁷⁷ Lu]Lu-DOTATOC: case report and discussion. <i>EJNMMI Research</i> , 2020, 10, 68.	1.1	9
1178	Pharmacokinetics, radiation dosimetry, acute toxicity and automated synthesis of [¹⁸ F]AmBF ₃ -TATE. <i>EJNMMI Research</i> , 2020, 10, 25.	1.1	10
1179	Design, synthesis, and biological evaluation of a multifunctional neuropeptide-Y conjugate for selective nuclear delivery of radiolanthanides. <i>EJNMMI Research</i> , 2020, 10, 16.	1.1	11
1180	Towards standardization of absolute SPECT/CT quantification: a multi-center and multi-vendor phantom study. <i>EJNMMI Physics</i> , 2019, 6, 29.	1.3	47
1181	Personalized radiation dosimetry for PRRT—how many scans are really required?. <i>EJNMMI Physics</i> , 2020, 7, 26.	1.3	21
1182	Radiation doses from ¹⁶¹ Tb and ¹⁷⁷ Lu in single tumour cells and micrometastases. <i>EJNMMI Physics</i> , 2020, 7, 33.	1.3	27
1183	Establishment of a clinical SPECT/CT protocol for imaging of ¹⁶¹ Tb. <i>EJNMMI Physics</i> , 2020, 7, 45.	1.3	20
1184	Uncertainty analysis of tumour absorbed dose calculations in molecular radiotherapy. <i>EJNMMI Physics</i> , 2020, 7, 63.	1.3	21

#	ARTICLE	IF	CITATIONS
1185	Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. <i>EJNMMI Physics</i> , 2020, 7, 5.	1.3	23
1186	Comprehensive SPECT/CT system characterization and calibration for ¹⁷⁷ Lu quantitative SPECT (QSPECT) with dead-time correction. <i>EJNMMI Physics</i> , 2020, 7, 10.	1.3	18
1187	Cellular dosimetry of [¹⁷⁷ Lu]Lu-DOTA-[Tyr ³]octreotate radionuclide therapy: the impact of modeling assumptions on the correlation with in vitro cytotoxicity. <i>EJNMMI Physics</i> , 2020, 7, 8.	1.3	23
1188	Variability in lutetium-177 SPECT quantification between different state-of-the-art SPECT/CT systems. <i>EJNMMI Physics</i> , 2020, 7, 9.	1.3	29
1189	Cost-effectiveness of lutetium (¹⁷⁷ Lu) oxodotretotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. <i>World Journal of Clinical Cases</i> , 2020, 8, 4793-4806.	0.3	3
1190	Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. <i>World Journal of Meta-analysis</i> , 2018, 6, 9-20.	0.1	2
1191	Astatine-211 labelled a small molecule peptide: specific cell killing <i>in vitro</i> and targeted therapy in a nude-mouse model. <i>Radiochimica Acta</i> , 2021, 109, 119-126.	0.5	5
1192	Multidisciplinary team management of carcinoid heart disease. <i>Endocrine Connections</i> , 2019, 8, R184-R199.	0.8	19
1193	¹⁷⁷ Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma. <i>Endocrine Connections</i> , 2020, 9, 864-873.	0.8	35
1194	Clinical pathological features, treatments and survival of malignant insulinomas: a multicenter study. <i>European Journal of Endocrinology</i> , 2020, 182, 439-446.	1.9	24
1195	Role of the tumor microenvironment in digestive neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, R519-R544.	1.6	13
1196	Neuroendocrine neoplasms: current and potential diagnostic, predictive and prognostic markers. <i>Endocrine-Related Cancer</i> , 2019, 26, R157-R179.	1.6	34
1197	Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study. <i>Endocrine-Related Cancer</i> , 2019, 26, 227-239.	1.6	114
1198	Local treatment for focal progression in metastatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2019, 26, 405-409.	1.6	10
1199	Management of carcinoid syndrome: a systematic review and meta-analysis. <i>Endocrine-Related Cancer</i> , 2019, 26, R145-R156.	1.6	59
1200	¹⁷⁷ Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition. <i>Endocrine-Related Cancer</i> , 2019, 26, 437-449.	1.6	14
1201	Molecular imaging and radionuclide therapy of pheochromocytoma and paraganglioma in the era of genomic characterization of disease subgroups. <i>Endocrine-Related Cancer</i> , 2019, 26, R627-R652.	1.6	72
1202	HEREDITARY ENDOCRINE TUMOURS: CURRENT STATE-OF-THE-ART AND RESEARCH OPPORTUNITIES: MEN1-related pancreatic NETs: identification of unmet clinical needs and future directives. <i>Endocrine-Related Cancer</i> , 2020, 27, T9-T25.	1.6	10

#	ARTICLE	IF	CITATIONS
1203	Health-related quality of life in neuroendocrine neoplasia: a critical review. <i>Endocrine-Related Cancer</i> , 2020, 27, R267-R280.	1.6	7
1204	Using genetics to inform the pharmacological targeting of neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2020, 27, R293-R305.	1.6	1
1205	c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs. <i>Journal of Molecular Endocrinology</i> , 2020, 65, R1-R17.	1.1	4
1206	Theranostics: Cancer imaging and therapy using injectable radionuclide-labeled ligands. <i>Pharmacy & Pharmacology International Journal</i> , 2020, 8, 325-331.	0.1	2
1209	Metastatic MEN1 Syndrome Treated with Lutetium-177 – A Case Report. <i>European Endocrinology</i> , 2019, 15, 92.	0.8	3
1210	High-dose Somatostatin Analogues for Progressive Neuroendocrine Tumours. <i>European Endocrinology</i> , 2020, 16, 93.	0.8	4
1211	Antiproliferative effect of somatostatin analogs in advanced gastro-entero-pancreatic neuroendocrine tumors: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 46624-46634.	0.8	20
1212	Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome. <i>Oncotarget</i> , 2017, 8, 49123-49132.	0.8	23
1213	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. <i>Oncotarget</i> , 2018, 9, 14922-14938.	0.8	29
1214	Potential of 177Lu-octreotate peptide receptor radionuclide therapy of human neuroendocrine tumor cells by PARP inhibitor. <i>Oncotarget</i> , 2018, 9, 24693-24706.	0.8	44
1215	177Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors. <i>Oncotarget</i> , 2018, 9, 33059-33059.	0.8	8
1216	Exploring the role of survivin in neuroendocrine neoplasms. <i>Oncotarget</i> , 2020, 11, 2246-2258.	0.8	11
1217	Australian experience of peptide receptor radionuclide therapy in lung neuroendocrine tumours. <i>Oncotarget</i> , 2020, 11, 2636-2646.	0.8	8
1218	Post FDA approval analysis of 200 gallium-68 DOTATATE imaging: A retrospective analysis in neuroendocrine tumor patients. <i>Oncotarget</i> , 2020, 11, 3061-3068.	0.8	8
1219	Advances on systemic treatment for lung neuroendocrine neoplasms. <i>Annals of Translational Medicine</i> , 2018, 6, 146-146.	0.7	19
1220	Clinical and Translational Research Challenges in Neuroendocrine Tumours. <i>Current Medicinal Chemistry</i> , 2020, 27, 4823-4839.	1.2	5
1221	Cholecystokinin-2 Receptor Targeting with Radiolabeled Peptides: Current Status and Future Directions. <i>Current Medicinal Chemistry</i> , 2020, 27, 7112-7132.	1.2	16
1222	Bench-to-Bedside Theranostics in Nuclear Medicine. <i>Current Pharmaceutical Design</i> , 2020, 26, 3804-3811.	0.9	8

#	ARTICLE	IF	CITATIONS
1223	Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumours. <i>Current Radiopharmaceuticals</i> , 2019, 12, 126-134.	0.3	20
1224	Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2019, 71, 445-456.	3.9	8
1225	Investigational PET tracers for high-grade gliomas. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 281-294.	0.4	10
1226	Volumetric 68Ga-DOTA-TATE PET/CT for assessment of whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 66, .	0.4	14
1227	Targeted alpha therapy: a critical review of translational dosimetry research with emphasis on actinium-225. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 265-277.	0.4	7
1228	Clinicopathological Features of Gastroenteropancreatic Neuroendocrine Neoplasms. <i>Journal of the College of Physicians and Surgeons–Pakistan: JCPSP</i> , 2020, 30, 863-867.	0.2	2
1229	Mars Shot for Nuclear Medicine, Molecular Imaging, and Molecularly Targeted Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 6-14.	2.8	13
1230	The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. <i>Journal of Nuclear Medicine</i> , 2020, 61, 263S-272S.	2.8	67
1231	Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis. <i>Health Technology Assessment</i> , 2018, 22, 1-326.	1.3	21
1232	Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask. <i>Frontiers in Endocrinology</i> , 2021, 12, 680305.	1.5	4
1233	Efficacy of 177Lu-Dotatate Induction and Maintenance Therapy of Various Types of Neuroendocrine Tumors: A Phase II Registry Study. <i>Current Oncology</i> , 2021, 28, 115-127.	0.9	14
1234	THERANOSTICS- NEUROENDOCRINE TUMOURS. <i>Journal of Cancer & Allied Specialties</i> , 2018, 4, .	0.1	1
1235	Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours. <i>World Journal of Gastroenterology</i> , 2018, 24, 671-679.	1.4	17
1236	Evaluation of ¹⁷⁷ Lu-Dotatate treatment in patients with metastatic neuroendocrine tumors and prognostic factors. <i>World Journal of Gastroenterology</i> , 2020, 26, 1513-1524.	1.4	18
1237	Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management. <i>World Journal of Gastroenterology</i> , 2020, 26, 2305-2322.	1.4	86
1238	The HSP90 inhibitor onalespib potentiates 177Lu-DOTATATE therapy in neuroendocrine tumor cells. <i>International Journal of Oncology</i> , 2019, 55, 1287-1295.	1.4	16
1239	A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. <i>Molecular and Clinical Oncology</i> , 2020, 14, 20.	0.4	4
1240	VIPoma: Mechanisms, clinical presentation, diagnosis and treatment (Review). <i>World Academy of Sciences Journal</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
1241	Peptide Receptor Radionuclide Therapy in the Management of Neuroendocrine Tumors (Neoplasms): Fundamentals and Salient Clinical Practice Points for Medical Oncologists. <i>Indian Journal of Medical and Paediatric Oncology</i> , 2019, 40, 165-171.	0.1	5
1242	Clinical efficacy of ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy in thyroglobulin-elevated negative iodine scintigraphy: A not-so-promising result compared to GEP-NETs. <i>World Journal of Nuclear Medicine</i> , 2020, 19, 205-210.	0.3	7
1243	Prevalence of hitherto unknown brain meningioma detected on ⁶⁸ Ga-DOTATATE positron-emission tomography/computed tomography in patients with metastatic neuroendocrine tumor and exploring potential of ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy as single-shot treatment approach targeting both tumors. <i>World Journal of Nuclear Medicine</i> , 2019, 18, 160-170.	0.3	25
1244	^{99m} Tc-Hynic-TOC imaging in the diagnostic of neuroendocrine tumors. <i>World Journal of Nuclear Medicine</i> , 2018, 17, 151.	0.3	7
1245	Gastric neuroendocrine tumor: A practical literature review. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 850-856.	0.8	25
1246	Use of DOTATATE PET/CT Scan in the Diagnosis and Staging of Thymic Atypical Carcinoid Tumor in a Patient with Secondary ACTH-dependent Cushing Syndrome: Look Twice and Cut Once. <i>World Journal of Endocrine Surgery</i> , 2018, 10, 127-133.	0.0	2
1247	Cost-Effectiveness of Initial Versus Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1200-1209.	2.3	3
1248	Stereotactic Radiosurgery for Carcinoid Brain Metastasis: A Case Report. <i>Cureus</i> , 2019, 11, e5509.	0.2	3
1249	One-step, kit-based radiopharmaceuticals for molecular SPECT imaging: a versatile diphosphine chelator for ^{99m} Tc radiolabelling of peptides. <i>Dalton Transactions</i> , 2021, 50, 16156-16165.	1.6	6
1250	Neuroendocrine Neoplasms (NENs). <i>UNIPA Springer Series</i> , 2021, , 1061-1089.	0.1	0
1252	Specific Cytotoxicity of Targeted ¹⁷⁷ Lu and ²¹² Pb-Based Radiopharmaceuticals. <i>Bulletin of Experimental Biology and Medicine</i> , 2021, 171, 627-632.	0.3	2
1253	Combination Therapies with PRRT. <i>Pharmaceuticals</i> , 2021, 14, 1005.	1.7	8
1254	Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy. <i>Molecules</i> , 2021, 26, 6042.	1.7	40
1255	Somatostatin Analogue Therapy in MEN1-Related Pancreatic Neuroendocrine Tumors from Evidence to Clinical Practice: A Systematic Review. <i>Pharmaceuticals</i> , 2021, 14, 1039.	1.7	6
1256	Preclinical study of ²¹² Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma. <i>British Journal of Cancer</i> , 2021, 125, 1657-1665.	2.9	11
1257	Optimizing antibody drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology. <i>Current Problems in Cancer</i> , 2021, 45, 100799.	1.0	2
1258	The association between lesion tracer uptake on ⁶⁸ Ga-DOTATATE PET with morphological response to ¹⁷⁷ Lu-DOTATATE therapy in patients with progressive metastatic neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2021, Publish Ahead of Print, 73-77.	0.5	3
1259	Multicenter Analysis of Presacral Neuroendocrine Neoplasms—Clinicopathological Characterization and Treatment Outcomes of a Rare Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 709256.	1.5	2

#	ARTICLE	IF	CITATIONS
1261	Combination of terbium-161 with somatostatin receptor antagonistsâ€™ a potential paradigm shift for the treatment of neuroendocrine neoplasms. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1113-1126.	3.3	32
1262	Radioembolization of Secondary Hepatic Malignancies. <i>Seminars in Interventional Radiology</i> , 2021, 38, 445-452.	0.3	7
1263	Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE. <i>Pharmaceuticals</i> , 2021, 14, 1022.	1.7	1
1264	Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. <i>Cancers</i> , 2021, 13, 5117.	1.7	31
1265	Comment on. <i>Annals of Surgery</i> , 2021, Publish Ahead of Print, .	2.1	0
1266	A multi-center post-market clinical study to confirm safety and performance of PuraStatÂ® in the management of bleeding during open liver resection. <i>Hpb</i> , 2022, 24, 700-707.	0.1	5
1267	Automated liver lesion detection in ⁶⁸ Ga DOTATATE PET/CT using a deep fully convolutional neural network. <i>EJNMMI Research</i> , 2021, 11, 98.	1.1	18
1268	Renal protection during ¹⁷⁷ lutetium DOTATATE molecular radiotherapy in children: a proposal for safe amino acid infusional volume during peptide receptor radionuclide therapy. <i>Nuclear Medicine Communications</i> , 2022, 43, 242-246.	0.5	3
1269	Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 125-137.	1.9	5
1270	Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours. <i>Cancer Medicine</i> , 2021, 10, 8405-8411.	1.3	6
1271	Perspectives on the diagnostic, predictive and prognostic markers of neuroendocrine neoplasms (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1479.	0.8	7
1272	Making Sense of a Complex Disease: A Practical Approach to Managing Neuroendocrine Tumors. <i>JCO Oncology Practice</i> , 2022, 18, 258-264.	1.4	14
1273	Hemorrhagic disseminated intravascular coagulation after ¹⁷⁷ Lu-Dotatate in metastatic midgut neuroendocrine tumor. <i>Medicine (United States)</i> , 2021, 100, e27455.	0.4	4
1274	Personalized First-Line Treatment of Metastatic Pancreatic Neuroendocrine Carcinoma Facilitated by Liquid Biopsy and Computational Decision Support. <i>Diagnostics</i> , 2021, 11, 1850.	1.3	0
1275	Genetic Drivers of Ileal Neuroendocrine Tumors. <i>Cancers</i> , 2021, 13, 5070.	1.7	6
1276	Neuroendocrine Tumors of the Lung. <i>Thoracic Surgery Clinics</i> , 2021, 31, 469-476.	0.4	8
1277	Benign and Malignant Tumors of the Liver. , 2017, , 1-20.		0
1278	Exceptional Therapeutic Outcome of Metastatic Neuroendocrine Tumor with Peptide Receptor Radionuclide Therapy with Brief Review of Literature. <i>Journal of Nuclear Medicine & Radiation Therapy</i> , 2017, 08, .	0.2	1

#	ARTICLE	IF	CITATIONS
1279	Somatostatin Receptor Avidity in Gastrointestinal Stromal Tumors: Theranostic Implications of Gallium-68 Scan and Eligibility for Peptide Receptor Radionuclide Therapy. <i>Cureus</i> , 2017, 9, e1710.	0.2	6
1281	Therapy for Metastatic Disease: Pancreas. , 2018, , 295-303.		0
1282	Neuroendocrine Tumors. , 2018, , .		0
1283	Somatostatin receptor imaging in nasopharyngeal cancer. <i>Annals of Nasopharynx Cancer</i> , 0, 1, 1-1.	0.5	0
1285	Therapy Monitoring of Oncologic Disease in the Abdomen (Including PET/CT). <i>IDKD Springer Series</i> , 2018, , 35-47.	0.8	0
1286	Long-Term Survival of a Patient with Non-Functioning Pancreatic Neuroendocrine Tumor (Pá~NET) with Liver Metastases in the Absence of Treatment. <i>Nihon Gekakei Rengo Gakkaishi (Journal of Japanese) Tj ETQq1 1 0.764314 rgBT /Overl</i>	0.764314	0
1287	Management of Ileal, Appendiceal and Colorectal Neuroendocrine Tumors. <i>Updates in Surgery Series</i> , 2018, , 169-182.	0.0	0
1288	PROSTATE AND BREAST CANCER. <i>The Professional Medical Journal</i> , 2018, 25, 703-708.	0.0	0
1289	Liver Transplantation in a Young Patient with Severe and Refractory Carcinoid Syndrome. <i>AACE Clinical Case Reports</i> , 2018, 4, e289-e293.	0.4	0
1290	Reply to: Appearances are often deceptive. <i>Nuklearmedizin - NuclearMedicine</i> , 2018, 57, 168-169.	0.3	0
1292	Treatment of Neuroendocrine Tumour Disease. , 2019, , 259-273.		0
1293	Hindgut and Midgut Neuroendocrine Tumors - Therapeutic Approach. <i>Chirurgia (Romania)</i> , 2019, 114, 243.	0.2	0
1294	Metal-based Radiotherapeutics. <i>2-Oxoglutarate-Dependent Oxygenases</i> , 2019, , 271-307.	0.8	0
1295	Advances in Diagnosis and Treatment of Primary Hepatic Neuroendocrine Neoplasms. <i>Advances in Clinical Medicine</i> , 2019, 09, 225-234.	0.0	0
1296	Gastroenteropancreatic Neuroendocrine Tumours. , 2019, , 21-33.		0
1297	Navigating the treatment landscape in gastroenteropancreatic neuroendocrine neoplasms. <i>OnCOREview</i> , 2019, 9, 31-39.	0.1	0
1298	Molecular imaging for neuroendocrine tumours. <i>Swiss Medical Weekly</i> , 2019, 149, w20017.	0.8	5
1299	Utility of somatostatin receptor scintigraphy in pancreatic neuroendocrine neoplasms. <i>Suizo</i> , 2019, 34, 78-85.	0.1	2

#	ARTICLE	IF	CITATIONS
1300	Traitement des néoplasmes neuroendocrines digestifs. <i>Oncologie</i> , 2019, 21, 97-103.	0.2	0
1302	Liver transplantation in patients with liver metastases from neuroendocrine tumors. <i>Minerva Chirurgica</i> , 2019, 74, 399-406.	0.8	7
1303	Long-Term Follow-Up of a Patient with Primary Presacral Neuroendocrine Tumor: A Case Report with Literature Review. <i>American Journal of Case Reports</i> , 2019, 20, 1969-1975.	0.3	3
1304	Radiation-Based Medical Imaging Techniques: An Overview. , 2020, , 1-27.		0
1305	Whole-body and single-photon emission computed tomography/computed tomography postpeptide receptor alpha radionuclide therapy images of actinium 225-tetraazacyclododecanetetraacetic Acid Octreotide as a primary modality of treatment in a patient with advanced rectal neuroendocrine tumor with metastases. <i>Indian Journal of Nuclear Medicine</i> , 2020, 35, 226.	0.1	8
1306	Neuroendocrine Tumors (Gastroenteropancreatic). , 2020, , 345-381.		0
1307	Management of pancreatic neuroendocrine tumors in patients with Multiple Endocrine Neoplasia type 1. Clinical case and literature review. <i>Profilakticheskaya Meditsina</i> , 2020, 23, 101.	0.2	0
1308	Design and practical evaluation of a shielded application system for intravenously administered radionuclide therapies. <i>Nuklearmedizin - NuclearMedicine</i> , 2020, 59, 323-331.	0.3	0
1309	Narrowing the focus: Therapeutic cell surface targets for refractory triple-negative breast cancer. <i>World Journal of Clinical Oncology</i> , 2020, 11, 169-179.	0.9	1
1310	Imaging and Diagnostic Challenges in a Patient With Refractory Hypoglycemia Caused by Insulinomas Related to Multiple Endocrine Neoplasia Type 1. <i>Cureus</i> , 2020, 12, e8208.	0.2	1
1312	Radioligand Theranostics in the Management of Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 599-603.	0.5	2
1313	A Perspective in TRT and TAT "Clinical Topics and Current Status". <i>Radioisotopes</i> , 2020, 69, 213-216.	0.1	0
1314	Evaluation of ¹⁷⁷ Lu and ⁴⁷ Sc Picagala-Linked, Prostate-Specific Membrane Antigen-Targeting Constructs for Their Radiotherapeutic Efficacy and Dosimetry. <i>Molecular Pharmaceutics</i> , 2021, 18, 4511-4519.	2.3	8
1315	Optimizing the Schedule of PARP Inhibitors in Combination with ¹⁷⁷ Lu-DOTATATE: A Dosimetry Rationale. <i>Biomedicines</i> , 2021, 9, 1570.	1.4	4
1316	Nuclear medicine theranostics comes of age. <i>Lancet Oncology</i> , The, 2021, 22, 1497-1498.	5.1	11
1317	PET/PET-CT. <i>Springer Reference Medizin</i> , 2020, , 1-12.	0.0	0
1318	Liver-Directed Therapy for Neuroendocrine Tumor Liver Metastases in the Era of Peptide Receptor Radionuclide Therapy. <i>Seminars in Interventional Radiology</i> , 2020, 37, 499-507.	0.3	8
1320	Radionuclide Cancer Therapy: Unsealed Alpha- and Beta-Emitters. , 2021, , 61-87.		1

#	ARTICLE	IF	CITATIONS
1321	Future Directions of PET and Molecular Imaging and Therapy with an Emphasis on Melanoma and Sarcoma. , 2021, , 233-246.		0
1322	Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors. Expert Opinion on Drug Safety, 2021, 20, 321-334.	1.0	4
1324	Radiolabelled Peptides: Optimal Candidates for Theranostic Application in Oncology. Australian Journal of Chemistry, 2021, , .	0.5	5
1325	Radiotheranostics - Precision Medicine in Nuclear Medicine and Molecular Imaging. Nanotheranostics, 2022, 6, 103-117.	2.7	25
1326	Chilean experience using "Theranostics" for treating metastatic neuroendocrine tumors with [177Lu]Lu DOTA-TATE. Archives of Clinical Gastroenterology, 0, , 036-040.	0.1	0
1327	Gastroenteropancreatic Neuroendocrine Neoplasms. , 2020, , 658-666.		0
1328	Internal Radiation Therapy. Recent Results in Cancer Research, 2020, 216, 881-902.	1.8	3
1329	Malignome endokriner Organe. , 2020, , 945-1001.		0
1330	Pancreas; Endocrine Tumors. , 2020, , 10-23.		0
1332	Benign and Malignant Tumors of the Liver. , 2020, , 855-874.		0
1333	Peptide Receptor Radionuclide Therapy. , 2020, , 867-898.		0
1334	Radiopharmaceutical Sciences. , 2020, , 49-191.		2
1335	Neue Arzneimittel 2019. , 2020, , 43-150.		2
1336	Liver Resection and Transplantation for Metastases from Gastroenteropancreatic Neuroendocrine Tumors. Updates in Surgery Series, 2020, , 221-233.	0.0	0
1337	Neuroendocrine Neoplasms. , 2020, , 181-195.		0
1338	Radioth�rapie. , 2020, , 48-55.e4.		0
1339	Prolonged survival in a patient with multiple liver metastases from a pancreatic neuroendocrine tumor treated with Peptide Receptor Radiotherapy (PRRT). Suizo, 2020, 35, 97-103.	0.1	0
1340	Peptide receptor radionuclide therapy of gastroenteropancreatic neuroendocrine tumours: effectiveness and safety profile, decision criteria for the method. Practical Oncology, 2020, 2, 20-25.	0.1	0

#	ARTICLE	IF	CITATIONS
1341	Treatment of neuroendocrine liver metastases: a patent landscape review. <i>Pharmaceutical Patent Analyst</i> , 2020, 9, 29-32.	0.4	0
1342	Chapter 33: Therapeutic Applications of Radioactive Agents. , 2020, , .		0
1343	Unlocking the Code to Management of Neuroendocrine Neoplasms: A Clinician's Perspective. <i>JCO Oncology Practice</i> , 2021, , OP2100628.	1.4	0
1344	Clinical outcome of Lu-177 PSMA in metastatic castration-resistant prostate cancer: An initial experience from a tertiary care cancer hospital. <i>Annals of Cancer Research and Therapy</i> , 2020, 28, 156-163.	0.1	0
1346	Characterisation of a hand-held CZT-based gamma camera for 177Lu imaging. <i>EJNMMI Physics</i> , 2020, 7, 46.	1.3	7
1347	Liver-Directed Therapy for Gastroenteropancreatic NETs in the Era of Peptide Receptor Radionuclide Therapy. <i>Digestive Disease Interventions</i> , 2020, 04, 282-290.	0.3	1
1349	Functional and Radiological Imaging of Neuroendocrine Neoplasms. , 2021, , 29-53.		1
1350	Somatostatin receptor scintigraphy in the follow up of neuroendocrine neoplasms of appendix. <i>World Journal of Clinical Cases</i> , 2020, 8, 3697-3707.	0.3	2
1351	131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma. <i>Current Opinion in Oncology</i> , 2021, 33, 33-39.	1.1	9
1352	Y90 selective internal radiation therapy and peptide receptor radionuclide therapy for the treatment of metastatic neuroendocrine tumors: combination or not?. <i>Nuclear Medicine Communications</i> , 2020, 41, 1242-1249.	0.5	5
1353	Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors. <i>Clinical Nuclear Medicine</i> , 2021, 46, 111-118.	0.7	14
1354	A Rapid and Safe Infusion Protocol for ¹⁷⁷ Lu Peptide Receptor Radionuclide Therapy. <i>Journal of Nuclear Medicine</i> , 2021, 62, 816-822.	2.8	4
1355	Somatostatin receptor PET ligands - the next generation for clinical practice. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 311-331.	1.0	55
1356	Peritoneal Carcinomatosis in Well-Differentiated Small-Intestinal Neuroendocrine Tumors with Mesenteric Tumor Deposits. <i>Journal of Medical & Surgical Pathology</i> , 2019, 4, 1-10.	0.2	1
1357	One decade of 'Bench-to-Bedside' peptide receptor radionuclide therapy with indigenous [Lu]Lu-DOTATATE obtained through 'Direct' neutron activation route: lessons learnt including practice evolution in an Indian setting. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 10, 178-211.	1.0	3
1358	Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor. <i>Case Reports in Oncology</i> , 2020, 13, 1373-1380.	0.3	0
1359	Safety and tolerability of Miltuximab - a first in human study in patients with advanced solid cancers. <i>Asia Oceania Journal of Nuclear Medicine and Biology</i> , 2021, 9, 86-100.	0.1	2
1360	Combining radionuclide therapy with radiotherapy. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
1361	Gastroentero-pankreatische neuroendokrine Neoplasien (GEP-NEN). , 2022, , 391-404.		0
1362	Nephrotoxicity after radionuclide therapies. <i>Translational Oncology</i> , 2022, 15, 101295.	1.7	8
1363	¹⁷⁷ Lu-dotatate use in chronic kidney disease patients: A single center experience. <i>Journal of Onco-Nephrology</i> , 2021, 5, 162-171.	0.3	4
1364	Progress in the Management of Pancreatic Neuroendocrine Tumors. <i>Annual Review of Medicine</i> , 2022, 73, .	5.0	4
1365	Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 2021, 11, 687925.	1.3	6
1366	Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis. <i>The Cochrane Library</i> , 2021, 2021, CD013700.	1.5	7
1367	p53-Mediated Radiosensitization of ¹⁷⁷ Lu-DOTATATE in Neuroblastoma Tumor Spheroids. <i>Biomolecules</i> , 2021, 11, 1695.	1.8	4
1368	Use of [¹⁷⁷ Lu]Lu-DOTA-TATE in the treatment of gastroenteropancreatic neuroendocrine tumours: Results of a UK cost-effectiveness modelling study. <i>European Journal of Cancer, Supplement</i> , 2021, 16, 14-23.	2.2	2
1369	Life-Saving Cancer Care. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2021, 36, 711-719.	0.7	1
1371	Radiotheranostics of neuroendocrine neoplasms: "quo vadis". <i>Al&E1manah Klini&Aeskoj Mediciny</i> , 2021, 49, 297-303.	0.2	1
1372	The Quest for an Accurate Functional Tumor Volume with ⁶⁸Ga-DOTATATE PET/CT. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1027-1032.	2.8	11
1373	Can the peptide receptor radionuclide therapy [¹⁷⁷ Lu]Lu-DOTA-TATE provide a net benefit for NET&Apatients?. <i>European Journal of Cancer, Supplement</i> , 2021, 16, 1-4.	2.2	0
1374	Somatostatin and Its Receptor System in Colorectal Cancer. <i>Biomedicines</i> , 2021, 9, 1743.	1.4	7
1375	Radiotheranostic Agents Targeting Neuroblastoma: State-of-the-Art and Emerging Perspectives. <i>Onco</i> , 2021, 1, 123-139.	0.2	1
1376	Haematotoxicity during peptide receptor radionuclide therapy: Baseline parameters differences and effect on patient&A's therapy course. <i>PLoS ONE</i> , 2021, 16, e0260073.	1.1	3
1379	Neuroendocrine disorders. , 2022, , 627-650.		0
1380	Matching-adjusted indirect treatment comparison of [¹⁷⁷ Lu]Lu-DOTA-TATE, everolimus and sunitinib in advanced, unresectable gastroenteropancreatic neuroendocrine tumours: Relative effectiveness of [¹⁷⁷ Lu]Lu-DOTA-TATE in gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Cancer, Supplement</i> , 2021, 16, 5-13.	2.2	2
1381	Practical kidney dosimetry in peptide receptor radionuclide therapy using [¹⁷⁷ Lu]Lu-DOTATOC and [¹⁷⁷ Lu]Lu-DOTATATE with focus on uncertainty estimates. <i>EJNMMI Physics</i> , 2021, 8, 78.	1.3	13

#	ARTICLE	IF	CITATIONS
1382	Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12095.	1.8	13
1383	Efficacy and safety of ²²⁵ Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1595-1606.	3.3	33
1386	¹⁷⁷ Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1752-1763.	5.1	195
1387	Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms. <i>Biomedicines</i> , 2021, 9, 1810.	1.4	6
1388	Overall survival results from the NETTER-1 trial in neuroendocrine tumours: an important milestone. <i>Lancet Oncology</i> , The, 2021, 22, 1645-1646.	5.1	5
1390	PSMA targeting in metastatic castration-resistant prostate cancer: where are we and where are we going?. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110538.	1.4	21
1393	Accuracy of Two Dosimetry Software Programs for ¹⁷⁷ Lu Radiopharmaceutical Therapy Using Voxel-Based Patient-Specific Phantoms. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1394	Effect of peptide dose on radiation dosimetry for peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATOC: A pilot study. <i>Indian Journal of Nuclear Medicine</i> , 2021, 36, 412.	0.1	1
1395	Radiation-Based Medical Imaging Techniques: An Overview. , 2021, , 1145-1171.		0
1396	Costs of treatment change following first-line somatostatin analog monotherapy among patients with neuroendocrine tumors. <i>Journal of Medical Economics</i> , 2021, 24, 1337-1345.	1.0	1
1397	Position Statement on the Diagnosis, Treatment, and Response Evaluation to Systemic Therapies of Advanced Neuroendocrine Tumors, With a Special Focus on Radioligand Therapy. <i>Oncologist</i> , 2022, 27, e328-e339.	1.9	3
1398	Terapia con p ¹⁷⁷ Lu-DOTA-TATE radiomarcados con [177Lu]Lu-DOTA-TATE. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2022, 41, 55-65.	0.0	0
1399	Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. <i>Oncologist</i> , 2022, 27, 447-452.	1.9	5
1400	Upfront Small Bowel Resection for Small Bowel Neuroendocrine Tumors With Synchronous Metastases. <i>Annals of Surgery</i> , 2022, 276, e450-e458.	2.1	17
1401	Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor. <i>Case Reports in Oncology</i> , 2021, 13, 1373-1380.	0.3	4
1403	Non-Functioning Pancreatic Neuroendocrine Tumours. , 2022, , 991-998.		0
1404	Vasointestinal Polypeptide Secreting Tumours. , 2022, , 1023-1028.		0
1405	Carcinoid Syndrome. , 2022, , 971-977.		0

#	ARTICLE	IF	CITATIONS
1406	Insulinoma and Hypoglycaemia. , 2022, , 1007-1016.		0
1407	Side effects of theragnostic agents currently employed in clinical practice. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, 65, .	0.4	3
1408	Synthetic methodologies and PET imaging applications of fluorine-18 radiotracers: a patent review. Expert Opinion on Therapeutic Patents, 2022, 32, 455-473.	2.4	2
1409	Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT. Cancers, 2022, 14, 592.	1.7	12
1410	Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions. Cancers, 2022, 14, 584.	1.7	12
1411	Bronchial Carcinoids: From Molecular Background to Treatment Approach. Cancers, 2022, 14, 520.	1.7	6
1412	Dosing Therapeutic Radiopharmaceuticals in Obese Patients. International Journal of Molecular Sciences, 2022, 23, 818.	1.8	4
1413	Biomaterials for medical products. , 2022, , 25-62.		0
1414	Prospective Phase II Trial of Prognostication by ⁶⁸ Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy. Journal of Nuclear Medicine, 2022, 63, 1371-1377.	2.8	13
1415	Multimodal Management of Grade 1 and 2 Pancreatic Neuroendocrine Tumors. Cancers, 2022, 14, 433.	1.7	9
1416	Hyperfractionated Treatment with 177Lu-Octreotate Increases Tumor Response in Human Small-Intestine Neuroendocrine GOT1 Tumor Model. Cancers, 2022, 14, 235.	1.7	1
1417	Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers. International Journal of Molecular Sciences, 2022, 23, 1109.	1.8	6
1418	KSNM60 in Nuclear Endocrinology: from the Beginning to the Future. Nuclear Medicine and Molecular Imaging, 2022, 56, 17-28.	0.6	2
1419	Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 55-65.	0.1	1
1420	The Effect of VPA Treatment on Radiolabeled DOTATATE Uptake: Differences Observed In Vitro and In Vivo. Pharmaceutics, 2022, 14, 173.	2.0	3
1421	External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy. JAMA Network Open, 2022, 5, e2144170.	2.8	5
1422	Healthcare cost by primary tumour, functioning status and treatment among patients with metastatic neuroendocrine tumours: The LyREMeNET study. Journal of Neuroendocrinology, 2022, 34, e13092.	1.2	3
1423	Mutant <i>PPM1D</i> - and <i>TP53</i> -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. JCO Precision Oncology, 2022, 6, e2100309.	1.5	15

#	ARTICLE	IF	CITATIONS
1424	Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant. <i>Frontiers in Endocrinology</i> , 2021, 12, 793262.	1.5	7
1425	VIPoma: an unsuspecting culprit of severe secretory diarrhoea in a human immunodeficiency virus-infected patient. <i>Internal Medicine Journal</i> , 2022, 52, 125-129.	0.5	0
1426	Targeted ^{212}Pb -Emitter Therapy with ^{212}Pb -DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1326-1333.	2.8	58
1427	Treatment of neuroendocrine tumours with ^{177}Lu -peptide receptor radionuclide therapy: Challenging clinical scenarios and their management. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13088.	1.2	1
1428	Medical management of gastrointestinal neuroendocrine tumors. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2022, 29, 219-224.	1.2	2
1429	SPECT and PET Radiotracers in Renal Imaging. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 406-418.	2.5	10
1430	Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs) : The Role of Checkpoint Inhibitors. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	0
1431	Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We Now. <i>Cancers</i> , 2022, 14, 761.	1.7	6
1432	Comparison of Two Types of Amino Acid Solutions on ^{177}Lu -Dotatate Pharmacokinetics and Pharmacodynamics in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors. <i>Current Radiopharmaceuticals</i> , 2022, 15, 164-172.	0.3	3
1433	The Radiotherapy Learning Healthcare System – Working Together to Improve the Quality of Radiotherapy Nationally. <i>Clinical Oncology</i> , 2022, , .	0.6	0
1434	Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. <i>Lancet Oncology</i> , The, 2022, 23, e75-e87.	5.1	26
1435	Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 919.	1.0	6
1436	Theranostics before we found its name. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, 299-305.	0.4	1
1437	Dosimetry of nuclear medicine therapies: current controversies and impact on treatment optimization. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, .	0.4	5
1438	Challenges in theranostics. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, .	0.4	1
1439	Theranostic in neuroendocrine tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, .	0.4	2
1440	Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns. <i>Journal of Nuclear Medicine</i> , 2021, 62, 23S-35S.	2.8	32
1441	Side effects of radiopeptide therapy for neuroendocrine tumors. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
1443	Neuroendokrine Neoplasien. , 2022, , 77-96.		0
1445	Hypoglycemia in the Non-diabetic Patient. , 2022, , 363-373.		1
1446	Side effects of therapy for bone metastasis with alpha and beta emitters. , 2022, , .		0
1447	Therapy of NET with radiolabeled SST analogs. , 2022, , .		1
1448	Clinical and scientific considerations of genomics and metabolomics in radionuclide therapy. , 2022, , .		0
1451	New treatment strategies for advanced-stage gastrointestinal stromal tumours. Nature Reviews Clinical Oncology, 2022, 19, 328-341.	12.5	43
1452	Mixed neuroendocrineâ€“nonneuroendocrine neoplasms of the gastrointestinal system: An update. World Journal of Gastroenterology, 2022, 28, 794-810.	1.4	9
1453	Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers, 2022, 14, 1250.	1.7	6
1454	Therapeutic peptides: current applications and future directions. Signal Transduction and Targeted Therapy, 2022, 7, 48.	7.1	454
1455	Therapeutic strategies for gastroenteropancreatic neuroendocrine neoplasms: State-of-the-art and future perspectives. World Journal of Gastrointestinal Surgery, 2022, 14, 78-106.	0.8	0
1456	Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome. Cureus, 2022, 14, e22392.	0.2	2
1457	Management of bronchopulmonary neuroendocrine tumors. International Journal of Cancer Care and Delivery, 0, , .	0.0	0
1458	Safety of peptide receptor radionuclide therapy with ¹⁷⁷ Lutetium DOTATATE in neuroendocrine tumour patients with chronic kidney disease. Journal of Nuclear Medicine, 2022, , jnumed.121.263056.	2.8	2
1459	A Multinational Pilot Study on Patientsâ€™ Perceptions of Advanced Neuroendocrine Neoplasms on the EORTC QLQ-C30 and EORTC QLQ-GINET21 Questionnaires. Journal of Clinical Medicine, 2022, 11, 1271.	1.0	1
1460	Radiolabeled Somatostatin Analogues for Diagnosis and Treatment of Neuroendocrine Tumors. Cancers, 2022, 14, 1055.	1.7	17
1461	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Network Open, 2022, 5, e220290.	2.8	21
1462	Challenges in Von Hippelâ€“Lindauâ€™s disease: PRRT in patients on hemodialysis. Endocrinology, Diabetes and Metabolism Case Reports, 2022, 2022, .	0.2	0
1463	Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review. Cancers, 2022, 14, 1428.	1.7	6

#	ARTICLE	IF	CITATIONS
1464	A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of ¹⁷⁷ Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma—LuDO-N. <i>Frontiers in Pediatrics</i> , 2022, 10, 836230.	0.9	5
1465	Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population. <i>Medicine (United States)</i> , 2022, 101, e28970.	0.4	3
1466	Exploring the translational challenge for medical applications of ionising radiation and corresponding radiation protection research. <i>Journal of Translational Medicine</i> , 2022, 20, 137.	1.8	1
1467	Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers. <i>Molecular Imaging and Biology</i> , 2022, , 1.	1.3	2
1468	Long-term outcomes following ⁹⁰ Y Radioembolization of neuroendocrine liver metastases: evaluation of the radiation-emitting SIR-spheres in non-resectable liver tumor (RESiN) registry. <i>BMC Cancer</i> , 2022, 22, 224.	1.1	11
1469	What Gastroenterologists Should Know about Carcinoid Syndrome. <i>Gastroenterology Insights</i> , 2022, 13, 127-138.	0.7	3
1470	Diagnosis and Surgical Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms: A Literature Review. <i>Cancer Diagnosis & Prognosis</i> , 2022, 2, 115-125.	0.3	2
1471	Shining Damaged Hearts: Immunotherapy-Related Cardiotoxicity in the Spotlight of Nuclear Cardiology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3802.	1.8	3
1472	Neuroendocrine tumor theranostics. <i>Cancer Science</i> , 2022, 113, 1930-1938.	1.7	8
1473	Pharmacotherapeutic Management of Well-Differentiated Neuroendocrine Tumors in Older Patients: Current Status and Potential Therapies. <i>Drugs and Aging</i> , 2022, 39, 257.	1.3	0
1474	Integration of molecular imaging in the personalized approach to neuroendocrine tumours. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, , .	0.4	0
1475	Impact of cyclic changes in pharmacokinetics and absorbed dose in pediatric neuroblastoma patients receiving [¹⁷⁷ Lu]Lu-DOTATATE. <i>EJNMMI Physics</i> , 2022, 9, 24.	1.3	2
1476	Iodine-131 and Iodine-131-Meta-iodobenzylguanidine Dosimetry in Cancer Therapy. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 167-177.	2.5	7
1477	Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [¹⁷⁷ Lu]Lu-DOTATOC. <i>Cancers</i> , 2022, 14, 1768.	1.7	2
1479	Ga-DOTA PET/CT: the first-line functional imaging modality in the management of patients with neuroendocrine tumors. <i>Radiologia Brasileira</i> , 2022, 55, 3-4.	0.3	1
1480	The Impact of Radiopharmaceutical Therapy on Renal Function. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 467-474.	2.5	9
1481	Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors—Need for a Conductor. <i>Cancers</i> , 2022, 14, 1478.	1.7	3
1482	Combined use of ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy and fluzoparib for treatment of well-differentiated neuroendocrine tumors: A preclinical study. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13109.	1.2	4

#	ARTICLE	IF	CITATIONS
1483	New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms. Current Treatment Options in Oncology, 2022, 23, 703-720.	1.3	20
1484	Everolimus with or without bevacizumab in advanced pNET: CALGB 80701 (Alliance). Endocrine-Related Cancer, 2022, 29, 335-344.	1.6	8
1485	Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Oncologist, 2022, 27, 573-578.	1.9	30
1486	Severe Thrombocytopenia in Patients With Advanced Neuroendocrine Tumor Treated With Peptide Receptor Radioligand Therapy. Clinical Nuclear Medicine, 2022, 47, 409-413.	0.7	3
1487	ASTRO's Framework for Radiopharmaceutical Therapy Curriculum Development for Trainees. International Journal of Radiation Oncology Biology Physics, 2022, 113, 719-726.	0.4	9
1488	EANM dosimetry committee recommendations for dosimetry of ¹⁷⁷ Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1778-1809.	3.3	70
1489	Neuroendocrine Tumors: a Relevant Clinical Update. Current Oncology Reports, 2022, 24, 703-714.	1.8	9
1490	Heterogeneity of SSTR2 Expression Assessed by ⁶⁸ Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2022, 63, 1509-1514.	2.8	11
1491	Long-term survival and toxicity in patients with neuroendocrine tumors treated with ¹⁷⁷ Lu-octreotate peptide radionuclide therapy. Cancer, 2022, 128, 2182-2192.	2.0	9
1492	Efficacy and safety of ¹⁷⁷ Lu-DOTATATE in patients with advanced pancreatic neuroendocrine tumours: data from the NETTER-R international, retrospective study. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3529-3537.	3.3	6
1493	Therapeutic efficacy of heterogeneously distributed radiolabelled peptides: Influence of radionuclide choice. Physica Medica, 2022, 96, 90-100.	0.4	2
1494	Pancreatic neuroendocrine neoplasms: Updates on genomic changes in inherited tumour syndromes and sporadic tumours based on WHO classification. Critical Reviews in Oncology/Hematology, 2022, 172, 103648.	2.0	8
1495	Molecular Imaging of Neuroendocrine Neoplasms. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2662-e2670.	1.8	9
1496	New Insights in PRRT: Lessons From 2021. Frontiers in Endocrinology, 2022, 13, 861434.	1.5	11
1497	The Importance of Training, Accreditation, and Guidelines for the Practice of Theranostics: The Australian Perspective. Journal of Nuclear Medicine, 2022, 63, 819-822.	2.8	9
1498	Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, Publish Ahead of Print, .	0.6	0
1499	Estimation of Absorbed Doses of Indigenously Produced ¹⁷⁷ Lu-DOTA-TATE PRRT in Normal Organs and Tumor Lesions in Patients of Metastatic Neuroendocrine Tumors: Comparison with No-Carrier-Added [¹⁷⁷ Lu]Lu-DOTA-TATE and the Trend with Multiple Cycles. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 214-225.	0.7	1
1500	Assessment of Clinical Response Following Atezolizumab and Bevacizumab Treatment in Patients With Neuroendocrine Tumors. JAMA Oncology, 2022, 8, 904.	3.4	13

#	ARTICLE	IF	CITATIONS
1501	Clinical Pharmacology of Radiotheranostics in Oncology. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 260-274.	2.3	9
1502	Management of incidentally discovered appendiceal neuroendocrine tumors after an appendectomy. <i>World Journal of Gastroenterology</i> , 2022, 28, 1304-1314.	1.4	10
1503	Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2022, 29, 225-239.	1.6	3
1504	Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy. <i>Nuclear Medicine and Biology</i> , 2022, 108-109, 44-53.	0.3	3
1505	Endocrine tumours. , 2021, , 265-274.		0
1506	A Case of Carcinoid Tumors in the Ear Canal With Long-Term Postoperative Follow-Up. , 2021, 17, 577-580.		0
1507	Updates on therapy for medullary thyroid cancer in 2021. <i>Annales D'Endocrinologie</i> , 2022, 83, 114-118.	0.6	4
1508	Reimbursement Approaches for Radiopharmaceutical Dosimetry: Current Status and Future Opportunities. <i>Journal of Nuclear Medicine</i> , 2021, 62, 48S-59S.	2.8	11
1509	[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2037-2048.	3.3	7
1510	New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma. <i>Cancers</i> , 2022, 14, 134.	1.7	8
1512	Theranostics“ present and future. <i>Bio-Algorithms and Med-Systems</i> , 2022, 17, 213-220.	1.0	7
1513	Gallium-68-somatostatin receptor PET/CT parameters as potential prognosticators for clinical time to progression after peptide receptor radionuclide therapy: a cohort study. <i>European Journal of Hybrid Imaging</i> , 2021, 5, 22.	0.6	4
1514	Liver-Directed Therapy for Neuroendocrine Metastases: From Interventional Radiology to Nuclear Medicine Procedures. <i>Cancers</i> , 2021, 13, 6368.	1.7	11
1515	Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients. <i>Cancers</i> , 2021, 13, 6290.	1.7	4
1516	ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy. <i>Journal of the ICRU</i> , 2021, 21, 1-212.	6.0	52
1517	Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy. <i>Pharmaceuticals</i> , 2022, 15, 13.	1.7	22
1518	Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1822-1832.	3.3	31
1519	Absolute Quantification in Diagnostic SPECT/CT: The Phantom Premise. <i>Diagnostics</i> , 2021, 11, 2333.	1.3	7

#	ARTICLE	IF	CITATIONS
1520	Radiopharmaceutical Dosimetry for Cancer Therapy: From Theory to Practice. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1S-2S.	2.8	4
1521	Targeting Aggressive Pituitary Adenomas at the Molecular Level—A Review. <i>Journal of Clinical Medicine</i> , 2022, 11, 124.	1.0	9
1522	Dose–response relationship after yttrium-90-radioembolization with glass microspheres in patients with neuroendocrine tumor liver metastases. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1700-1710.	3.3	10
1523	Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice. <i>Journal of Nuclear Medicine</i> , 2021, 62, 60S-72S.	2.8	19
1524	Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms. <i>Journal of Neuroendocrinology</i> , 2022, 34, e13076.	1.2	9
1525	Dosimetry for Radiopharmaceutical Therapy: The European Perspective. <i>Journal of Nuclear Medicine</i> , 2021, 62, 73S-79S.	2.8	7
1526	A High Separation Factor for ¹⁶⁵ Er from Ho for Targeted Radionuclide Therapy. <i>Molecules</i> , 2021, 26, 7513.	1.7	3
1527	Safety and response after peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTATATE for neuroendocrine tumors in phase 1/2 prospective Japanese trial. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2022, 29, 487-499.	1.4	7
1528	Molecular imaging in oncology: Current impact and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 333-352.	157.7	106
1529	Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies. <i>Cancers</i> , 2022, 14, 129.	1.7	21
1530	Systematic Evaluation of the Immune Environment of Small Intestinal Neuroendocrine Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 2657-2668.	3.2	4
1531	PET-CT Imaging and Applications. , 0, , .		1
1532	Dose-Limiting Bone Marrow Toxicities After Peptide Receptor Radionuclide Therapy Are More Prevalent in Women Than in Men. <i>Clinical Nuclear Medicine</i> , 2022, 47, 599-605.	0.7	6
1533	Rechallenge With Additional Doses of ¹⁷⁷ Lu-DOTATOC After Failure of Maintenance Therapy With Cold Somatostatin Analogs. <i>Clinical Nuclear Medicine</i> , 2022, Publish Ahead of Print, .	0.7	2
1534	Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	4
1535	Real-world comparison of healthcare resource utilization and costs of [¹⁷⁷ Lu]Lu-DOTA-TATE in patients with progressive neuroendocrine tumors in England: a matched cohort analysis using data from the Hospital Episode Statistics dataset. <i>Current Medical Research and Opinion</i> . 2022. . 1-33.	0.9	0
1537	Status of radiobiology in molecular radionuclide therapy — Hope for the future. <i>Nuclear Medicine and Biology</i> , 2022, 110-111, 45-46.	0.3	1
1538	Advances in the Diagnosis and Therapeutic Management of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Cancers</i> , 2022, 14, 2028.	1.7	6

#	ARTICLE	IF	CITATIONS
1539	Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic ⁶⁸Ga- ⁶⁸ Ga-DOTATATE. Journal of Neuroendocrinology, 2022, 34, e13139.	1.2	2
1546	Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based ¹⁷⁷ Lu-DOTATATE treatment of NET patients. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3830-3840.	3.3	30
1548	Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment. Clinical Cancer Research, 2022, 28, 3652-3657.	3.2	12
1550	Clinical usefulness of Somatostatin Receptor Scintigraphy in the Diagnosis of Neuroendocrine Neoplasms.. Asia Oceania Journal of Nuclear Medicine and Biology, 2022, 10, 1-13.	0.1	1
1552	Phase 1 Study of No-Carrier Added ¹⁷⁷ Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea. Cancer Research and Treatment, 2023, 55, 334-343.	1.3	2
1554	Pancreatic neuroendocrine neoplasms: survival trend analysis of a comprehensive cancer center. Endocrine Oncology, 2022, , .	0.1	2
1555	Functional imaging for evaluation of cancers and biologically conformal radiotherapy: Past-history and present-day perspectives.. Presse Medicale, 2022, , 104124.	0.8	1
1556	Survival According to Therapy Regimen for Small Intestinal Neuroendocrine Tumors. Journal of Clinical Medicine, 2022, 11, 2358.	1.0	2
1557	Current and future strategies for radiation therapy in gastric cancer. Journal of Surgical Oncology, 2022, 125, 1161-1175.	0.8	2
1558	⁶⁸Ga-DOTATATE PET and functional imaging in pediatric pheochromocytoma and paraganglioma. Pediatric Blood and Cancer, 2022, 69, e29740.	0.8	4
1559	High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?. Current Treatment Options in Oncology, 2022, 23, 1001-1013.	1.3	2
1560	Multimodality imaging of ⁶⁸Ga-nanoparticle-based vaccines: Shedding light on immunology. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, , e1807.	3.3	1
1561	The Mount Sinai Clinical Pathway for the Diagnosis and Management of Hypercortisolism due to Ectopic ACTH Syndrome. Journal of the Endocrine Society, 2022, 6, .	0.1	8
1562	Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors. World Journal of Gastroenterology, 2022, 28, 1768-1780.	1.4	3
1563	Monte Carlo modelling of a compact CZT-based gamma camera with application to ¹⁷⁷ Lu imaging. EJNMMI Physics, 2022, 9, 35.	1.3	1
1564	²²⁵ Ac-DOTATATE therapy in a case of metastatic pheochromocytoma. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 3596-3597.	3.3	3
1565	Targeted Radionuclide Therapy with Low and High-Dose Lutetium-177-Labeled Single Domain Antibodies Induces Distinct Immune Signatures in a Mouse Melanoma Model. Molecular Cancer Therapeutics, 2022, 21, 1136-1148.	1.9	5
1566	Immunohistochemical Expression Pattern of Theragnostic Targets SSTR2 and PSMA in Endolymphatic Sac Tumors: A Single Institution Case Series. Head and Neck Pathology, 2022, , .	1.3	1

#	ARTICLE	IF	CITATIONS
1567	In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3841-3851.	3.3	6
1568	¹⁷⁷ Lu-DOTA-0-Tyr ³ -octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT. <i>EJNMMI Physics</i> , 2022, 9, 33.	1.3	1
1569	Prognostic value of dysnatremia for survival in neuroendocrine neoplasm patients. <i>European Journal of Endocrinology</i> , 2022, , .	1.9	1
1570	ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 233-242.	0.6	3
1571	Head and Neck Paragangliomas: An Update on the Molecular Classification, State-of-the-Art Imaging, and Management Recommendations. <i>Radiology Imaging Cancer</i> , 2022, 4, e210088.	0.7	17
1572	[¹⁷⁷ Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3332-3333.	3.3	2
1573	New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. <i>World Journal of Gastroenterology</i> , 2022, 28, 1751-1767.	1.4	8
1574	ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy. <i>Clinical Nuclear Medicine</i> , 2022, 47, 503-511.	0.7	2
1575	Pulmonary neuroendocrine tumours and somatostatin receptor status: an assessment of unlicensed use of somatostatin analogues in the clinical practice. <i>ESMO Open</i> , 2022, 7, 100478.	2.0	4
1576	Highly variable biodistribution of ⁶⁸ Ga labeled somatostatin analogues ⁶⁸ Ga-DOTA-NOC and ⁶⁸ Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 654-661.	0.7	1
1577	Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for ¹⁷⁷ Lu-DOTATATE therapy. <i>EJNMMI Physics</i> , 2022, 9, 37.	1.3	8
1578	Current updates and future directions in diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms. <i>World Journal of Gastrointestinal Endoscopy</i> , 2022, 14, 267-290.	0.4	5
1579	Best Practices for the Coordinated Care of Patients With Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. <i>Pancreas</i> , 2022, 51, 213-218.	0.5	2
1580	Metastatic pheochromocytomas and paragangliomas: where are we?. <i>Tumori</i> , 2022, 108, 526-540.	0.6	4
1581	A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1852-1858.	2.8	19
1584	Advances in medical treatment for pancreatic neuroendocrine neoplasms. <i>World Journal of Gastroenterology</i> , 2022, 28, 2163-2175.	1.4	1
1585	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. <i>Cancers</i> , 2022, 14, 2501.	1.7	7
1586	Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3651-3667.	3.3	57

#	ARTICLE	IF	CITATIONS
1589	Treatment Approaches and Outcome of Patients with Neuroendocrine Neoplasia Grade 3 in German Real-World Clinical Practice. <i>Cancers</i> , 2022, 14, 2718.	1.7	1
1590	Peptide Receptor Radionuclide Therapy in Thyroid Cancer. <i>Frontiers in Endocrinology</i> , 2022, 13, .	1.5	14
1591	Role of surgical treatments in high-grade or advanced gastroenteropancreatic neuroendocrine neoplasms. <i>World Journal of Gastrointestinal Surgery</i> , 2022, 14, 397-408.	0.8	0
1592	Early Whole-Body Diffusion-weighted MRI Helps Predict Long-term Outcome Following Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors. <i>Radiology Imaging Cancer</i> , 2022, 4, .	0.7	4
1593	Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging. <i>Cancers</i> , 2022, 14, 2514.	1.7	0
1594	Advancing therapy for neuroblastoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 515-533.	12.5	97
1595	Treatment response and clinical outcomes of well differentiated high grade neuroendocrine tumors to lutetium-177 DOTATATE. <i>Neuroendocrinology</i> , 0, , .	1.2	4
1596	A prospective head-to-head comparison of 68Ga-NOTA-3P-TATE-RGD and 68Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4218-4227.	3.3	2
1597	Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time?. <i>Journal of Clinical Oncology</i> , 2022, 40, 2818-2829.	0.8	13
1598	Prostate Cancer Treatment: ¹⁷⁷ Lu-PSMA-617 Considerations, Concepts, and Limitations. <i>Journal of Nuclear Medicine</i> , 2022, 63, 823-829.	2.8	6
1599	Perspectives on translational molecular imaging and therapy: an overview of key questions to be addressed. <i>EJNMMI Research</i> , 2022, 12, .	1.1	1
1600	Malignant insulinoma: Can we predict the long-term outcomes?. <i>World Journal of Clinical Cases</i> , 2022, 10, 5124-5132.	0.3	3
1601	Molecular imaging phenotyping for selecting and monitoring radioligand therapy of neuroendocrine neoplasms. <i>Cancer Imaging</i> , 2022, 22, .	1.2	5
1602	PSMA theragnostics for metastatic castration resistant prostate cancer. <i>Translational Oncology</i> , 2022, 22, 101438.	1.7	5
1603	Carcinoid tumors and carcinoid heart disease. , 2023, , 433-438.		0
1605	Combination of [177Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model. <i>Pharmaceutics</i> , 2022, 14, 1284.	2.0	3
1606	Radiotheranostics in oncology: current challenges and emerging opportunities. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 534-550.	12.5	92
1607	Cardiac theragnostics: A possible role of 177Lu-DOTATATE therapy in coronary atherosclerotic plaque inflammation. <i>Medecine Nucleaire</i> , 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
1608	Post-PRRT scans: which scans to make and what to look for. <i>Cancer Imaging</i> , 2022, 22, .	1.2	8
1609	Treatment strategies for neuroendocrine liver metastases: a systematic review. <i>Hpb</i> , 2022, 24, 1832-1843.	0.1	9
1610	Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT. <i>Pharmaceutics</i> , 2022, 14, 1278.	2.0	7
1611	Molecular deciphering of primary liver neuroendocrine neoplasms confirms their distinct existence with foregut-like profile. <i>Journal of Pathology</i> , 2022, 258, 58-68.	2.1	3
1612	Practical Considerations for Implementation of ¹⁷⁷ Lu-DOTATATE Neuroendocrine Tumor Treatment Programs. <i>Journal of Nuclear Medicine Technology</i> , 2022, 50, 195-202.	0.4	0
1613	Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With ¹⁷⁷ Lu-DOTATATE. <i>Clinical Nuclear Medicine</i> , 2022, 47, e692-e695.	0.7	2
1615	Comparison of [¹⁸ F]DOPA and [⁶⁸ Ga]DOTA-TOC as a PET imaging tracer before peptide receptor radionuclide therapy. <i>European Journal of Hybrid Imaging</i> , 2022, 6, .	0.6	3
1616	Differences in tumor-to-normal organ SUV ratios measured with ⁶⁸ Ga-DOTATATE PET compared with ¹⁷⁷ Lu-DOTATATE SPECT in patients with neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2022, 43, 892-900.	0.5	4
1617	Epigenetic Regulation in Gastroenteropancreatic Neuroendocrine Tumors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	7
1618	Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of ¹⁷⁷ Lu-DOTATATE. <i>Clinical Nuclear Medicine</i> , 0, Publish Ahead of Print, .	0.7	0
1619	CXCR4-targeted theranostics in oncology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4133-4144.	3.3	48
1621	Lutetium-177 DOTATATE: A Practical Review. <i>Practical Radiation Oncology</i> , 2022, 12, 305-311.	1.1	9
1622	Advances in Targeted Therapy for Patients with Neuroendocrine Tumours. <i>Touch Reviews in Oncology & Haematology</i> , 2022, 18, 66.	0.1	0
1623	Advances in the treatment of gastroenteropancreatic neuroendocrine neoplasms with somatostatin analogs. <i>Journal of Pancreatology</i> , 0, Publish Ahead of Print, .	0.3	0
1625	Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report. <i>Exploration of Targeted Anti-tumor Therapy</i> , 0, , 392-397.	0.5	0
1626	The Increasing Incidence of Neuroendocrine Neoplasms Worldwide: Current Knowledge and Open Issues. <i>Journal of Clinical Medicine</i> , 2022, 11, 3794.	1.0	12
1627	Long-Term Outcomes of Submaximal Activities of Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE in Neuroendocrine Tumor Patients. <i>Journal of Nuclear Medicine</i> , 2023, 64, 40-46.	2.8	5
1628	The Utility of Ga-68 DOTA-TATE PET/CT on Clinical Management of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET). <i>European Archives of Medical Research</i> , 2022, 38, 132-137.	0.0	0

#	ARTICLE	IF	CITATIONS
1629	Sequencing of Therapies in Progressive Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
1630	The efficacy, toxicity and survival of salvage retreatment PRRT with ¹⁷⁷ Lu-DOTATATE in patients with progressive NET following initial course of PRRT. <i>British Journal of Radiology</i> , 2022, 95, .	1.0	6
1631	Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. <i>Expert Review of Endocrinology and Metabolism</i> , 2022, 17, 389-403.	1.2	11
1632	Radiotheranostic Agents in Hematological Malignancies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1633	Accuracy of two dosimetry software programs for ¹⁷⁷ Lu radiopharmaceutical therapy using voxel-based patient-specific phantoms. <i>Heliyon</i> , 2022, 8, e09830.	1.4	3
1634	Efficacy, safety and unmet needs of evolving medical treatments for carcinoid syndrome. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	3
1635	Novel gold nanoparticles targeting somatostatin receptor subtype two with near-infrared light for neuroendocrine tumour therapy. <i>Nano Research</i> , 2022, 15, 9149-9159.	5.8	2
1636	Individualization of Radionuclide Therapies: Challenges and Prospects. <i>Cancers</i> , 2022, 14, 3418.	1.7	7
1637	Gastrointestinal neuroendocrine tumor with discordant metastatic disease on ¹¹¹ In-pentetreotide SPECT/CT, ¹⁸ F-DOPA PET/CT and ⁶⁸ Ga-HA-DOTATATE PET/CT. <i>European Journal of Hybrid Imaging</i> , 2022, 6, .	0.6	0
1638	Neutrophil to lymphocyte ratio as a prognosis biomarker of PRRT in NET patients. <i>Endocrine</i> , 0, , .	1.1	0
1639	Theranostic Radiolabeled Nanomaterials for Molecular Imaging and potential Immunomodulation Effects. <i>Journal of Medical and Biological Engineering</i> , 2022, 42, 555-578.	1.0	1
1640	Safety and Efficacy of ⁹⁰ Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities. <i>Clinical Cancer Research</i> , 2022, 28, 4346-4353.	3.2	45
1641	Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
1642	Factors Contributing to Tumor Shrinkage after Peptide Receptor Radionuclide Therapy in Patients with Unresectable Neuroendocrine Tumors. <i>Cancers</i> , 2022, 14, 3317.	1.7	2
1643	Neuroendocrine prostate cancer treated with multimodal examination and therapy: A case report. <i>Urology Case Reports</i> , 2022, 44, 102158.	0.1	2
1644	Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study. <i>European Journal of Cancer</i> , 2022, 172, 252-263.	1.3	5
1645	Theranostics: Nuclear medicine for diagnosis and treatment of cancer. <i>Tenri Medical Bulletin</i> , 2022, 25, 1-13.	0.1	0
1646	Pancreatic Neuroendocrine Tumors. , 2023, , 197-217.		26

#	ARTICLE	IF	CITATIONS
1647	Personalized Cancer Care. , 2023, , 83-90.		0
1648	Small Bowel Malignant Tumors. , 2023, , 250-267.		0
1649	Present and future of target therapies and theranostics: refining traditions and exploring new frontiersâ€”highlights from annals of Nuclear Medicine 2021. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	3.3	2
1650	Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients Receiving Concomitant ²²⁵ Ac-DOTATATEâ€”Targeted Î±-Therapy and Capecitabine: A Real-World-Scenario Management-Based Long-Term Outcome Study. Journal of Nuclear Medicine, 2023, 64, 211-218.	2.8	27
1651	Editorial: Response assessment of radioligand therapies. Frontiers in Oncology, 0, 12, .	1.3	1
1652	Immune Checkpoint Inhibitor Therapy in Neuroendocrine Tumors. Hormone and Metabolic Research, 2022, 54, 795-812.	0.7	1
1653	Separation of Ytterbium and Lutetium with Solutions of (2-Ethylhexyl)phosphonic Acid Mono-2-ethylhexyl Ester in Hydrocarbons from Nitric Acid Solutions and Its Simulation. Radiochemistry, 2022, 64, 300-307.	0.2	2
1654	AplicaciÃ³n de la metodologÃ­a de matrices de riesgo para un centro de medicina nuclear de alta complejidad basado en el seguimiento y anÃ¡lisis de incidentes radiolÃ³gicos y desviaciones. Revista Investigaciones Y Aplicaciones Nucleares, 2022, , .	0.1	0
1655	Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors. Digestive Diseases and Sciences, 2022, 67, 4633-4653.	1.1	4
1656	Medulloblastoma in the Modern Era: Review of Contemporary Trials, Molecular Advances, and Updates in Management. Neurotherapeutics, 2022, 19, 1733-1751.	2.1	13
1657	Peptide Receptor Radionuclide Therapy Using ¹⁷⁷ Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment. World Journal of Nuclear Medicine, 0, , .	0.3	0
1658	A Primer on Radiopharmaceutical Therapy. International Journal of Radiation Oncology Biology Physics, 2022, , .	0.4	3
1659	DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist, 2022, 27, 940-951.	1.9	16
1660	Performances of Functional and Anatomic Imaging Modalities in Succinate Dehydrogenase A-Related Metastatic Pheochromocytoma and Paraganglioma. Cancers, 2022, 14, 3886.	1.7	3
1661	Cutting edge rare earth radiometals: prospects for cancer theranostics. EJNMMI Radiopharmacy and Chemistry, 2022, 7, .	1.8	11
1662	Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics. Frontiers in Molecular Biosciences, 0, 9, .	1.6	5
1664	Lesion Quantification Accuracy of Digital ⁹⁰ Y PET Imaging in the Context of Dosimetry in Systemic Fibroblast Activation Protein Inhibitor Radionuclide Therapy. Journal of Nuclear Medicine, 2023, 64, 329-336.	2.8	1
1665	Role of Radioembolization in Metastatic Neuroendocrine Tumors. CardioVascular and Interventional Radiology, 2022, 45, 1590-1598.	0.9	6

#	ARTICLE	IF	CITATIONS
1666	Frequency and Prognostic Significance of Intertumoural Heterogeneity in Multifocal Jejunoileal Neuroendocrine Tumours. <i>Cancers</i> , 2022, 14, 3963.	1.7	3
1667	Treatment options of metastatic and nonmetastatic VIPoma: a review. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 2629-2636.	0.8	2
1668	Metastatic Grade 3 Neuroendocrine Tumor in Multiple Endocrine Neoplasia Type 1 (MEN1) Expressing Somatostatin Receptors. <i>Journal of the Endocrine Society</i> , 0, , .	0.1	0
1669	Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis. <i>Annals of Surgery</i> , 2023, 277, e1063-e1071.	2.1	9
1670	Systemic Therapy of Advanced Well-differentiated Small Bowel Neuroendocrine Tumors Progressive on Somatostatin Analogues. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1233-1246.	1.3	1
1671	Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review. <i>Endocrine</i> , 2022, 78, 255-261.	1.1	6
1673	Automated Radiosynthesis, Preliminary In Vitro/In Vivo Characterization of OncoFAP-Based Radiopharmaceuticals for Cancer Imaging and Therapy. <i>Pharmaceuticals</i> , 2022, 15, 958.	1.7	5
1674	Application of Cleavable Linkers to Improve Therapeutic Index of Radioligand Therapies. <i>Molecules</i> , 2022, 27, 4959.	1.7	3
1675	Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer. <i>Molecules</i> , 2022, 27, 4936.	1.7	3
1676	Other rare ovarian cancers: Transitional cell carcinoma, malignant Brenner tumor, endometrioid carcinoma, mesothelioma, squamous cell carcinoma, sarcoma. , 2023, , 121-141.		0
1677	Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors. , 2022, 10, e004854.		8
1678	Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art. <i>World Journal of Methodology</i> , 2022, 12, 381-391.	1.1	4
1679	Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷ Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. <i>Theranostics</i> , 2022, 12, 6437-6445.	4.6	3
1680	Radiobiology and Radiation Dosimetry in Nuclear Medicine. , 2022, , 345-410.		0
1681	Neuroendocrine Tumors: Therapy with Radiolabeled Peptides. , 2022, , 1431-1459.		0
1682	Precision Radiomolecular Oncology: Challenging the Classical Statistical Evidence-Based Medicine. , 2022, , 97-110.		2
1683	Non-surgical Management of Pancreatic Neuroendocrine Tumors (PNETs). , 2022, , 683-709.		0
1684	Pulmonary Carcinoid. <i>Medical Radiology</i> , 2022, , .	0.0	0

#	ARTICLE	IF	CITATIONS
1685	Radionuclide Therapy in Neuroendocrine Tumors. , 2022, , 173-186.		0
1686	Fundamentals of Radiation Safety and Dosimetric Approach in Radionuclide Therapy Applications. , 2022, , 29-62.		0
1687	Personalized Medicine for Patients with Liver, Biliary Tract, and Pancreatic Cancer. , 2022, , 761-776.		0
1688	Systemic Therapy for Pancreatic Neuroendocrine Tumors. <i>Clinical Colorectal Cancer</i> , 2023, 22, 34-44.	1.0	1
1691	Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy. <i>Neuroendocrinology</i> , 2023, 113, 281-288.	1.2	5
1692	Feasibility and therapeutic potential of the ⁶⁸ Ga/ ¹⁷⁷ Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma. <i>Annales D'Endocrinologie</i> , 2023, 84, 45-51.	0.6	5
1693	¹⁷⁷ Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods. <i>European Journal of Hospital Pharmacy</i> , 0, , ejhpharm-2022-003489.	0.5	0
1694	¹⁷⁷ Lu-“Prostate-specific Membrane Antigen Radioligand Therapy in Patients with Metastatic Castration-resistant Prostate Cancer. <i>Radiology</i> , 2023, 306, .	3.6	2
1695	Glucose Metabolism Modification Induced by Radioligand Therapy with [¹⁷⁷ Lu]Lu/[⁹⁰ Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial. <i>Pharmaceutics</i> , 2022, 14, 2009.	2.0	8
1697	Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2022, 14, 4769.	1.7	3
1698	Gastroenteropancreatic Neuroendocrine Tumors. <i>Gastroenterology Clinics of North America</i> , 2022, 51, 625-647.	1.0	6
1699	Novel therapeutic approaches in GEP-NETs based on genetic and epigenetic alterations. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188804.	3.3	2
1700	Active bone marrow S-values for the low-energy electron emitter terbium-161 compared to S-values for lutetium-177 and yttrium-90. <i>EJNMMI Physics</i> , 2022, 9, .	1.3	2
1701	Addressing the Role of Angiogenesis in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus: A Biological Prospective Analysis of Soluble Biomarkers and Clinical Outcomes. <i>Cancers</i> , 2022, 14, 4471.	1.7	5
1702	Substantial External Dose Rate Variability Observed in a Cohort of LU-177 Patients Independent of Bmi and Sex. <i>Radiation Protection Dosimetry</i> , 0, , .	0.4	5
1703	An EANM position paper on advancing radiobiology for shaping the future of nuclear medicine. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 242-246.	3.3	16
1704	Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors. <i>Pharmaceutics</i> , 2022, 15, 1155.	1.7	4
1705	Venous invasion and lymphatic invasion are correlated with the postoperative prognosis of pancreatic neuroendocrine neoplasm. <i>Surgery</i> , 2023, 173, 365-372.	1.0	3

#	ARTICLE	IF	CITATIONS
1706	Molecular and Anatomic Imaging of Neuroendocrine Tumors. <i>Surgical Oncology Clinics of North America</i> , 2022, , .	0.6	0
1707	Dosimetry in Radiopharmaceutical Therapy. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1467-1474.	2.8	12
1708	Peptide Receptor Radionuclide Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 3199-3208.	1.8	14
1709	Survival in patients with neuroendocrine tumors of the colon, rectum and small intestine. <i>American Journal of Surgery</i> , 2023, 225, 58-65.	0.9	4
1710	Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation. <i>Advanced Drug Delivery Reviews</i> , 2022, 190, 114538.	6.6	13
1711	Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy. <i>European Journal of Cancer</i> , 2022, 176, 110-120.	1.3	6
1712	PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable?. <i>Current Opinion in Pharmacology</i> , 2022, 67, 102293.	1.7	5
1713	Theragnostic applications. , 2022, , 197-213.		0
1714	Impact of Alpha-Radiotherapy on the Tumor Microenvironment. , 2022, , 1-24.		0
1715	Neuroendocrine Tumors Radionuclide Therapy. , 2022, , 319-327.		0
1716	Procedures and Techniques in Pheochromocytomas and Paragangliomas. , 2022, , 243-264.		0
1717	Pheochromocytomas and Paragangliomas Radionuclide Treatments. , 2022, , 281-294.		0
1718	Impact of FDG PET/CT Scan in Changing Management of Well-Differentiated Neuroendocrine Tumors With Ki67 Index Less Than or Equal to 5%. <i>Clinical Nuclear Medicine</i> , 2022, 47, e676-e681.	0.7	2
1719	Technical note: Assessment of radiation measurement devices for the detection of [¹⁷⁷ Lu]Lu-labeled radiopharmaceuticals containing [^{177m} Lu]Lu-impurities. <i>Medical Physics</i> , 0, , .	1.6	1
1720	Differential Detection of Hepatic Metastases on 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE SPECT/CT. <i>Clinical Nuclear Medicine</i> , 0, Publish Ahead of Print, .	0.7	0
1721	Optimisation of radioligand therapy in neuroendocrine tumours: Current and evolving evidence. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	2
1722	The NET G3 enigma: dealing with a "new" entity. <i>Memo - Magazine of European Medical Oncology</i> , 0, , .	0.3	1
1723	Single centre retrospective review of outcome of ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine tumours: Survival, toxicity, and prognostic factors. <i>Journal of Neuroendocrinology</i> , 2022, 34, .	1.2	6

#	ARTICLE	IF	CITATIONS
1724	Surgery, Liver Directed Therapy and Peptide Receptor Radionuclide Therapy for Pancreatic Neuroendocrine Tumor Liver Metastases. <i>Cancers</i> , 2022, 14, 5103.	1.7	1
1725	The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	18
1726	Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. <i>Journal of Hematology and Oncology</i> , 2022, 15, .	6.9	59
1727	Imaging and treatment with ⁶⁸ Gallium and ¹⁷⁷ Lutetium-DOTATATE in a rare SSTR2 and ESWR1-CREM fusion positive undifferentiated round cell tumour of the lung. <i>BJR case Reports</i> , 2023, 9, .	0.1	0
1728	Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). <i>Journal of Clinical Oncology</i> , 2023, 41, 1359-1369.	0.8	53
1731	The Antiproliferative Activity of High-Dose Somatostatin Analogs in Gastro-Entero-Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2022, 11, 6127.	1.0	3
1732	Understanding the Radiobiological Mechanisms Induced by ¹⁷⁷ Lu-DOTATATE in Comparison to External Beam Radiation Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12369.	1.8	7
1733	Treatment Sequencing Strategies in Advanced Neuroendocrine Tumors: A Review. <i>Cancers</i> , 2022, 14, 5248.	1.7	3
1734	Molecular Characterization and Therapeutic Approaches to Small Cell Lung Cancer: Imaging Implications. <i>Radiology</i> , 2022, 305, 512-525.	3.6	6
1735	Emerging Targets in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2022, 14, 4843.	1.7	10
1736	Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy. <i>Cellular Oncology (Dordrecht)</i> , 2022, 45, 1401-1419.	2.1	4
1737	Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 16-32.	12.5	11
1739	Management of Carcinoid Syndrome and Carcinoid Crisis in the Perioperative Environment. <i>Journal of Perianesthesia Nursing</i> , 2022, , .	0.3	0
1740	A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms. <i>Clinical Cancer Research</i> , 2023, 29, 731-741.	3.2	11
1741	Preparation and Evaluation of [¹⁸ F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [⁶⁸ Ga]Ga-DOTA/NOTA-NOC. <i>Molecules</i> , 2022, 27, 6818.	1.7	0
1742	Amino Acid Solutions for ¹⁷⁷ Lu-Oxodotreotide Premedication: A Tolerance Study. <i>Cancers</i> , 2022, 14, 5212.	1.7	2
1743	The Evolving Landscape of Neuroendocrine Tumors. <i>Surgical Oncology Clinics of North America</i> , 2023, 32, 185-198.	0.6	3
1744	Integrating Theranostics Into Patient Care Pathways: <i>AJR</i> Expert Panel Narrative Review. <i>American Journal of Roentgenology</i> , 2023, 220, 619-629.	1.0	2

#	ARTICLE	IF	CITATIONS
1745	Pituitary Adenoma & Nuclear Medicine: recent outcomes and ongoing developments.. Presse Medicale, 2022, , 104144.	0.8	2
1746	Growth Hormone-Releasing Hormone-Secreting Neuroendocrine Tumors. Contemporary Endocrinology, 2022, , 15-29.	0.3	0
1747	Efficacy of Everolimus Combined with ¹⁷⁷ Lu-Dotatate in the Treatment of Neuroendocrine Tumors. Cancer Biotherapy and Radiopharmaceuticals, 0, , .	0.7	1
1748	Quo Vadis, Teragnosis?. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2022, 41, 341-344.	0.1	0
1749	Determinants of target absorbed dose in radionuclide therapy. Zeitschrift Fur Medizinische Physik, 2022, , .	0.6	1
1750	Protein and Gene Delivery Systems for Neurodegenerative Disorders: Where Do We Stand Today?. Pharmaceutics, 2022, 14, 2425.	2.0	8
1751	Therapiekonzepte bei fernmetastasierten GEP-NEN – medikamentöse und interventionelle Therapie. Springer Reference Medizin, 2023, , 577-588.	0.0	0
1752	Immunohistochemical assessment and clinical, histopathologic, and molecular correlates of membranous somatostatin type-2A receptor expression in high-risk pediatric central nervous system tumors. Frontiers in Oncology, 0, 12, .	1.3	4
1753	Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics. Annals of Nuclear Medicine, 2022, 36, 1007-1009.	1.2	2
1755	Alpha-particle Therapy of Endocrine Tumors: Current State and Future Directions. , 2022, , .		0
1756	Prospective Cohort Real-World Study on Neuroendocrine Tumor Patient's Quality of Life During Peptide Receptor Radionuclide Therapy With ¹⁷⁷ Lu-DOTATATE. Pancreas, 2022, 51, 784-789.	0.5	0
1757	Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of ¹⁷⁷ Lu-DOTATATE in Neuroendocrine Tumors. Journal of Nuclear Medicine, 2023, 64, 567-573.	2.8	6
1758	Theranostics: a fifth pillar of contemporary cancer care?. ANZ Journal of Surgery, 2022, 92, 2782-2783.	0.3	0
1759	Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options. Cancers, 2022, 14, 5669.	1.7	1
1760	²²⁵ Ac-MACROPATATE: A Novel α -Particle Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors. Journal of Nuclear Medicine, 2023, 64, 549-554.	2.8	12
1761	Pre-clinical investigation of astatine-211-parthanatine for high-risk neuroblastoma. Communications Biology, 2022, 5, .	2.0	4
1762	Treatment patterns and oncological outcome of patients with advanced small intestinal neuroendocrine tumors: real-world data from the Medical University of Vienna. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211383.	1.4	0
1763	Epigenetic drugs in somatostatin type 2 receptor radionuclide theranostics and radiation transcriptomics in mouse pheochromocytoma models. Theranostics, 2023, 13, 278-294.	4.6	5

#	ARTICLE	IF	CITATIONS
1764	A multidisciplinary approach to the work up and management of pulmonary carcinoid tumors and DIPNECH: a narrative review. <i>Translational Lung Cancer Research</i> , 2022, 11, 2567-2587.	1.3	7
1765	Diagnosis and management of gastroenteropancreatic neuroendocrine neoplasms by nuclear medicine: Update and future perspective. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
1766	Current Practice in Carcinoid Heart Disease and Burgeoning Opportunities. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1793-1803.	1.3	1
1767	A Clinical Guide to Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE in Neuroendocrine Tumor Patients. <i>Cancers</i> , 2022, 14, 5792.	1.7	9
1768	Exploring new frontiers in prostate cancer research: Report from the 2022 Coffey Holden prostate cancer academy meeting. <i>Prostate</i> , 2023, 83, 207-226.	1.2	0
1769	Radiometal-theranostics: the first 20 years*. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2023, 332, 1557-1576.	0.7	3
1770	An Update of Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer. <i>The Korean Journal of Urological Oncology</i> , 2022, 20, 207-222.	0.1	2
1771	ACR Appropriateness Criteria Management of Liver Cancer: 2022 Update. <i>Journal of the American College of Radiology</i> , 2022, 19, S390-S408.	0.9	1
1772	Relationships between uptake of [⁶⁸ Ga]Ga-DOTA-TATE and absorbed dose in [¹⁷⁷ Lu]Lu-DOTA-TATE therapy. <i>EJNMMI Research</i> , 2022, 12, .	1.1	6
1773	Efficacy and safety of peptide receptor radionuclide therapy with [¹⁷⁷ Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1195-1204.	3.3	6
1774	¹⁷⁷ Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials. <i>Cancers</i> , 2022, 14, 6022.	1.7	1
1775	Use of imaging-based dosimetry for personalising radiopharmaceutical therapy of cancer. <i>Cancer Imaging</i> , 2022, 22, .	1.2	1
1776	Lymphopenia during ¹⁷⁷ Lu-DOTATATE therapy leading to recurrence of tuberculosis: a case report. <i>European Journal of Hybrid Imaging</i> , 2022, 6, .	0.6	0
1777	Interventional Radiology in the Era of Radiotheranostics: An Update for Interventional Radiologists!. <i>Seminars in Interventional Radiology</i> , 2022, 39, 587-590.	0.3	0
1778	Mechanisms of Resistance in Gastroenteropancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2022, 14, 6114.	1.7	2
1779	The Effects of Radioligand Therapy on Quality of Life and Sexual Function in Patients with Neuroendocrine Neoplasms. <i>Cancers</i> , 2023, 15, 115.	1.7	0
1780	A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH). <i>BMC Cancer</i> , 2022, 22, .	1.1	3
1781	Thymic neuroendocrine tumours. <i>Diagnostic Histopathology</i> , 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
1782	Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	15
1783	Light It Up! The Use of DOTATATE in Diagnosis and Treatment of Neuroendocrine Neoplasms. <i>Surgical Pathology Clinics</i> , 2023, 16, 151-161.	0.7	1
1784	Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs): A Systematic Review and Pooled Analysis. <i>Cancer Management and Research</i> , 0, Volume 14, 3507-3523.	0.9	4
1785	EANM practice guideline for quantitative SPECT-CT. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 980-995.	3.3	19
1786	PET Imaging of the Neurotensin Targeting Peptide NOTA-NT-20.3 Using Cobalt-55, Copper-64 and Gallium-68. <i>Pharmaceutics</i> , 2022, 14, 2724.	2.0	4
1787	Development of radiopharmaceuticals for targeted alpha therapy: Where do we stand?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	13
1788	Evaluation of the Efficacy of a Combined Treatment Using the mTOR-Inhibitor Everolimus and [177Lu]Lu-DOTA-TATE in Nude CD1 Mice with SSTR-Expressing Pancreatic AR42J Xenograft Tumors. <i>Biomedicines</i> , 2022, 10, 3102.	1.4	0
1789	Targeting mTORC1 Activity to Improve Efficacy of Radioligand Therapy in Cancer. <i>Cancers</i> , 2023, 15, 17.	1.7	1
1790	Radiopharmaceuticals heat anti-tumor immunity. <i>Theranostics</i> , 2023, 13, 767-786.	4.6	4
1791	Molecular imaging Theranostics of Neuroendocrine Tumors. <i>Seminars in Nuclear Medicine</i> , 2023, 53, 539-554.	2.5	3
1792	Recent Advances in Radiopharmaceutical Theranostics of Pheochromocytoma and Paraganglioma. <i>Seminars in Nuclear Medicine</i> , 2023, 53, 503-516.	2.5	3
1793	Successful Treatment with ¹⁷⁷ Lutetium-Dotatate and Maintenance Octreotide in a Patient with Esthesioneuroblastoma with Central Nervous System Invasion: Case Report and Review of the Literature. <i>International Journal of Otolaryngology and Head & Neck Surgery</i> , 2023, 12, 8-20.	0.1	0
1794	Peptide Drug Conjugates and Their Role in Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 829.	1.8	18
1795	Prospective Multicentric Assessment of 68Ga-DOTANOC PET/CT in Grade 1-2 GEP-NET. <i>Cancers</i> , 2023, 15, 513.	1.7	2
1796	Radiotheranostics in oncology: Making precision medicine possible. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 255-274.	157.7	17
1797	The effect of long-acting somatostatin analogues on the uptake of [177Lu]Lu-HA-DOTATATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1434-1441.	3.3	6
1798	Characterization and Efficacy of a Nanomedical Radiopharmaceutical for Cancer Treatment. <i>ACS Omega</i> , 2023, 8, 2357-2366.	1.6	0
1799	Recent progress of experimental model in pancreatic neuroendocrine tumors: drawbacks and challenges. <i>Endocrine</i> , 2023, 80, 266-282.	1.1	3

#	ARTICLE	IF	CITATIONS
1800	Theranostic Targeting of CUB Domain-Containing Protein 1 (CDCP1) in Multiple Subtypes of Bladder Cancer. <i>Clinical Cancer Research</i> , 2023, 29, 1232-1242.	3.2	1
1801	Enzymological Characterization of ⁶⁴ Cu-Labeled Neprilysin Substrates and Their Application for Modulating the Renal Clearance of Targeted Radiopharmaceuticals. <i>Journal of Medicinal Chemistry</i> , 2023, 66, 516-537.	2.9	4
1802	Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2023, 12, 717.	1.0	3
1803	Prospective Evaluation of MGMT-Promoter Methylation Status and Correlations with Outcomes to Temozolomide-Based Chemotherapy in Well-Differentiated Neuroendocrine Tumors. <i>Current Oncology</i> , 2023, 30, 1381-1394.	0.9	3
1804	Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors: A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures. <i>Cancers</i> , 2023, 15, 392.	1.7	1
1805	Tumor-specific intracellular delivery: peptide-guided transport of a catalytic toxin. <i>Communications Biology</i> , 2023, 6, .	2.0	1
1806	Same-day comparative protocol PET/CT-PET/MRI [⁶⁸ Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine. <i>Cancer Imaging</i> , 2023, 23, .	1.2	1
1807	Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort. <i>Endocrine-Related Cancer</i> , 2023, 30, .	1.6	0
1808	Diagnosis and Treatment of Lung Neuroendocrine Neoplasms. <i>PET Clinics</i> , 2022, , .	1.5	0
1809	Management of Appendix Neuroendocrine Neoplasms: Insights on the Current Guidelines. <i>Cancers</i> , 2023, 15, 295.	1.7	9
1810	Imaging of the Glucose-Dependent Insulinotropic Polypeptide Receptor Using a Novel Radiolabeled Peptide Rationally Designed Based on Endogenous GIP and Synthetic Exendin-4 Sequences. <i>Pharmaceuticals</i> , 2023, 16, 61.	1.7	2
1811	Predicting subacute hematological toxicity of ¹⁷⁷ Lu-DOTATATE therapy using healthy organs' uptake on post-treatment quantitative SPECT: A pilot study. <i>Medicine (United States)</i> , 2022, 101, e32212.	0.4	2
1812	A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [¹⁷⁷ Lu]Lu-DOTATATE to favor its use in clinical practice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	3.3	1
1813	Towards accurate ¹⁷⁷ Lu SPECT activity quantification and standardization using lesion-to-background voxel ratio. <i>EJNMMI Physics</i> , 2023, 10, .	1.3	2
1814	Extended therapy with [¹⁷⁷ Lu]Lu-PSMA-617 in responding patients with high-volume metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1811-1821.	3.3	9
1815	Complete Remission Upon Peptide Receptor Radionuclide Therapy in a G2 Pancreatic Neuroendocrine Tumor. <i>Clinical Nuclear Medicine</i> , 0, Publish Ahead of Print, .	0.7	2
1816	Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review. <i>European Journal of Radiology Open</i> , 2023, 10, 100477.	0.7	5
1817	Neuroendocrine Neoplasms. <i>PET Clinics</i> , 2023, 18, 161-168.	1.5	2

#	ARTICLE	IF	CITATIONS
1818	A Lymph Node Ratio Model for Prognosis of Patients with Pancreatic Neuroendocrine Tumors. <i>Biomedicines</i> , 2023, 11, 407.	1.4	1
1819	Gastro-Entero-Pancreatic Tumors. <i>PET Clinics</i> , 2023, 18, 243-250.	1.5	1
1820	Diphosphine Bioconjugates via Pt(0)-Catalyzed Hydrophosphination. A Versatile Chelator Platform for Technetium-99m and Rhenium-188 Radiolabeling of Biomolecules. <i>Inorganic Chemistry</i> , 0, , .	1.9	1
1822	Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer. <i>Clinical Nuclear Medicine</i> , 2023, 48, 221-227.	0.7	1
1823	Comparison of somatostatin receptor expression in patients with neuroendocrine tumours with and without somatostatin analogue treatment imaged with [18F]SITATE. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	4
1824	La evolución de la medicina nuclear: el reconocimiento de una especialidad relegada. <i>Revista Colombiana De Cancerología</i> , 2022, 26, 359-61.	0.0	0
1825	From netrin-1-targeted ⁶⁷ Ge-CT to internal radiotherapy for management of advanced solid tumors. <i>EMBO Molecular Medicine</i> , 2023, 15, .	3.3	5
1826	The prognostic role of whole-body volumetric ⁶⁸ Ga-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with ¹⁷⁷ Lu-DOTATATE. <i>Nuclear Medicine Communications</i> , 2023, 44, 509-517.	0.5	1
1827	Superior Tumor Detection for ⁶⁸ Ga-FAPI-46 Versus ¹⁸ F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma. <i>Journal of Nuclear Medicine</i> , 2023, 64, 1049-1055.	2.8	10
1828	Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2023, 64, 1056-1061.	2.8	3
1829	Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment. <i>PET Clinics</i> , 2023, 18, 201-214.	1.5	2
1830	Neuroendocrine Neoplasms. <i>PET Clinics</i> , 2023, 18, 169-187.	1.5	0
1831	Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with ¹⁷⁷ Lu-DOTATATE. <i>Cancers</i> , 2023, 15, 2332.	1.7	0
1832	Drug-induced Changes on the Biodistribution of Theranostic Radiopharmaceuticals. , 2023, 9, 49-57.		0
1833	Addressing the need for more therapeutic options in neuroendocrine prostate cancer. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 177-185.	1.1	3
1834	Standardized classification schemes in reporting oncologic PET/CT. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	2
1835	SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2023, 64, 204-210.	2.8	23
1836	Epidemiological trends and novel prognostic evaluation approaches of patients with stage II-IV colorectal neuroendocrine neoplasms: A population-based study with external validation. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	3

#	ARTICLE	IF	CITATIONS
1837	Evolving landscape of clinical trials in gastroenteropancreatic neuroendocrine neoplasms in the past two decades. <i>Endocrine Connections</i> , 2023, 12, .	0.8	2
1838	In Vivo Efficacy Testing of Peptide Receptor Radionuclide Therapy Radiosensitization Using Olaparib. <i>Cancers</i> , 2023, 15, 915.	1.7	2
1839	Commercial and business aspects of alpha radioligand therapeutics. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
1840	The Role of Somatostatin Analogues in the Control of Diarrhea and Flushing as Markers of Carcinoid Syndrome: A Systematic Review and Meta-Analysis. <i>Journal of Personalized Medicine</i> , 2023, 13, 304.	1.1	0
1841	Correlations between [68Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [177Lu]Lu-DOTA-TATE. <i>Cancers</i> , 2023, 15, 1134.	1.7	4
1842	Acute Disseminated Intravascular Coagulation Precipitated by 177Lu-Dotatate in Metastatic Midgut Neuroendocrine Tumor: A Case Report. <i>Journal of Gastrointestinal Cancer</i> , 2023, 54, 1370-1372.	0.6	0
1843	The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years. <i>Current Medical Imaging</i> , 2023, 19, .	0.4	1
1844	Wnt/ β -catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cells. <i>Nuclear Medicine Communications</i> , 2023, 44, 259-269.	0.5	0
1845	Operational nuclear research reactors in the Asia-Pacific with potential for medical radionuclide production. <i>Nuclear Medicine Communications</i> , 2023, 44, 227-243.	0.5	0
1846	Radioligand Therapy of Patients with Metastatic Castrate-Resistant Prostate Cancer. <i>Biology Bulletin</i> , 2022, 49, 2285-2297.	0.1	0
1847	PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score. <i>Life</i> , 2023, 13, 611.	1.1	4
1848	Case report: Efficacy of lutetium-177 oxodotreotide for neuroendocrine tumor with central nervous system metastases. <i>Frontiers in Nuclear Medicine</i> , 0, 3, .	0.7	0
1849	Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN). <i>Current Oncology Reports</i> , 2023, 25, 465-478.	1.8	0
1850	Progress in the Treatment of Small Intestine Cancer. <i>Current Treatment Options in Oncology</i> , 2023, 24, 241-261.	1.3	6
1851	PET tracers in glioblastoma: Toward neurotheranostics as an individualized medicine approach. <i>Frontiers in Nuclear Medicine</i> , 0, 3, .	0.7	2
1852	Case report: Metastatic pancreatic neuroendocrine tumour associated with portal vein thrombosis; successful management with subsequent pregnancies. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	1
1853	[111In]In/[177Lu]Lu-AAZTA5-LM4 SST2R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results. <i>Pharmaceutics</i> , 2023, 15, 776.	2.0	4
1855	Gastro-Enteric-Pancreatic Neuroendocrine Tumor Treatment. <i>PET Clinics</i> , 2023, 18, 215-221.	1.5	1

#	ARTICLE	IF	CITATIONS
1856	Neuroendocrine Tumor Therapy Response Assessment. PET Clinics, 2023, 18, 267-286.	1.5	0
1857	Perspective of molecular imaging and peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors: where do we stand?. Journal of Pancreatology, 0, Publish Ahead of Print, .	0.3	0
1858	SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2250-2257.	3.3	5
1859	Efficacy of [177Lu]Lu-DOTATATE in metastatic neuroendocrine neoplasms of different locations: data from the SEPTRALU study. European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50, 2486-2500.	3.3	5
1861	Synthesis and radiolabelling of PSMA-targeted derivatives containing GYK/MVK cleavable linkers. Royal Society Open Science, 2023, 10, .	1.1	2
1863	Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease. Cancers, 2023, 15, 1739.	1.7	2
1864	An Engineered Probiotic Platform for Cancer Epitope-Independent Targeted Radionuclide Therapy of Solid Tumors. Advanced Healthcare Materials, 2023, 12, .	3.9	1
1865	Simulation studies of a full-ring, CZT SPECT system for whole-body imaging of ^{99m} Tc and ¹⁷⁷ Lu. Medical Physics, 2023, 50, 3726-3737.	1.6	3
1866	Next generation radiotheranostics promoting precision medicine. Annals of Oncology, 2023, 34, 507-519.	0.6	8
1867	Partial Response Upon Peptide Receptor Radionuclide Therapy in a Highly Proliferative Pancreatic Neuroendocrine Tumor. Clinical Nuclear Medicine, 2023, 48, 547-548.	0.7	1
1868	Advances in Molecular Imaging and Therapy and Its Impact in Oncologic Imaging. IDKD Springer Series, 2023, , 31-45.	0.8	0
1869	Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. Journal of Neuroendocrinology, 2023, 35, .	1.2	1
1870	Radiomics and theranostics with molecular and metabolic probes in prostate cancer: toward a personalized approach. Expert Review of Molecular Diagnostics, 2023, 23, 243-255.	1.5	9
1871	Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review. Clinical Genitourinary Cancer, 2023, , .	0.9	2
1873	Tumour Heterogeneity and the Consequent Practical Challenges in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Cancers, 2023, 15, 1861.	1.7	4
1875	Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 2676-2685.	1.8	8
1876	All you need to know about gastrinoma today Gastrinoma and Zollinger-Ellison syndrome: A thorough update. Journal of Neuroendocrinology, 2023, 35, .	1.2	2
1877	An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics. Diagnostics, 2023, 13, 1210.	1.3	4

#	ARTICLE	IF	CITATIONS
1878	Protección radiológica en terapias con ¹⁷⁷ Lu DOTATOC: tiempo de aislamiento, estimaciones de dosis a personas representativas y recomendaciones al paciente. <i>Revista Colombiana De Cancerología</i> , 2022, 26, 432-41.	0.0	0
1879	Diagnosis and management of neuroendocrine tumours. <i>Clinical Medicine</i> , 2023, 23, 119-124.	0.8	2
1880	Immunomodulatory effects of targeted radionuclide therapy. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	0
1881	Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2023, 38, 225-231.	0.7	1
1882	Defining a New Classification System for the Surgical Management of Neuroendocrine Tumor Liver Metastases. <i>Journal of Clinical Medicine</i> , 2023, 12, 2456.	1.0	1
1883	²²⁵ Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic. <i>Pharmaceutics</i> , 2023, 15, 1051.	2.0	8
1884	Validation of the SSTR-RADS 1.0 for the structured interpretation of SSTR-PET/CT and treatment planning in neuroendocrine tumor (NET) patients. <i>European Radiology</i> , 2023, 33, 3416-3424.	2.3	2
1885	Radionuclide-based theranostics – a promising strategy for lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	3.3	1
1886	Fibroblast Activation Protein Inhibitor Theranostics. <i>PET Clinics</i> , 2023, 18, 409-418.	1.5	1
1887	Efficacy and Safety of [¹⁷⁷ Lu]Lu-DOTA-TATE in Adults with Inoperable or Metastatic Somatostatin Receptor-Positive Pheochromocytomas/Paragangliomas, Bronchial and Unknown Origin Neuroendocrine Tumors, and Medullary Thyroid Carcinoma: A Systematic Literature Review. <i>Biomedicines</i> , 2023, 11, 1024.	1.4	0
1888	Fibroblast Activation Protein Inhibitor Theranostics. <i>PET Clinics</i> , 2023, 18, 361-367.	1.5	3
1890	Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET. <i>Journal of Nuclear Medicine</i> , 2023, 64, 1017-1023.	2.8	2
1891	Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors. <i>Oncologist</i> , 0, , .	1.9	0
1892	Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with ¹⁷⁷ Lu-DOTATATE. <i>Pharmaceutics</i> , 2023, 15, 1110.	2.0	6
1893	Theranostics in Neuroendocrine Tumors. , 2023, , 609-654.		0
1895	The predictive impact of dual somatostatin receptor/fluorodeoxyglucose (FDG) positron emission tomography (PET) in metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs): review of literature and a single institution experience. <i>Journal of Gastrointestinal Oncology</i> , 2023, 14, 1087-1094.	0.6	2
1896	Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
1897	Heterogeneity of absorbed dose distribution in kidney tissues and dose-response modelling of nephrotoxicity in radiopharmaceutical therapy with beta-particle emitters: A review. <i>Zeitschrift Fur Medizinische Physik</i> , 2023, , .	0.6	3

#	ARTICLE	IF	CITATIONS
1898	Neuroendocrine Neoplasms of the Gastrointestinal Tract versus Neuroendocrine Neoplasms of the Gynaecological Tractâ€”Comparison of the Risk Factors and Non-Surgical Treatment Efficacy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6853.	1.8	0
1899	An International Study of Factors Affecting Variability of Dosimetry Calculations, Part 2: Overall Variabilities in Absorbed Dose. <i>Journal of Nuclear Medicine</i> , 2023, 64, 1109-1116.	2.8	2
1900	Clinical Practice for Nuclear Medicine Therapy; Part 1. <i>Japanese Journal of Health Physics</i> , 2023, 57, 172-180.	0.1	0
1901	A dosimetric comparison of systemic peptide receptor radionuclide therapy and intra-arterial peptide receptor radionuclide therapy in patients with liver dominant gastroenteropancreatic neuroendocrine tumours. <i>Nuclear Medicine Communications</i> , 0, Publish Ahead of Print, .	0.5	0
1902	Therapy-related myeloid neoplasms after ¹⁷⁷ Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy. <i>Leukemia and Lymphoma</i> , 2023, 64, 1355-1357.	0.6	0
1903	Peptide cargo administration: current state and applications. <i>Applied Microbiology and Biotechnology</i> , 2023, 107, 3153-3181.	1.7	4
1904	Radioligand therapies in cancer: mapping the educational landscape in Europe. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 2692-2698.	3.3	1
1905	Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals. <i>Pharmaceutics</i> , 2023, 15, 1240.	2.0	1
1906	Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists. <i>Cancer Treatment Reviews</i> , 2023, 117, 102560.	3.4	6
1907	Co-administration with A1M does not influence apoptotic response of ¹⁷⁷ Lu-octreotate in GOT1 neuroendocrine tumors. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
1908	Evaluation of Hepatotoxicity from Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors and a Very High Liver Tumor Burden. <i>Journal of Nuclear Medicine</i> , 2023, 64, 880-884.	2.8	2
1911	Survival and Symptomatic Relief After Cytoreductive Hepatectomy for Neuroendocrine Tumor Liver Metastases: Long-Term Follow-up Evaluation of More Than 500 Patients. <i>Annals of Surgical Oncology</i> , 2023, 30, 4840-4851.	0.7	5
1919	Opportunities and challenges of low-dose radiation to enable immunotherapy efficacy. <i>International Review of Cell and Molecular Biology</i> , 2023, , .	1.6	0
1922	Enzymatic Bioconjugation: A Perspective from the Pharmaceutical Industry. <i>Jacs Au</i> , 2023, 3, 1267-1283.	3.6	10
1932	Advances in PET imaging of cancer. <i>Nature Reviews Cancer</i> , 2023, 23, 474-490.	12.8	20
1944	Antibodyâ€”drug conjugates come of age in oncology. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 641-661.	21.5	82
1972	A case of frequent hypoglycemic attacks successfully controlled with capecitabine plus temozolomide and ¹⁷⁷ Lu-DOTATATE peptide receptor radionuclide therapy in a patient with recurrent pancreatic insulinoma. <i>Clinical Journal of Gastroenterology</i> , 2023, 16, 767-771.	0.4	1
1974	Pancreatic Neuroendocrine Neoplasms. V-2. Staging and Treatment. , 2023, , 465-474.		0

#	ARTICLE	IF	CITATIONS
1976	Lower Gastrointestinal Tract NEN (Small Bowel and Colorectum). IV-2. Staging and Treatment. , 2023, , 451-457.		0
1978	Molecular Imaging and Therapy of Neuroendocrine Tumors. , 0, , .		0
1991	Case report: Peptide receptor radioligand therapy in metastatic pediatric neuroendocrine tumors. Frontiers in Nuclear Medicine, 0, 3, .	0.7	0
1995	Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story. Journal of Endocrinological Investigation, 2024, 47, 35-46.	1.8	1
2009	From FDG and beyond: the evolving potential of nuclear medicine. Annals of Nuclear Medicine, 2023, 37, 583-595.	1.2	1
2012	Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review. Clinical and Translational Imaging, 0, , .	1.1	0
2038	Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities. , 2023, , 311-386.		0
2041	Emergency Presentation of Small Bowel Tumours. Hot Topics in Acute Care Surgery and Trauma, 2023, , 93-108.	0.1	0
2047	A paradigm shift: Dosimetry approaches in theranostic nuclear medicine. AIP Conference Proceedings, 2023, , .	0.3	0
2052	The cycle effect quantified: reduced tumour uptake in subsequent cycles of [177Lu]Lu-HA-DOTATATE during peptide receptor radionuclide therapy. European Journal of Nuclear Medicine and Molecular Imaging, 0, , .	3.3	0
2068	Theranostic Imaging and Radiopharmaceutical Therapy. , 2023, , 455-481.		0
2078	Case Study #6: [177Lu]Lu-DOTA-JR11: A Somatostatin Receptor Subtype 2 Antagonist for Radiopharmaceutical Therapy. , 2023, , 335-348.		0
2079	Artificial Intelligence and Machine Learning. , 2023, , 499-516.		0
2080	A Brief History of Radiopharmaceutical Therapy. , 2023, , 13-38.		0
2081	Dosimetry in Radiopharmaceutical Therapy. , 2023, , 173-190.		0
2082	Introduction: The Case for Radiopharmaceutical Therapy. , 2023, , 3-11.		0
2083	Radiotherapeutics and Nuclear Pharmacy. , 2023, , 549-560.		0
2084	Case Study #4: Lutathera, a Gold Standard for Peptide Receptor Radiopharmaceutical Therapy. , 2023, , 297-317.		0

#	ARTICLE	IF	CITATIONS
2085	Optimising Radioligand Therapy for Patients with Gastro-Entero-Pancreatic Neuroendocrine Tumours: Expert Opinion from an Italian Multidisciplinary Group. <i>Advances in Therapy</i> , 0, , .	1.3	0
2098	Case report: 177Lu DOTA-TATE: a new scheme for the treatment of prostate neuroendocrine cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
2109	Dosimetry for targeted radionuclide therapy in routine clinical practice: experts advice vs. clinical evidence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2024, 51, 947-950.	3.3	1
2112	Theragnostic: radiopharmaceuticals and nuclear medicine as viewed through Hegel's eyes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2024, 51, 942-946.	3.3	0
2120	Theranostics in Nuclear Medicine. <i>Nanobiotechnology Reports</i> , 2023, 18, 569-576.	0.2	0
2121	Neuroendocrine Neoplasm Imaging and Image-Guided Therapies. , 2023, , 419-439.		0
2129	Technological evolution in cancer diagnosis and therapeutics. , 2024, , 33-54.		0
2133	A Tree Can Be Recognized by Its Fruit. , 2024, , 95-99.		0
2134	Analyzing the Science Footprint of Richard P. Baum. , 2024, , 245-253.		0
2135	Nuclear Medicine and Surgery on the Way to Personalized Medicine. Ten Years of Clinical and Translational Oncology and Research. , 2024, , 177-180.		0
2136	Theranostics with Somatostatin Receptor Antagonists. , 2024, , 349-359.		0
2137	Surgery in Combination with Peptide Receptor Radionuclide Therapy: A Novel Approach for the Treatment of Advanced Neuroendocrine Tumours. , 2024, , 31-40.		0
2138	The Evolution of n.c.a. 177Lu to n.c.a. 177Lu-Edotreotide for the Treatment of Neuroendocrine Tumours. Sixteen Years of Collaboration Between Zentralklinik Bad Berka and ITM. , 2024, , 147-153.		0
2139	Terbium – Sisters – More Than just a – Swiss Army Knife – , 2024, , 225-236.		0
2140	From Concept to Clinic and Commercialization: Cowboys Wanted. , 2024, , 41-51.		0
2176	Malignome endokriner Organe. , 2024, , 993-1051.		0
2205	Theranostik. , 2024, , 639-653.		0